

CITATION REPORT

List of articles citing

Cancer statistics, 2005

DOI: 10.3322/canjclin.55.1.10

Ca-A Cancer Journal for Clinicians, 2005, 55, 10-30.

Source: <https://exaly.com/paper-pdf/38302302/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2266	NETWORK EXPLORATION VIA THE ADAPTIVE LASSO AND SCAD PENALTIES. 2009 , 3, 521-541		60
2265	Diffusion-weighted MRI of female pelvic tumors. 119-143		1
2264	Rare multiple primary malignancies among surgical patients-a single surgical unit experience. 2014 , 8, 438		7
2263	Cancer: general. 2001 , 584-591		1
2262	Pathophysiology of malignant bone pain. 2001 , 23-34		
2261	Bone pain. 2001 , 515-532		
2260	Minimally Invasive Breast Biopsy: A New Standard in the New Millennium. 2004 , 7, 148-152		1
2259	The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery. 2004 , 2, 47		27
2258	Breast Cancer Risk Assessment: Identifying and Managing High Risk Patients. 2004 , 7, 153-158		
2257	Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. 2005 , 11, 7376-83		62
2256	Recent developments in advanced urothelial cancer. 2005 , 15, 342-9		5
2255	Predicting outcomes in renal cell carcinoma. 2005 , 15, 289-97		43
2254	Augmented, pulsating tactile feedback facilitates simulator training of clinical breast examinations. 2005 , 47, 670-81		16
2253	Endoscopic palliation of pancreatic adenocarcinoma. 2005 , 21, 601-5		12
2252	Sonography of thyroid nodules: a "classic pattern" diagnostic approach. 2005 , 21, 157-65		113
2251	A culturally targeted intervention to promote breast cancer screening among low-income women in East Baltimore, Maryland. 2005 , 12 Suppl 2, 34-41		28
2250	Molecularly targeted therapies for breast cancer. 2005 , 12, 73-81		30

2249	Targeted therapy in multiple myeloma. 2005 , 12, 91-104	24
2248	High-affinity Near-infrared Fluorescent Small-molecule Contrast Agents for In Vivo Imaging of Prostate-specific Membrane Antigen. 2005 , 4, 7290.2005.05163	61
2247	Time is money for both the healthy and the sick. 2005 , 43, 637-9	9
2246	Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats. 2005 , 16, 855-61	6
2245	Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. 2005 , 31, 275-82	18
2244	Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. 2005 , 70, 73-81	34
2243	Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. 2005 , 31, 317-24	53
2242	Current status of therapeutic vaccines for non-Hodgkin's lymphoma. 2005 , 17, 432-40	30
2241	Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer. 2005 , 28, 631-3	2
2240	What's new in the management of penile cancer?. 2005 , 15, 350-7	25
2239	Current status of establishing standards for lymphadenectomy in the treatment of bladder cancer. 2005 , 15, 315-9	7
2238	Proteomics in prostate cancer. 2005 , 15, 151-6	21
2237	A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. 2005 , 242, 584-90; discussion 590-2	36
2236	After the smoke clears: environmental and occupational risks for carcinoma of the upper aerodigestive tract. 2005 , 11, 96-103	17
2235	Prevention of cancer in the older person. 2005 , 11, 442-8	11
2234	Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. 2005 , 11, 404-11	21
2233	Psychosocial determinants and outcomes of chemotherapy in older women with breast cancer: what do we know? What do we need to know?. 2005 , 11, 518-28	7
2232	Lymphatic Drainage Patterns of Thoracic Malignancies. 2005 , 12, 254-266	

2231	How to market colorectal cancer screening awareness and colonoscopy services. 2005 , 28, 435-7	2
2230	Minimally invasive approaches: cryoablation. 2005 , 8,	
2229	Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Woman with Small Cell Lung Cancer. 2005 , 7, 190-195	
2228	Should African Americans be screened for colorectal cancer at an earlier age?. 2005 , 2, 352-3	9
2227	A review of prostate motion with considerations for the treatment of prostate cancer. 2005 , 30, 155-61	75
2226	5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. 2005 , 9, 1068-77; discussion 1077-9	47
2225	American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy. 2005 , 63, 1502-7	76
2224	Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. 2005 , 1, 101-9	248
2223	Organ-preservation laryngeal surgery in the era of chemoradiation. 2005 , 29, 169-79	5
2222	Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. 2005 , 12, 886-94	184
2221	A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. 2005 , 12, 282-8	102
2220	Cardiovascular alteration and treatment of hypertension: do men and women differ?. 2005 , 28, 199-207	24
2219	Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via cyclic GMP. 2005 , 36, 77-87	23
2218	Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. 2005 , 310, 644-8	3022
2217	Systemic therapy for colorectal cancer. 2005 , 352, 476-87	925
2216	Florida adults' oral cancer knowledge and examination experiences. 2005 , 65, 221-30	53
2215	Vitamin D and the epidemiology of prostate cancer. 2005 , 18, 276-89	83
2214	Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. 2005 , 15, 952-63	30

2213	Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. 2005 , 96, 281-5	25
2212	Epothilones and the next generation of phase III trials for prostate cancer. 2005 , 96, 296-302	22
2211	Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. 2005 , 96, 483-8	26
2210	A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. 2005 , 96, 787-90	10
2209	The immunotherapy of prostate and bladder cancer. 2005 , 96, 728-35	12
2208	Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. 2005 , 96, 999-1004	140
2207	Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery. 2005 , 96, 1268-74	5
2206	Lung cancer in Asian women-the environment and genes. 2005 , 10, 408-17	78
2205	Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. 2005 , 18, 400-5	25
2204	Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose. 2005 , 30, 459-70	6
2203	Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CARG elements. 2005 , 96, 706-12	8
2202	Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. 2006 , 132, 385-97	64
2201	Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells. 2005 , 35, 700-10	25
2200	Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. 2005 , 93, 195-9	136
2199	Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. 2005 , 11, 481-3	144
2198	Akt-regulated pathways in prostate cancer. 2005 , 24, 7465-74	297
2197	Anatomic distribution and pathologic characterization of small-volume prostate cancer (. 2005 , 18, 1022-6	101
2196	Regulatory T cells in ovarian cancer: biology and therapeutic potential. 2005 , 54, 369-77	180

2195	Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. 2005 , 162, 115-21	12
2194	In vitro age-related responses of endothelial cells to breast cancer cell addition. 2005 , 29, 518-27	3
2193	Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder. 2005 , 48, 691-8	88
2192	PSA testing in office-based clinics: are we testing as much as we think?. 2005 , 201, 906-12	5
2191	Standards for follow-up care of patents with breast cancer. 2005 , 14, 500-8	8
2190	Surgical Robotics in Urology: Robotic Assisted Radical Prostatectomy. 2005 , 7, 201-208	
2189	Palliative chemotherapy: historical perspective, applications, and controversies. 2005 , 32, 145-55	21
2188	Management of cancer pain. 2005 , 32, 179-93	26
2187	Novel strategies for the early detection and prevention of lung cancer. 2005 , 32, 259-68	34
2186	Current management of advanced non-small cell lung cancer: targeted therapy. 2005 , 32, 315-28	39
2185	Prophylactic cranial irradiation with combined modality therapy for patients with locally advanced non-small cell lung cancer. 2005 , 32, 293-8	8
2184	Experience with docetaxel in the treatment of gastric cancer. 2005 , 32, S24-38	15
2183	Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy. 2005 , 32, S40-2	22
2182	Targeting the epigenome for the treatment and prevention of lung cancer. 2005 , 32, 488-502	38
2181	Introduction. 2005 , 32, 1-2	25
2180	Evaluation and Management of Metastatic Disease of the Spine. 2005 , 17, 223-232	1
2179	Radioactive iodine offers survival improvement in patients with follicular carcinoma of the thyroid. 2005 , 138, 1072-6; discussion 1076-7	16
2178	Squamous cell carcinoma of the anal canal. 2005 , 14, 121-32	35

2177	Induction of Cyp1a1 and Cyp1b1 and formation of DNA adducts in C57BL/6, Balb/c, and F1 mice following in utero exposure to 3-methylcholanthrene. 2005 , 209, 28-38	19
2176	The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. 2005 , 130, 979-86	147
2175	Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. 2005 , 130, 1422-9	30
2174	The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution. 2005 , 130, 1601-10	14
2173	Sentinel lymph node biopsy in the management of ductal carcinoma in situ. 2005 , 6, 216-22	11
2172	Ductal carcinoma in situ of the breast in men: a review. 2005 , 6, 310-4	13
2171	Tissue-type plasminogen activator is upregulated in metastatic breast cancer cells exposed to insulin-like growth factor-I. 2005 , 6, 340-8	4
2170	Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial. 2005 , 6, 433-8	21
2169	Prostate cancer therapy with high-intensity focused ultrasound. 2005 , 4, 187-92	18
2168	What constitutes high-risk locally advanced prostate cancer?. 2005 , 4, 193-6	1
2167	Dose-intensive thoracic radiation therapy for patients at high risk with early-stage non-small-cell lung cancer. 2005 , 6, 350-4	9
2166	Chemoprevention strategies for patients with lung cancer in the context of screening. 2005 , 7, 92-9	10
2165	The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. 2005 , 7, 221-3	27
2164	Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. 2005 , 7 Suppl 1, S6-12	6
2163	Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. 2005 , 7 Suppl 1, S31-8	20
2162	Bortezomib-based combinations in the treatment of non-small-cell lung cancer. 2005 , 7 Suppl 2, S59-63	8
2161	Novel combinations with docetaxel in the treatment of non-small-cell lung cancer. 2005 , 7 Suppl 3, S83-6	1
2160	Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283]. <i>BMC Cancer</i> , 2005 , 5, 131	4.8 54

2159	JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats. <i>BMC Cancer</i> , 2005 , 5, 26	4.8	8
2158	Management of early-stage cutaneous melanoma. 2005 , 42, 460-534		2
2157	Predictors of vaginal relapse in stage I endometrial cancer. 2005 , 97, 820-7		46
2156	Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. 2005 , 97, 755-63		96
2155	Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. 2005 , 98, 242-8		36
2154	Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. 2005 , 98, 360-8		25
2153	Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. 2005 , 98, 309-12		49
2152	Surgical care of elderly women with ovarian cancer: a population-based perspective. 2005 , 99, 352-7		49
2151	Cervical sarcomas: an analysis of incidence and outcome. 2005 , 99, 348-51		48
2150	Endometrial cancer in young, normal-weight women. 2005 , 99, 388-92		59
2149	Predictors of outcomes for women with cervical carcinoma. 2005 , 99, 432-6		27
2148	Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. 2005 , 99, 301-8		48
2147	Preoperative chemoradiotherapy in locally advanced cervical cancer: long-term outcome and complications. 2005 , 99, S166-70		54
2146	Predictors of esophageal cancer risk: assessment of susceptibility to DNA damage using comet assay. 2005 , 44, 415-22		22
2145	Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: a case series. 2005 , 27, 748-56		21
2144	Meta-analysis of soy food and risk of prostate cancer in men. 2005 , 117, 667-9		110
2143	Clinical management of osteoporosis in women with a history of breast carcinoma. 2005 , 104, 443-56		35
2142	A model for care across the cancer continuum. 2005 , 104, 2638-42		29

2141	Psychological responses to cancer recurrence. 2005 , 104, 1540-7	77
2140	Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. 2005 , 104, 1312-21	36
2139	Treatment decision-making strategies and influences in patients with localized prostate carcinoma. 2005 , 104, 1381-90	97
2138	Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma. 2005 , 104, 1372-80	11
2137	Should women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion, receive reflex human papillomavirus-DNA testing?. 2005 , 105, 457-60	35
2136	Results of a randomized controlled trial to increase colorectal cancer screening in a managed care health plan. 2005 , 104, 2072-83	28
2135	Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. 2005 , 104, 2373-83	132
2134	Clonal origin of lymph node metastases in bladder carcinoma. 2005 , 104, 1901-10	40
2133	Modern approach to lymphoma diagnosis by fine-needle aspiration: restoring respect to a valuable procedure. 2005 , 105, 429-31	30
2132	Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. 2005 , 104, 2484-91	140
2131	Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma. 2005 , 92, 230-8	15
2130	Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. 2005 , 37, 114-22	75
2129	Clinical relevance of ion channels for diagnosis and therapy of cancer. 2005 , 205, 175-84	78
2128	Positron tomographic assessment of androgen receptors in prostatic carcinoma. 2005 , 32, 344-50	186
2127	Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes. 2005 , 56 Suppl 1, 69-77	2
2126	Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. 2005 , 56, 510-20	34
2125	Novel approaches in the therapy of metastatic renal cell carcinoma. 2005 , 23, 202-12	178
2124	Surgical strategies for early esophageal adenocarcinoma. 2005 , 19, 927-40	16

- 2123 Einsatz von Erlotinib: prognostische und prädiktive Faktoren beim nichtkleinzelligen Lungenkarzinom. **2005**, 11, 36-39
- 2122 Coloscopie virtuelle [par tomographie (CTDM) et résonance magnétique (CRM)] dans la détection des polypes coliques et des lésions néoplasiques. **2005**, 35, 569-579
- 2121 Borderline resectable pancreatic cancer. **2005**, 8, 377-84 43
- 2120 Strategies and methodologies for identifying molecular targets in sarcomas and other tumors. **2005**, 6, 487-97 5
- 2119 Environmental risk factors and colorectal neoplasia: Recent developments. **2005**, 1, 67-72
- 2118 New developments in therapy for metastatic colorectal cancer. **2005**, 1, 13-17
- 2117 Optimizing adjuvant therapy for colon cancer: Ongoing investigations. **2005**, 1, 27-33
- 2116 Chemoradiation for localized rectal cancer: Neoadjuvant versus adjuvant approaches. **2005**, 1, 51-57 1
- 2115 Chemoprophylaxis of colon cancer. **2005**, 7, 389-95 16
- 2114 Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. **2005**, 7, 419-34 62
- 2113 Lymphatic mapping and sentinel node detection in gynecologic malignancies of the lower genital tract. **2005**, 7, 435-43 9
- 2112 Secondary cytoreduction for patients with recurrent ovarian cancer. **2005**, 7, 451-8 31
- 2111 Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. **2005**, 7, 241-7 21
- 2110 Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future. **2005**, 7, 248-54 2
- 2109 A discussion of general prostate cancer screening versus targeted diagnosis in younger men. **2005**, 3, 99-111
- 2108 Biomarkers for the detection and prognosis of prostate cancer. **2005**, 3, 112-117
- 2107 Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated?. **2005**, 3, 153-159 1
- 2106 Chemotherapy agents and timing of chemotherapy in prostate cancer management. **2005**, 3, 58-61

2105	Biomarkers for the detection and prognosis of prostate cancer. 2005 , 6, 171-6		3
2104	Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?. 2005 , 6, 183-9		9
2103	The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer. 2005 , 6, 194-209		7
2102	Chemotherapy agents and timing of chemotherapy in prostate cancer management. 2005 , 6, 224-7		
2101	A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. 2005 , 50, 2218-23		43
2100	Phase II trial of dolastatin-10 in patients with advanced breast cancer. 2005 , 23, 257-61		84
2099	Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. 2005 , 94, 237-47		34
2098	Anthropometric factors and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. <i>Cancer Causes and Control</i> , 2005 , 16, 1235-44	2.8	57
2097	Cancer-related disparities: weathering the perfect storm through comprehensive cancer control approaches. <i>Cancer Causes and Control</i> , 2005 , 16 Suppl 1, 41-50	2.8	15
2096	Inadequate follow-up of abnormal screening mammograms: findings from the race differences in screening mammography process study (United States). <i>Cancer Causes and Control</i> , 2005 , 16, 809-21	2.8	88
2095	Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. 2005 , 22, 674-84		62
2094	Cutaneous melanoma: prognostic factors. 2005 , 12, 223-9		82
2093	Plasmacytoma of the testis. 2005 , 24, 1721-5		12
2092	Head and neck melanoma. 2005 , 12, 242-7		46
2091	The Systemic Theory of Living Systems and Relevance to CAM: The Theory (Part II). 2005 , 2, 129-137		13
2090	Small molecule and monoclonal antibody therapies in neurooncology. 2005 , 12, 116-24		21
2089	Renal cell carcinoma: diagnosis and treatment, 1994-2003. 2005 , 18, 337-40		13
2088	P53 Alteration in Oral Tongue Cancer is Not Significantly Associated with Age at Diagnosis or Tobacco Exposure. 2005 , 91, 346-350		16

2087	Prevalence, causes, and impact of cancer-associated thrombosis. 2005 , 62, S4-S6	16
2086	Bevacizumab in combination chemotherapy for colorectal and other cancers. 2005 , 62, 1021-32	42
2085	Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. 2005 , 65, 8022-7	54
2084	Expectant management: an option for localized prostate cancer. 2005 , 8, 311-5	6
2083	Radiation therapy for prostate cancer and erectile (dys)function: the role of imaging. 2005 , 44, 673-8	13
2082	Advanced colorectal cancer: current treatment and nursing management with economic considerations. 2005 , 9, 541-52	20
2081	Gene expression profiling predicts survival in conventional renal cell carcinoma. 2006 , 3, e13	154
2080	Targeted therapies for esophageal cancer. 2005 , 10, 590-601	114
2079	Optimizing first-line treatment options for patients with advanced NSCLC. 2005 , 10 Suppl 3, 1-10	72
2078	Obesity and prostate cancer: a growing problem. 2005 , 11, 6763-6	50
2077	Opportunities for targeted therapies in hepatocellular carcinoma. 2005 , 23, 8093-108	145
2076	Chemoradiotherapy for colorectal cancer. 2005 , 54, 1194-202	66
2075	The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. 2005 , 65, 11536-44	74
2074	Preventive health behaviors and familial breast cancer. 2005 , 14, 2340-5	48
2073	Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. 2005 , 16, 1320-5	46
2072	Deguelin as a chemopreventive agent in mouse lung tumorigenesis induced by tobacco smoke carcinogens. 2005 , 97, 1634-5	5
2071	In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. 2005 , 97, 1822-31	44
2070	Adjuvant therapy in colon cancer: which treatment in 2005?. 2005 , 16 Suppl 4, iv69-73	1

2069	Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer. 2005 , 9, 177-84	17
2068	The changing face of prostate cancer. 2005 , 23, 8146-51	263
2067	Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. 2005 , 23, 9097-104	102
2066	What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. 2005 , 60, 1059-65	164
2065	Acid increases MAPK-mediated proliferation in Barrett's esophageal adenocarcinoma cells via intracellular acidification through a Cl-/HCO ₃ ⁻ exchanger. 2005 , 289, G991-7	36
2064	Locally advanced pancreatic cancer. 2005 , 23, 4538-44	175
2063	Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. 2005 , 4, 16	15
2062	Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. 2005 , 11, 8829-36	84
2061	Progesterone isoforms and endometrial cancer. 2005 , 12, 219-21	1
2060	Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. 2005 , 23, 8198-203	91
2059	Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. 2005 , 65, 10524-35	71
2058	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. 2005 , 11, 5539-48	234
2057	Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. 2005 , 97, 1124-32	302
2056	Spectral markers in preneoplastic intestinal mucosa: an accurate predictor of tumor risk in the MIN mouse. 2005 , 14, 1639-45	19
2055	Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area. 2005 , 14, 2093-7	117
2054	Building upon the standard of care in adjuvant therapy of high-risk melanoma. 2005 , 23, 8559-63	7
2053	Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. 2005 , 65, 6910-8	560
2052	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. 2005 , 23, 3227-34	343

2051	Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. 2005 , 23, 9329-37	184
2050	Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. 2005 , 102, 5156-61	85
2049	Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. 2005 , 97, 846-53	183
2048	Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. 2005 , 102, 10628-33	19
2047	Carcinogen exposure and gene promoter hypermethylation in bladder cancer. 2006 , 27, 112-6	139
2046	YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells. 2005 , 4, 1628-35	47
2045	Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway. 2005 , 26, 1956-64	109
2044	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. 2005 , 65, 5561-70	285
2043	Plasma carotenoids and recurrence-free survival in women with a history of breast cancer. 2005 , 23, 6631-8	77
2042	Promoter hypermethylation profile of ovarian epithelial neoplasms. 2005 , 11, 5365-9	118
2041	Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. 2005 , 26, 2196-206	42
2040	A review of the diagnosis and management of male breast cancer. 2005 , 10, 471-9	220
2039	Vitamin E supplementation in cardiovascular disease and cancer prevention: Part 1. 2005 , 39, 1870-8	46
2038	Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. 2005 , 65, 9953-61	190
2037	Molecular evidence supporting field effect in urothelial carcinogenesis. 2005 , 11, 6512-9	134
2036	The multiplicity of thyroid nodules and carcinomas. 2005 , 352, 2376-8	30
2035	Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183. 2005 , 23, 7454-9	59
2034	Targeting HER1/EGFR in cancer therapy: experience with erlotinib. 2005 , 1, 449-60	17

2033	Atypical PKC α contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. 2005 , 102, 12519-24	206
2032	Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). 2005 , 2, 436-42	48
2031	Targeting signal transduction pathways in colorectal cancer--more than skin deep. 2005 , 23, 5374-85	59
2030	Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. 2005 , 14, 1402-10	16
2029	Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. 2005 , 11, 6574-81	125
2028	Automated segmentation of pigmented skin lesions in multispectral imaging. 2005 , 50, N345-57	12
2027	Colon cancer screening update and management of the malignant polyp. 2005 , 18, 141-9	9
2026	Drug insight: thalidomide as a treatment for multiple myeloma. 2005 , 2, 262-70	29
2025	Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. 2005 , 2, 434-42	30
2024	Pancreatic cancer screening: identifying premalignant disease. 2005 , 1, 191-5	6
2023	Hedgehog signaling in prostate cancer. 2005 , 1, 331-8	17
2022	Recent advances in the treatment of bladder cancer. 2005 , 5, 1023-30	1
2021	Positron emission tomography: clinical applications in oncology. Part 1. 2005 , 5, 1079-94	31
2020	Exisulind in the treatment of prostate cancer. 2005 , 5, 957-62	12
2019	Risks and benefits of phase 1 oncology trials, revisited. 2005 , 352, 930-2	78
2018	Molecular screening for the Lynch syndrome--better than family history?. 2005 , 352, 1920-2	34
2017	Bortezomib for myeloma -- much ado about something. 2005 , 352, 2546-8	18
2016	Counting human somatic cell replications: methylation mirrors endometrial stem cell divisions. 2005 , 102, 17739-44	89

2015	Identification of cyanidin glycosides as constituents of freeze-dried black raspberries which inhibit anti-benzo[a]pyrene-7,8-diol-9,10-epoxide induced NFkappaB and AP-1 activity. 2006 , 27, 1617-26	60
2014	The role of proteomics in the diagnosis and treatment of ovarian cancer. 2005 , 1, 365-74	2
2013	Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. 2005 , 146, 5188-96	65
2012	The ODAC chronicles: Part 5. Prostate cancer endpoints. 2005 , 5, 405-10	1
2011	Chemoprevention of lung cancer: concepts and strategies. 2005 , 5, 549-65	4
2010	Preoperative and adjuvant therapies for upper gastrointestinal cancers. 2005 , 5, 719-25	8
2009	Paclitaxel: cost-effectiveness in ovarian cancer. 2005 , 5, 235-43	2
2008	Lymphocyte therapy of renal cell carcinoma. 2005 , 5, 1041-51	10
2007	Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. 2005 , 172, 729-37	70
2006	Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. 2005 , 65, 7917-25	179
2005	Serum protein markers for early detection of ovarian cancer. 2005 , 102, 7677-82	369
2004	Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. 2005 , 23, 8646-54	736
2003	Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. 2005 , 10, 205-14	128
2002	Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. 2005 , 6, 2015-26	19
2001	An accurate closed-form analytical model of single nanoshells for cancer treatment. 2005 ,	10
2000	Diabetes mellitus and risk of colorectal cancer: a meta-analysis. 2005 , 97, 1679-87	781
1999	Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer. 2005 , 62, 1365-9	1
1998	Correspondence in texture features between two mammographic views. 2005 , 32, 1598-606	21

1997	Effects of soy protein and soy phytochemicals on mammary tumor development in female transgenic mice overexpressing human pituitary growth hormone. 2005 , 8, 556-9	3
1996	Can we preoperatively identify men who are at high risk for aggressive prostate cancer?. 2005 , 2, 584-5	1
1995	A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. 2005 , 12, 835-41	51
1994	Successful pregnancies following fertility-preserving treatment for ovarian carcinoma. 2005 , 2, 647-51; quiz 652	4
1993	Does lung cancer screening motivate smoking cessation?. 2005 , 2, 616-7	2
1992	Endoprevention of esophageal cancer: endoscopic ablation of Barrett's metaplasia and dysplasia. 2005 , 2, 713-23	11
1991	Hepatocellular carcinoma: the need for progress. 2005 , 23, 2892-9	339
1990	Prostate stem cell antigen is overexpressed in prostate cancer metastases. 2005 , 11, 2591-6	183
1989	Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. 2005 , 23, 6976-81	98
1988	Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. 2005 , 65, 8388-96	26
1987	Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2005 , 11, 8418-24	201
1986	Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. 2005 , 11, 7523-31	98
1985	Fertility-sparing options for patients with gynecologic malignancies. 2005 , 10, 613-22	29
1984	Unique gene expression profile based on pathologic response in epithelial ovarian cancer. 2005 , 23, 7911-8	114
1983	Sun exposure and risk of melanoma. 2006 , 91, 131-8	158
1982	Risk factors for fatal breast cancer in African-American women and White women in a large US prospective cohort. 2005 , 162, 734-42	32
1981	Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. 2005 , 11, 8680-5	64
1980	Phase III prostate cancer prevention trials: are the costs justified?. 2005 , 23, 8161-4	23

1979	Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. 2005 , 23, 5746-56	123
1978	Knowledge of oral cancer risk factors and diagnostic concepts among North Carolina dentists. Implications for diagnosis and referral. 2005 , 136, 602-10; quiz 682	52
1977	Evolving paradigms and perceptions of cancer. 2005 , 2, 618-24	6
1976	Septa design for a prostate specific PET camera. 2005 , 52, 107-113	7
1975	Cardiovascular risk in testicular cancer survivors treated with chemotherapy: incidence, significance, and practice implications. 2005 , 32, 1005-9; quiz 1010-1	4
1974	Strengths and limitations of breast cancer risk assessment. 2005 , 32, 605-16	4
1973	Cancer in Older Adults. 2005 , 32, 913-917	
1972	A teachable moment for oncologists: cancer survivors, 10 million strong and growing!. 2005 , 23, 5458-60	133
1971	Gene expression profiling and genetic markers in glioblastoma survival. 2005 , 65, 4051-8	263
1970	A molecular classification of papillary renal cell carcinoma. 2005 , 65, 5628-37	185
1969	A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. 2005 , 65, 9426-35	178
1968	Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. 2005 , 65, 9891-8	177
1967	Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. 2005 , 65, 11185-92	62
1966	Genetic variants of DNA repair genes and prostate cancer: a population-based study. 2005 , 14, 1703-9	60
1965	Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. 2005 , 11, 4365-71	145
1964	Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. 2005 , 11, 5128-39	123
1963	DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. 2005 , 11, 6544-9	32
1962	Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. 2005 , 11, 8295-303	101

1961	A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. 2005 , 11, 7743-8	129
1960	SELDI-TOF-MS proteomics of breast cancer. 2005 , 43, 1314-20	42
1959	Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). 2005 , 23, 6854-64	179
1958	An ovarian cancer diagnosis-seeking process: unraveling the diagnostic delay problem. 2005 , 32, 1036-42	14
1957	Information needs of wives of men following prostatectomy. 2005 , 32, 557-63	14
1956	Therapeutic targeting of receptor tyrosine kinases in lung cancer. 2005 , 9, 533-59	20
1955	A randomized trial of an intervention to increase fruit and vegetable intake in curatively treated patients with early-stage head and neck cancer. 2005 , 14, 2848-54	15
1954	Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. 2005 , 102, 14034-9	105
1953	T-oligo treatment decreases constitutive and UVB-induced COX-2 levels through p53- and NFkappaB-dependent repression of the COX-2 promoter. 2005 , 280, 32379-88	31
1952	Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study. 2005 , 16, 367-76	24
1951	Lung cancer immunotherapy. 2005 , 3, 221-8	47
1950	Present status and perspectives in the treatment of hormone-refractory prostate cancer. 2005 , 69, 273-82	19
1949	Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. 2005 , 1, 461-6	6
1948	Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. 2005 , 11, 8258-64	36
1947	FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. 2005 , 23, 3311-3	20
1946	Thalidomide and dexamethasone: therapy for multiple myeloma. 2005 , 5, 759-66	21
1945	Microwave Reflectometry as a Novel Diagnostic Method for Detection of Skin Cancers.	3
1944	Endometrial cancer. 2005 , 366, 491-505	1103

1943	Statins and the risk of colorectal cancer. 2005 , 352, 2184-92	607
1942	Advances in the treatment of metastatic colorectal cancer. 2005 , 10 Suppl 3, 40-8	73
1941	[Update of the treatment of advanced prostate cancer and management of its complications]. 2005 , 125, 671-7	0
1940	Molecular Diagnostics in Prostate Cancer. 2005 , 3, 200-213	9
1939	Does surgery induce angiogenesis in breast cancer? Indirect evidence from relapse pattern and mammography paradox. 2005 , 3, 179-87	41
1938	A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. 2005 , 76, 54-8	8
1937	Role of 5 α -reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. 2005 , 3, 211-4	4
1936	Diagnostic precision and accuracy in interpretation of specimens from cancer screening programs. 2005 , 22, 147-55	5
1935	Adjuvant therapies for non-small cell lung cancer: introduction. 2005 , 17, 179	
1934	Adjuvant chemotherapy for non-small cell lung cancer. 2005 , 17, 195-8	
1933	Molecular staging and the selection of therapy for non-small cell lung cancer. 2005 , 17, 180-5	2
1932	Surgical strategies and outcomes after induction therapy for non-small cell lung cancer. 2005 , 17, 186-90	5
1931	Targeted therapy for non-small cell lung cancer. 2005 , 17, 199-204	8
1930	Molecular markers of early pancreatic cancer. 2005 , 23, 4524-31	173
1929	Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. 2005 , 310, 1504-10	748
1928	Principles of Total Mesorectal Excision for Rectal Cancer. 2005 , 16, 117-127	
1927	Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. 2005 , 65, 5654-61	130
1926	The role of cetuximab in the treatment of squamous cell cancer of the head and neck. 2005 , 5, 1085-93	57

1925	90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. 2005 , 16, 1641-51	152
1924	Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. 2005 , 16, 937-45	137
1923	Multiple myeloma: diagnosis and treatment. 2005 , 80, 1371-82	183
1922	Endoluminal palliation. 2005 , 15, 467-84, viii	15
1921	Screening for prostate cancer: opportunities and challenges. 2005 , 14, 747-60	6
1920	Quality research in radiation oncology: a self-improvement initiative 30 years ahead of its time?. 2005 , 2, 1001-7	12
1919	Neoadjuvant chemotherapy in patients with invasive bladder cancer. 2005 , 32, 231-7	14
1918	Introduction to a cancer symposium for the practitioner. 2005 , 80, 1085-6	4
1917	Multislice CT colonography: current status and limitations. 2005 , 43, 1049-62, viii	10
1916	Determinants of cancer disparities: barriers to cancer screening, diagnosis, and treatment. 2005 , 14, 655-69, v	121
1915	Radical Hysterectomy Versus Extrafascial Hysterectomy in the Management of Stage II Endometrial Carcinoma. 2005 , 21, 111-116	1
1914	Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. 2005 , 5, 841-52	22
1913	Endoscopic ultrasonography in the diagnosis and management of cancer. 2005 , 5, 585-97	9
1912	Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. 2005 , 102, 14813-8	322
1911	Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. 2005 , 6, 1269-75	
1910	Chemoradiotherapy for lung cancer. 2005 , 6, 2793-804	3
1909	Cancer chemoprevention: scientific promise, clinical uncertainty. 2005 , 2, 518-25	112
1908	Vascular damage after fractionated whole-brain irradiation in rats. 2005 , 164, 662-8	128

1907	Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. 2005 , 23, 1107-22	137
1906	The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. 2005 , 19, 309-22	13
1905	Silibinin efficacy against human hepatocellular carcinoma. 2005 , 11, 8441-8	108
1904	Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells. 2005 , 52, 213-24	103
1903	Screening for cutaneous melanoma. 2005 , 14, 799-811	9
1902	Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. 2005 , 23, 7135-42	218
1901	Prognostic features in men who died of prostate cancer. 2005 , 174, 553-6; discussion 556	22
1900	Genomic medicine: genetic variation and its impact on the future of health care. 2005 , 360, 1543-50	50
1899	Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. 2005 , 23, 3219-26	78
1898	A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. 2005 , 65, 11203-13	103
1897	Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. 2005 , 237, 794-800	881
1896	Sunlight, tanning booths, and vitamin D. 2005 , 52, 868-76	62
1895	Vitamin D and prevention of colorectal cancer. 2005 , 97, 179-94	250
1894	Drug discovery from medicinal plants. 2005 , 78, 431-41	880
1893	Ultraviolet B exposure activates Stat3 signaling via phosphorylation at tyrosine705 in skin of SKH1 hairless mouse: a target for the management of skin cancer?. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 333, 241-6	3-4 25
1892	Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 337, 498-504	3-4 15
1891	Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. 2005 , 27, 1513-34	82
1890	Adding temozolomide to radiotherapy prolongs survival in people with glioblastoma. 2005 , 31, 577-81	1

1889	Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?. 2005 , 41, 941-53	44
1888	Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins. 2005 , 41, 1824-30	11
1887	Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. 2005 , 41, 2196-202	28
1886	Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. 2005 , 41, 2735-44	36
1885	Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation. 2005 , 579, 3497-502	25
1884	Effect of new antioxidant cysteinyl-flavanol conjugates on skin cancer cells. 2005 , 579, 4219-25	36
1883	Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. 2005 , 167, 1739-52	89
1882	Neuropathic pain associated with non-surgical treatment of breast cancer. 2005 , 118, 10-4	66
1881	Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. 2005 , 119, 233-246	74
1880	Alternatives in cancer pain treatment: the application of chiropractic care. 2005 , 21, 184-9	14
1879	Secondary prevention of cancer. 2005 , 21, 252-9	3
1878	Modifying cancer risk factors: the gene-environment interaction. 2005 , 21, 271-7	8
1877	Chemoprevention: a primary cancer prevention strategy. 2005 , 21, 243-51	12
1876	Performance-enhancing supplement use in patients with testicular cancer. 2005 , 66, 242-5	3
1875	Strategies to increase living donor kidney transplants. 2005 , 66, 43-6	12
1874	Who is the average patient presenting with prostate cancer?. 2005 , 66, 76-82	41
1873	Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. 2005 , 66, 1-9	82
1872	Quality of life in patients with localized prostate cancer. 2005 , 23, 208-15	19

1871	Treatment of nonretroperitoneal residual germ cell tumor masses. 2005 , 23, 431-9	3
1870	The polyp detection rate of colonoscopy: a national study of Medicare beneficiaries. 2005 , 118, 1413	20
1869	Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. 2005 , 118 Suppl 12B, 136-41	66
1868	Inhibition of melanoma growth by hemocyanin occurs via early apoptotic pathways. 2005 , 190, 713-6	14
1867	Java Web Start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia. 2005 , 4, 31	10
1866	Ovarian cancer, the coagulation pathway, and inflammation. 2005 , 3, 25	90
1865	Docetaxel in hormone-refractory metastatic prostate cancer. 2005 , 65, 2287-94; discussion 2295-7	13
1864	Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. 2005 , 6, 125-31	16
1863	Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. 2005 , 6, 158-62	21
1862	Concepts and clinical trials of dose-dense chemotherapy for breast cancer. 2005 , 6, 402-11	7
1861	Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. 2005 , 6, 446-54	22
1860	Changing patterns of bone and brain metastases in patients with colorectal cancer. 2005 , 5, 108-13	144
1859	Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways. 2005 , 5, 114-8	13
1858	Management of colorectal cancer in pregnancy: a multimodality approach. 2005 , 5, 247-56	27
1857	Clinicopathologic significance of synchronous and metachronous adenomas in colorectal cancer. 2005 , 5, 274-8	5
1856	An overview of approaches to adjuvant therapy for colorectal cancer in the United States. 2005 , 5 Suppl 1, S11-8	14
1855	Epidermal Growth Factor Receptor as a Target for Chemotherapy. 2005 , 5, S19-S27	47
1854	Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway. 2005 , 5 Suppl 2, S89-97	

1853	Is there a role for less invasive therapeutic approaches for low- and intermediate-grade organ-confined prostate cancer?. 2005 , 3, 205	
1852	Update on fused capromab pendetide imaging of prostate cancer. 2005 , 3, 230-8	34
1851	Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. 2005 , 4, 55-60	52
1850	Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. 2005 , 4, 61-4	10
1849	Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. 2005 , 4, 91-9	11
1848	A measure of health-related quality of life among patients with localized prostate cancer: results from ongoing scale development. 2005 , 4, 100-8	26
1847	Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. 2005 , 4, 113-7	2
1846	A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. 2005 , 4, 138-41	49
1845	A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. 2005 , 4, 215-8	11
1844	Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial. 2005 , 6, 287-92	18
1843	Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. 2005 , 7, 30-9	38
1842	Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. 2005 , 7, 47-53	27
1841	First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel. 2005 , 7 Suppl 3, S77-82	6
1840	The role of docetaxel in N2 locally advanced non-small-cell lung cancer. 2005 , 7 Suppl 3, S87-92	1
1839	Emerging trends in the clinical use of bortezomib in multiple myeloma. 2005 , 6, 84-8	6
1838	The emerging role of alemtuzumab in chronic lymphocytic leukemia. 2005 , 6, 115-21	9
1837	Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics. 2005 , 6, 200-7	5
1836	Advances in multiple myeloma and spine disease. 2005 , 6, 228-33	17

1835	Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. 2005 , 25 Suppl 1, S41-55	270
1834	Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. 2005 , 5, 605-11	20
1833	Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. 2005 , 242, 566-73; discussion 573-5	333
1832	Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. 2005 , 128, 620-6	431
1831	Ionizing radiation and rectal cancer: victims of our own success. 2005 , 128, 1114-7	9
1830	Carpe luz--seize the light: endoprevention of esophageal adenocarcinoma when using photodynamic therapy with porfimer sodium. 2005 , 62, 499-503	16
1829	Changes in sexual function after treatment of male cancer. 2005 , 2, 236-243	3
1828	The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. 2005 , 6, 575-84	14
1827	Screening for breast cancer. 2005 , 14, 671-97	14
1826	The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. 2005 , 7, 912-20	27
1825	The Changing Paradigm of Lobular Neoplasia of the Breast. 2005 , 8, 112-118	
1824	Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. 2005 , 22, 785-91	22
1823	Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy. 2005 , 22, 709-15	12
1822	Front-line treatment of epithelial ovarian cancer. 2005 , 4, 221-231	1
1821	Current Status and Future Prospects of Gene Therapy. 2005 , 4, 137-144	3
1820	Phase II Study of Pemetrexed Plus Gemcitabine in Advanced Pancreatic Cancer. 2005 , 4, 185-191	1
1819	Neoadjuvant Chemotherapy in Bladder Cancer. 2005 , 4, 71-75	
1818	Status of Newer Chemotherapeutic Strategies for the Treatment of Metastatic Gastric Cancer. 2005 , 4, 65-70	

1817	Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. 2005 , 65, 10602-12	269
1816	Renal-cell carcinoma. 2005 , 353, 2477-90	1231
1815	Update on drug-eluting coronary stents. 2005 , 3, 953-68	29
1814	Impact of diet on prostate cancer: a review. 2005 , 8, 304-10	121
1813	Mammary epithelial cell transformation: insights from cell culture and mouse models. 2005 , 7, 171-9	99
1812	Association between manganese superoxide dismutase promoter gene polymorphism and breast cancer survival. 2006 , 8, R45	15
1811	Large-scale and high-confidence proteomic analysis of human seminal plasma. 2006 , 7, R40	286
1810	Immunotherapy for Prostate Cancer. 2006 , 5, 331-339	
1809	Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer. 2006 , 5, 213-221	1
1808	Role of Non-Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer. 2006 , 5, 245-257	1
1807	Vascular Targeting and Therapeutics for Squamous Cell Carcinoma of the Head and Neck. 2006 , 5, 7-18	
1806	Management strategies for locally advanced prostate cancer. 2006 , 23, 119-29	8
1805	Lung cancer preneoplasia. 2006 , 1, 331-48	150
1804	Pulsed cavitation ultrasound: a noninvasive technology for controlled tissue ablation (histotripsy) in the rabbit kidney. 2006 , 175, 734-8	240
1803	Complementary and alternative medicine for advanced prostate cancer. 2006 , 33, 237-46, viii	28
1802	Image-guided brachytherapy for prostate cancer. 2006 , 44, 735-48, viii-ix	5
1801	Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. 2006 , 8, 534-42	29
1800	Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. 2006 , 8, 279-89	161

1799	Lung cancer and radiofrequency ablation. 2006 , 17, 927-51; quiz 951	78
1798	PET and PET/CT in Management of the Lymphomas. 2006 , 1, 243-50	1
1797	In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. 2006 , 8, 772-80	91
1796	Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor-deficient mutants. 2006 , 8, 984-94	18
1795	Radiation oncology emergencies. 2006 , 20, 505-22	13
1794	Colon pathology detected after a positive screening flexible sigmoidoscopy: a prospective study in an ethnically diverse cohort. 2006 , 101, 823-30	41
1793	Morphological segmentation and partial volume analysis for volumetry of solid pulmonary lesions in thoracic CT scans. 2006 , 25, 417-34	197
1792	Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. 2006 , 176, 81-6	20
1791	Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. 2006 , 4, 717-25; quiz 664	182
1790	Breast specimen radiography: can it predict margin status of excised breast carcinoma?. 2006 , 13, 1453-9	21
1789	The role of imaging in the surveillance of urologic malignancies. 2006 , 33, 377-96	16
1788	Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. 2006 , 103, 5947-52	463
1787	FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. 2006 , 66, 3593-602	261
1786	Epidemiology of Thyroid Cancer. 2006 , 9-13	4
1785	Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. 2006 , 12, 2591-6	117
1784	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. 2006 , 355, 2542-50	4760
1783	Intraperitoneal cisplatin and paclitaxel in ovarian cancer. 2006 , 354, 34-43	2065
1782	Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. 2006 , 12, 4018-26	351

1781	Telephone care management to improve cancer screening among low-income women: a randomized, controlled trial. 2006 , 144, 563-71	138
1780	Hormone replacement therapy in menopausal women: Past problems and future possibilities. 2006 , 22, 564-77	15
1779	Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. 2006 , 84, 713-9	34
1778	Approaching clinical problems in prostate cancer radiotherapy using the number needed to treat (NNT) technique. 2006 , 24, 318-27	2
1777	Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. 2006 , 20, 13-23	22
1776	Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease. 2006 , 20, 201-7	3
1775	Hexyl aminolevulinate in the detection of bladder cancer: profile report. 2006 , 20, 317-20	
1774	Outcomes of patients with differentiated thyroid carcinoma following initial therapy. 2006 , 16, 1229-42	483
1773	Anal cancer: current and future methodology. 2006 , 24, 535-44	33
1772	Prostate mechanical imaging: 3-D image composition and feature calculations. 2006 , 25, 1329-40	50
1771	Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. 2006 , 12, 4755-65	36
1770	Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. 2006 , 6, 1593-607	30
1769	Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. 2006 , 21, 263-8	7
1768	Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. 2006 , 17, 661-8	51
1767	Recent developments in colorectal cancer treatment by monoclonal antibodies. 2006 , 6, 1175-92	15
1766	Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. 2006 , 98, 1108-17	261
1765	Potential use of humanized antibodies in the treatment of breast cancer. 2006 , 6, 1065-74	14
1764	Serous Endometrial Intraepithelial Carcinoma: Diagnosis and Clinical Management. 2006 , 22, 69-72	

1763	Clinical experiences with G17DT in gastrointestinal malignancies. 2006 , 6, 487-92	4
1762	Panitumumab in colon cancer: a review and summary of ongoing trials. 2006 , 6, 1229-35	25
1761	Multidisciplinary Symposium on Head and Neck Cancer. 2 December 2005, Philadelphia, PA, USA. 2006 , 7, 489-94	
1760	Controversial issues and optimal management of stage T1G3 bladder cancer. 2006 , 6, 1283-94	10
1759	Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. 2006 , 6, 951-62	6
1758	The burden of gastrointestinal and liver diseases, 2006. 2006 , 101, 2128-38	465
1757	American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. 2006 , 24, 2917-31	1573
1756	Purine analogue combinations for indolent lymphomas. 2006 , 43, S11-21	5
1755	Single-photon emission computed tomography/computed tomography in lung cancer and malignant lymphoma. 2006 , 36, 275-85	24
1754	Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. 2006 , 78, 464-79	234
1753	CSR1 suppresses tumor growth and metastasis of prostate cancer. 2006 , 168, 597-607	45
1752	Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. 2006 , 169, 233-46	87
1751	Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. 2006 , 7, 230-40	359
1750	Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. 2006 , 7, 416-24	42
1749	Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. 2006 , 7, 556-64	194
1748	Reassessment of the role of induction chemotherapy for head and neck cancer. 2006 , 7, 565-74	48
1747	Initial 10-year experience of sperm cryopreservation services for cancer patients. 2006 , 105, 1022-6	14
1746	Fludarabine in chronic lymphocytic leukaemia. 2006 , 7, 1641-51	32

1745	Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. 2006 , 12, 6415-20	81
1744	Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. 2006 , 66, 10683-90	136
1743	Recruiting more elderly patients for clinical trials. 2006 , 3, 197-198	1
1742	Reducing the risk of recurrence in postmenopausal women with early breast cancer: a role for aromatase inhibitors. 2006 , 3, 275-281	
1741	The TAILORx trial: individualized options for treatment. 2006 , 3, 494-496	9
1740	The emerging role of novel therapeutic agents in the management of patients with multiple myeloma. 2006 , 3, 575-582	
1739	Treating elderly cancer patients: what you need to know about their physiology and specific medical needs. 2006 , 3, 730-734	
1738	La cuantificaci3n del volumen tumoral en las biopsias transrectales de pr3stata. 2006 , 39, 155-158	1
1737	Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). 2006 , 81, 163-7	74
1736	Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. 2006 , 312, 831-43	66
1735	Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. 2006 , 312, 974-82	99
1734	The Case for Prostate Cancer Screening with Prostate-Specific Antigen. 2006 , 5, 737-745	6
1733	Future innovations in treating advanced prostate cancer. 2006 , 33, 247-72, viii	3
1732	Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. 2006 , 175, 1347-52	28
1731	Chemoprevention for bladder cancer. 2006 , 176, 1914-20	25
1730	Prostate cancer prevention and finasteride. 2006 , 176, 2010-2; discussion 2012-3	16
1729	Radiotherapy in the management of common genitourinary malignancies. 2006 , 20, 321-46	1
1728	Hablando claro del c3ncer Ovarico. 2006 , 24, 8-13	

1727	Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. 2006 , 8, 465-9	149
1726	Prostate cancer imaging--what the urologic oncologist needs to know. 2006 , 44, 711-22, viii	4
1725	Management of Hodgkin lymphoma. 2006 , 81, 419-26	39
1724	The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. 2006 , 175, 1634-9; discussion 1639-40	114
1723	The evolution of imaging in advanced prostate cancer. 2006 , 33, 133-46, v	11
1722	Transrectal sonography in prostate evaluation. 2006 , 44, 679-87, viii	23
1721	The volume-performance relationship in esophagectomy. 2006 , 16, 87-94	48
1720	HIV and skin cancer. 2006 , 24, 521-30, vii	12
1719	Cancer screening in men. 2006 , 33, 115-38, ix	
1718	Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. 2006 , 175, 523-7	43
1717	Cancer of the gastroesophageal junction: combined modality therapy. 2006 , 15, 803-24	14
1716	Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. 2006 , 176, 1108-13	68
1715	Chemoprevention of prostate cancer. 2006 , 20, 831-43	7
1714	Adjuvant Therapy for Breast Cancer: No Pain, No Gain?. 2006 , 16, 320-322	2
1713	Molecular upstaging of sentinel lymph nodes in melanoma: where are we now?. 2006 , 15, 331-40	8
1712	Targeting the epigenome for the treatment of thoracic malignancies. 2006 , 16, 367-77, vi	4
1711	Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis. 2006 , 176, 1957-62	62
1710	Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. 2006 , 176, 985-90	91

1709	Radiation therapy for gastrointestinal cancer. 2006 , 20, 287-320	5
1708	[Growing incidence in renal cell carcinoma]. 2006 , 30, 295-300	3
1707	Sarcoma and skin radiation oncology. 2006 , 20, 401-29	25
1706	Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. 2006 , 176, 2033-8; discussion 2038-9	146
1705	[Epidemiology and delays in the management of 355 patients with lung cancer]. 2006 , 23, 43-8	7
1704	Minimally invasive approaches to localized prostate carcinoma. 2006 , 20, 879-95	11
1703	Combined resection of liver and lung metastases for colorectal cancer. 2006 , 16, 145-55, vi	13
1702	Venacavoscopy during nephrectomy for renal cell carcinoma with inferior vena caval thrombus. 2006 , 176, 468-71	5
1701	Evolving techniques in the treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, microwave coagulation, hepatic arterial chemotherapy, indications and contraindications for resection, role of transplantation, and timing of chemotherapy. 2006 , 86, 1005-22	22
1700	Challenges and Progress in the Treatment of Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. 2006 , 1, 19-27	
1699	Papillary thyroid cancer. 2006 , 15, 585-601	31
1698	Racial disparity in bladder cancer: trends in tumor presentation at diagnosis. 2006 , 176, 927-33; discussion 933-4	47
1697	Prevalence of clinically important histology in small adenomas. 2006 , 4, 343-8	227
1696	Eliminate the term "superficial" bladder cancer. 2006 , 175, 417-8	22
1695	The role of radiation therapy in thoracic tumors. 2006 , 20, 363-400	17
1694	Preoperative serum prostate specific antigen remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy. 2006 , 175, 1663-7; discussion 1667	12
1693	Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. 2006 , 175, 1245-52	104
1692	The role of bisphosphonates in preventing skeletal complications of hormonal therapy. 2006 , 33, 191-9, vi	3

1691	Immunotherapy for prostate cancer: what's the future?. 2006 , 20, 965-83, xi	5
1690	Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. 2006 , 81, 1290-302	154
1689	Prostate specific antigen testing in men older than 75 years in the United States. 2006 , 176, 511-4	26
1688	Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. 2006 , 17, 217-23	90
1687	Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. 2006 , 176, 44-7	96
1686	Surgical implications of colorectal cancer genetics. 2006 , 15, 51-66, vi	11
1685	Adjuvant therapy for patients who have node-positive breast cancer. 2006 , 40, 77-98	3
1684	Mechanisms leading to the development of hormone-resistant prostate cancer. 2006 , 33, 201-10, vii	49
1683	Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. 2006 , 175, 2312-6	37
1682	Clinical implications of our advancing knowledge of colorectal cancer genetics: inherited syndromes, prognosis, prevention, screening and therapeutics. 2006 , 86, 787-817	19
1681	Molecular biology of oral cavity squamous cell carcinoma. 2006 , 39, 229-47	18
1680	Are patients aware of the association between smoking and bladder cancer?. 2006 , 176, 2405-8; discussion 2408	46
1679	Small bowel tumors. 2006 , 16, 267-75	19
1678	Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. 2006 , 176, 787-92	29
1677	The continuing search for meaningful prognostic information from prostate biopsy. 2006 , 175, 16-7	16
1676	Lung cancer disparities in African Americans: health versus health care. 2006 , 27, 431-9, vi	21
1675	Novel imaging techniques in melanoma. 2006 , 15, 253-83	11
1674	The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. 2006 , 175, 1320-4; discussion 1324-5	168

1673	New clinical imaging modalities in prostate cancer. 2006 , 20, 811-30	8
1672	Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. 2006 , 176, 1349-53; discussion 1353	61
1671	New agents, combinations, and opportunities in the treatment of advanced and early-stage colon cancer. 2006 , 86, 1023-43	8
1670	New-onset diabetes and pancreatic cancer. 2006 , 4, 1366-72; quiz 1301	67
1669	Intraperitoneal chemotherapy for the prevention of transitional cell carcinoma implantation. 2006 , 175, 2317-22	10
1668	Predictive value of a positive fecal occult blood test increases as the severity of CKD worsens. 2006 , 48, 580-6	21
1667	A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. 2006 , 131, 797-808	147
1666	Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer. 2006 , 131, 900-10	53
1665	Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. 2006 , 131, 1418-30	93
1664	Optimizing therapy for patients with brain metastases. 2006 , 33, 299-306	11
1663	Hexyl aminolevulinate: in the detection of bladder cancer. 2006 , 66, 571-8; discussion 579-80	18
1662	Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. 2006 , 66, 791-820	80
1661	A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. 2006 , 26, 257-66	2
1660	TAILORx: trial assigning individualized options for treatment (Rx). 2006 , 7, 347-50	217
1659	A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. 2006 , 5, 363-7	26
1658	Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. 2006 , 4, 287-92	6
1657	Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer. 2006 , 8, 122-9	1
1656	Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma. 2006 , 6, 301-5	10

1655	[New prognostic and predictive factors in advanced colorectal cancer]. 2006 , 126, 541-8	1
1654	[Evaluation of efficacy and clinical impact of FDG-PET on patients with suspicion of recurrent cutaneous melanoma]. 2006 , 25, 301-11	3
1653	MR thermometry characterization of a hyperthermia ultrasound array designed using the k-space computational method. 2006 , 5, 56	4
1652	Methylation mediated silencing of TMS1/ASC gene in prostate cancer. 2006 , 5, 28	82
1651	Ether α -go-go potassium channel expression in soft tissue sarcoma patients. 2006 , 5, 42	76
1650	Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. 2006 , 5, 62	73
1649	Harnessing information and communication technologies to leverage scarce resources for cancer education, research and practice in developing countries. 2006 , 4, 1	23
1648	Cytokines, GM-CSF and IFN γ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. 2006 , 4, 16	11
1647	Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. 2006 , 4, 32	66
1646	The new era in cancer research. 2006 , 312, 1162-5	221
1645	Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. 2006 , 24, 3089-94	871
1644	Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. 2006 , 13, 508-17	193
1643	Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens. 2006 , 42, 58-62	14
1642	Secondary hormonal therapy for advanced prostate cancer. 2006 , 175, 27-34	125
1641	DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. 2006 , 355, 983-91	1424
1640	Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. 2006 , 7, 67-88	51
1639	Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. 2006 , 23, 74-9	96
1638	Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. 2006 , 5, 2169-76	32

1637	Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. 2006 , CD002093	79
1636	Current status of cetuximab for the treatment of patients with solid tumors. 2006 , 40, 241-50	30
1635	Enhancing the therapeutic index of radiation in multiple myeloma. 2006 , 3, 515-522	5
1634	Is there a role for immunotherapy in hepatocellular carcinoma?. 2006 , 38, 221-5	14
1633	Routine EUS-guided FNA for preoperative nodal staging in patients with esophageal carcinoma: is the juice worth the squeeze?. 2006 , 63, 212-4	6
1632	Determination of qualitative telomerase activity as an adjunct to the diagnosis of pancreatic adenocarcinoma by EUS-guided fine-needle aspiration. 2006 , 63, 648-54	43
1631	Preoperative diagnosis and management of thick-walled gallbladder based on bile cytology obtained by endoscopic transpapillary gallbladder drainage tube. 2006 , 64, 512-9	24
1630	ASGE guideline: colorectal cancer screening and surveillance. 2006 , 63, 546-57	277
1629	Is endoscopic screening before major surgical procedures warranted?. 2006 , 64, 375-8	3
1628	Synchronous abdominal soft-tissue sarcomas: an unusual case of upper-GI bleeding diagnosed by EUS-guided FNA. 2006 , 64, 655-8	
1627	Endoscopic management of radiation-induced complete upper esophageal obstruction with an antegrade-retrograde rendezvous technique. 2006 , 64, 822-8	66
1626	Successful recovery of esophageal patency in 2 patients with complete obstruction by using combined antegrade retrograde dilation procedure, needle knife, and EUS needle. 2006 , 64, 789-92	33
1625	Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. 2006 , 51, 143-58	277
1624	Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. 2006 , 51, 237-43	15
1623	Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. 2006 , 52, 67-74	25
1622	Detection of occult tumor cells in lymph nodes from non-small cell lung cancer patients using reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA with the evaluation of its sensitivity. 2006 , 52, 235-40	18
1621	Exercise capacity before and after an 8-week multidisciplinary inpatient rehabilitation program in lung cancer patients: a pilot study. 2006 , 52, 257-60	141
1620	Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. 2006 , 52, 207-12	38

1619	A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. 2006 , 52, 305-11	8
1618	Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer. 2006 , 52, 291-7	28
1617	Management of venous thromboembolism in patients with primary and metastatic brain tumors. 2006 , 24, 1310-8	125
1616	Wheat bran oil and its fractions inhibit human colon cancer cell growth and intestinal tumorigenesis in Apc(min/+) mice. 2006 , 54, 9792-7	37
1615	Cytotoxicity of organic compounds against ovarian cancer cells: a quantitative structure-activity relationship study. 2006 , 3, 441-50	18
1614	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. 2006 , 66, 944-50	446
1613	Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. 2006 , 12, 6403-9	640
1612	Tumor-protective and tumor-promoting actions of dietary whey proteins in an N-methyl-N-nitrosourea model of rat mammary carcinogenesis. 2006 , 55, 171-7	5
1611	Fractionation of grape seed extract and identification of gallic acid as one of the major active constituents causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. 2006 , 27, 1445-53	143
1610	Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. 2006 , 17, 220-9	15
1609	Preoperative diagnosis of extrapancreatic neural invasion in pancreatic cancer. 2006 , 4, 1479-82	37
1608	Clinical activity of pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. 2006 , 24, 4324-32	209
1607	Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. 2006 , 15, 1674-87	208
1606	Emerging and widening colorectal carcinoma disparities between Blacks and Whites in the United States (1975-2002). 2006 , 15, 792-7	91
1605	Altered levels of Smad2 and Smad4 are associated with human prostate carcinogenesis. 2006 , 9, 185-9	14
1604	Paternal relatives and family history of breast cancer. 2006 , 31, 265-8	22
1603	Screening for colorectal cancer in average-risk populations. 2006 , 119, 728-35	23
1602	Colon cancer and apoptosis. 2006 , 191, 517-26	114

1601	The evaluation and treatment implications of isolated pulmonary nodules in patients with a recent history of breast cancer. 2006 , 191, 641-5		21
1600	Prognostic factors for survival in pancreatic cancer: a population-based study. 2006 , 192, 322-9		90
1599	Cancer risk in endoscopically unresectable colon polyps. 2006 , 192, 644-8		22
1598	Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. 2006 , 192, 873-7		65
1597	Impact of hysterectomy and bilateral oophorectomy on race-specific rates of corpus, cervical, and ovarian cancers in the United States. 2006 , 16, 880-7		29
1596	Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. 2006 , 81, 1982-7; discussion 1987		13
1595	Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. 2006 , 81, 2004-7		54
1594	Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines. 2006 , 580, 5836-44		27
1593	Molecular advances in medullary thyroid cancer diagnostics. 2006 , 370, 2-8		26
1592	Total laparoscopic versus open surgery for stage 1 endometrial cancer: the LACE randomized controlled trial. 2006 , 27, 353-63		55
1591	Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. 2006 , 28, 953-9		16
1590	Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. 2006 , 12, 697-702		34
1589	Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 341, 478-82	3-4	43
1588	Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 342, 1263-72	3-4	61
1587	Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 343, 571-7	3-4	54
1586	[Breast cancer in men: are there similarities with breast cancer in women?]. 2006 , 34, 413-9		13
1585	Response to "Use of cervical cancer screening among insured women: the extent of missed opportunities" [Health Policy 73 (2005) 194-201]. 2006 , 77, 245-6		2
1584	Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs. 2006 , 236, 95-104		15

1583	Endocrine disrupting compounds and prostate cancer. 2006 , 241, 1-12	36
1582	Role of bone morphogenetic proteins in transitional cell carcinoma cells. 2006 , 241, 118-23	10
1581	Quantitative analysis of early chemically-induced pulmonary lesions in mice of varying susceptibilities to lung tumorigenesis. 2006 , 241, 197-202	33
1580	Delivery of hypericin for photodynamic applications. 2006 , 241, 23-30	35
1579	Apoptotic and proliferation indexes in primary superficial bladder tumors. 2006 , 242, 266-72	17
1578	Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. 2006 , 244, 274-88	43
1577	Chemoradiation therapy: the evolving role in head and neck cancer and its application to oral cavity tumors. 2006 , 18, 605-14	1
1576	Advances in the detection and diagnosis of oral precancerous and cancerous lesions. 2006 , 18, 465-82	10
1575	Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. 2006 , 61, 142-53	77
1574	Imaging of endometrial adenocarcinoma. 2006 , 61, 545-55	77
1573	Hormone refractory prostate cancer: Management and advances. 2006 , 32, 90-100	24
1572	Antibiotics plus granulocyte colony-stimulating factor reduces febrile neutropenia in the first cycle of chemotherapy in people with small-cell lung cancer. 2006 , 32, 234-8	1
1571	Irinotecan in the treatment of colorectal cancer. 2006 , 32, 491-503	111
1570	Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. 2006 , 32, 456-70	26
1569	Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. 2006 , 32, 471-82	60
1568	Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. 2006 , 35, 21-8	90
1567	PSA and the Detection of Prostate Cancer After 2005. Part I. 2006 , 4, 2-12	7
1566	PSA and the Detection of Prostate Cancer After 2005. Part II: Ways Out of the PSA Dilemma?. 2006 , 4, 71-81	2

1565	Therapy of Treatment Failure After Curative Treatment of Prostate Cancer. 2006 , 4, 228-240	6
1564	Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice?. 2006 , 42, 8-16	28
1563	Thalidomide and lenalidomide in the treatment of multiple myeloma. 2006 , 42, 1612-22	97
1562	Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique. 2006 , 42, 3073-8	19
1561	Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel. 2006 , 42, 3267-73	22
1560	Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha. 2006 , 32, 371-80	53
1559	Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. 2006 , 66, 11840-50	88
1558	Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer. 2006 , 27, 192-223	31
1557	Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. 2006 , 247, 4-21	139
1556	An adjunctive preventive treatment for cancer: ultraviolet light and ginkgo biloba, together with other antioxidants, are a safe and powerful, but largely ignored, treatment option for the prevention of cancer. 2006 , 66, 1152-6	5
1555	Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesis. 2006 , 358, 310-29	11
1554	Prostaglandins and the colon cancer connection. 2006 , 12, 240-4	10
1553	Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. 2006 , 37, 1583-91	107
1552	Skin cancer in skin of color. 2006 , 55, 741-60; quiz 761-4	365
1551	Clinical outcomes from skin screening clinics within a community-based melanoma screening program. 2006 , 54, 105-14	80
1550	Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. 2006 , 100, 24-33	15
1549	Inositol hexaphosphate (IP6) inhibits cellular proliferation in melanoma. 2006 , 133, 3-6	31
1548	Cytotoxic gene therapy for human breast cancer in vitro. 2006 , 136, 154-60	4

1547	Annual productivity costs due to cervical cancer mortality in the United States. 2006 , 16, 236-42	24
1546	Quality of life outcomes in laryngeal and oropharyngeal cancer patients after chemoradiation. 2006 , 135, 565-70	24
1545	The trajectory of biomarkers in symptom management for older adults with cancer. 2006 , 22, 31-5	8
1544	Radioprotectants: adding quality of life to survivorship?. 2006 , 22, 249-56	13
1543	Leptomeningeal carcinomatosis in a patient with metastatic prostate cancer: case report and literature review. 2006 , 65, 372-5, discussion 375-6	29
1542	Prevention and early detection of oral and pharyngeal cancer in veterans. 2006 , 102, 625-31	5
1541	Bone sarcomas. 2006 , 1, 65-74	3
1540	Cancers of the bowel and hepatobiliary tract. 2006 , 1, 353-365	1
1539	New approaches to identification of antigenic candidates for future prostate cancer immunotherapy. 2006 , 1, 273-284	4
1538	Does year of radical prostatectomy independently predict outcome in prostate cancer?. 2006 , 67, 368-72	7
1537	Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. 2006 , 67, 354-9	20
1536	Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. 2006 , 67, 349-53	18
1535	Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. 2006 , 67, 1257-61	75
1534	Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. 2006 , 67, 1235-40	46
1533	Introduction. 2006 , 67, 1-2	1
1532	Neuroendocrine differentiation in prostate cancer. 2006 , 68, 2-8	43
1531	Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma. 2006 , 68, 296-301	31
1530	Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. 2006 , 68, 337-41	17

1529	Inactivation of myopodin expression associated with prostate cancer relapse. 2006 , 68, 578-82	18
1528	Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. 2006 , 68, 518-22	29
1527	Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer. 2006 , 68, 898-904	9
1526	Association between family history of prostate and breast cancer among African-American men with prostate cancer. 2006 , 68, 1072-6	11
1525	Prostate adenocarcinoma manifesting as generalized lymphadenopathy. 2006 , 24, 216-9	12
1524	Surveillance in stage I testicular seminoma. 2006 , 24, 75-9	15
1523	Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: preliminary results. 2006 , 24, 109-15	17
1522	Single nucleotide polymorphisms: early diagnosis and risk assessment in genitourinary malignancy. 2006 , 24, 224-30	
1521	The use of thalidomide in androgen-independent prostate cancer. 2006 , 24, 246-9	12
1520	Current status of anti-angiogenesis therapy for prostate cancer. 2006 , 24, 260-8	16
1519	Molecular markers in bladder cancer: a critical appraisal. 2006 , 24, 326-37	84
1518	Anti-angiogenic and cytotoxic targeted systemic therapy for high-risk prostate cancer. 2006 , 24, 243-245	
1517	Bladder cancer: toward state of the art multidisciplinary molecular medicine. 2006 , 24, 322-3	1
1516	Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. 2006 , 24, 465-71	16
1515	Nucleic acid-based marker approaches to urologic cancers. 2006 , 24, 510-27	16
1514	Molecular markers of prostate cancer. 2006 , 24, 538-51	58
1513	The epidemiology of genital human papillomavirus infection. 2006 , 24 Suppl 1, S1-15	266
1512	Tp53-associated growth arrest and DNA damage repair gene expression is attenuated in mammary epithelial cells of rats fed whey proteins. 2006 , 136, 1156-60	8

1511	Epidemiology of Hodgkin's and Non-Hodgkin's Lymphomas. 2006 , 127-138	1
1510	Radioactive seed localization for excision of non-palpable in-transit metastatic melanoma. 2006 , 1, 54-7	5
1509	Modern management of rectal cancer: a 2006 update. 2006 , 12, 3186-95	99
1508	Self-surveillance for genetic predisposition to cancer: behaviors and emotions. 2006 , 33, 221-31	11
1507	Changes in the sonographic appearance of the uterus after discontinuation of tamoxifen therapy. 2006 , 25, 469-73	14
1506	Analysis of the risk factors for incidental carcinoma of the prostate in patients with benign prostatic hyperplasia. 2006 , 61, 545-50	13
1505	Location of lung carcinoma in relation to the smoking habit and gender. 2006 , 32, 510-4	11
1504	Updates on esophageal and gastric cancers. 2006 , 12, 3237-42	97
1503	Bleomycin, Vincristine, Lomustine, and Dacarbazine (BOLD) with Interferon Regimen for Metastatic Melanoma. 2006 , 41, 232-294	
1502	The KISS1 metastasis suppressor: mechanistic insights and clinical utility. 2006 , 11, 647-59	63
1501	Chemotherapeutic implications in microsatellite unstable colorectal cancer. 2006 , 2, 51-60	62
1500	Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. 2006 , 12, 3878-82	29
1499	Screening for colon cancer. 2006 , 6, S13-21	7
1498	High dry bean intake and reduced risk of advanced colorectal adenoma recurrence among participants in the polyp prevention trial. 2006 , 136, 1896-903	75
1497	The BARD1 Cys557Ser variant and breast cancer risk in Iceland. 2006 , 3, e217	54
1496	A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma. 2006 , 2006, 64374	23
1495	Prostate Cancer. 2006 , 377-392	
1494	Resection of colorectal liver metastases: current perspectives. 2006 , 13, 32-41	67

1493	Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer. 2006 , 13, 42-7	22
1492	Carcinosarcoma of the Pancreas Arising in a Mucinous Cystic Neoplasm. 2006 , 72, 351-355	20
1491	North Carolina dental hygienists' oral cancer knowledge and opinions: implications for education. 2006 , 21, 151-6	6
1490	Editorial. 2006 , 7, 1-2	78
1489	Anti-Estrogenic Activity of Prenylated Isoflavones from <i>Millettia pachycarpa</i> : Implications for Pharmacophores and Unique Mechanisms. 2006 , 52, 186-191	31
1488	Soyfood intake in the prevention of breast cancer risk in women: a meta-analysis of observational epidemiological studies. 2006 , 52, 428-36	72
1487	Herbal medicine for relapse and metastasis in patients operated for colorectal cancer. 2006 ,	1
1486	Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative ¹⁵³ Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. 2006 , 107, 4063-70	33
1485	CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. 2006 , 108, 2384-91	77
1484	Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells. 2006 , 136, 75-82	48
1483	Nucleic acid quantification and disease outcome prediction in colorectal cancer. 2006 , 3, 207-216	6
1482	Both selenoproteins and low molecular weight selenocompounds reduce colon cancer risk in mice with genetically impaired selenoprotein expression. 2006 , 136, 1311-7	125
1481	Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact. 2006 , 331, 139-49	10
1480	Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care. 2006 , 1, 692-696	10
1479	A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report. 2006 , 1, 972-978	16
1478	Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients with Advanced Non-small Cell Lung Cancer. 2006 , 1, 832-836	4
1477	Lung Cancer Late-Detection, Multimodality Strategy. 2006 , 1, 105	
1476	Definitive Radiotherapy for Stage I Non-small Cell Lung Cancer: Ain???t Nothing Like the Real Thing?. 2006 , 1, 763-765	1

1475	Microimaging Characterization of a B16-F10 Melanoma Metastasis Mouse Model. 2006 , 5, 7290.2006.00011	32
1474	Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. 2006 , 8, 576-82	58
1473	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. 2006 , 1, 1010-1019	1
1472	Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care. 2006 , 1, 692-696	35
1471	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. 2006 , 1, 52-60	
1470	Traitement conservateur du cancer du col utérin. 2006 , 1, 1-13	
1469	A population-based study of the quality of life of cancer survivors and their family caregivers. 2006 , 29, 120-31; quiz 132-3	163
1468	Pancreaticoduodenectomy (classical Whipple) versus pylorus-preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma. 2006 ,	3
1467	Pancreatic cancer: from bench to 5-year survival. 2006 , 33, 111-8	98
1466	Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. 2006 , 16, 555-63	18
1465	Microcarcinoma of the thyroid. 2006 , 13, 69-75	74
1464	New approaches in hormone refractory prostate cancer. 2006 , 29, 196-201	11
1463	Effect of long-term treatment with raloxifene on mammary density in postmenopausal women. 2006 , 13, 787-92	15
1462	PET/CT imaging of lung cancer. 2006 , 21, 123-36	44
1461	Utility of positron emission tomography in sarcomas. 2006 , 18, 369-73	44
1460	The Influence of relational factors on men's adjustment to their partners' newly-diagnosed breast cancer. 2005 , 23, 23-43	19
1459	Clinically Significant Molecular Markers for Urologic Disease: Focus on Bladder, Kidney, and Prostate Cancer. 2006 , 37, 429-435	
1458	Dairy products and health: a review of the epidemiological evidence. 2006 , 96 Suppl 1, S94-9	49

1457	The shifting paradigm of cancer care. The many needs of cancer survivors are starting to attract attention. 2006 , 106, 16-9	6
1456	Proposed screening recommendations for male breast cancer. 2006 , 31, 62-3	4
1455	Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer?. 2006 , 1, 205-10	76
1454	A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report. 2006 , 1, 972-978	26
1453	Methodological issues in the investigation of ginseng as an intervention for fatigue. 2006 , 20, 183-9	12
1452	The shifting paradigm of cancer care. 2006 , 29, 16-9	2
1451	Supporting health promotion in adults with cancer. 2006 , 29, 52S-60S	6
1450	A review of first-line treatment for small-cell lung cancer. 2006 , 1, 270-8	88
1449	Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. 2006 , 107, 997-1005	25
1448	A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. 2006 , 130, 694-701	54
1447	Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer. 2006 , 1, 635-647	3
1446	Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. 2006 , 1, 245-51	21
1445	The incidental postmenopausal adnexal mass. 2006 , 49, 506-16	47
1444	Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients with Advanced Non-small Cell Lung Cancer. 2006 , 1, 832-836	10
1443	Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. 2006 , 12, 299-304	9
1442	Definitive Radiotherapy for Stage I Non-small Cell Lung Cancer: Ain't Nothing Like the Real Thing?. 2006 , 1, 763-765	1
1441	Lung Cancer Late-Detection, Multimodality Strategy. 2006 , 1, 105	
1440	Prognostic Value of Fluorodeoxyglucose Positron Emission Tomography in Non-small Cell Lung Cancer: A Review. 2006 , 1, 152-159	24

1439	Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594. 2006 , 1, 441-446	24
1438	Qualitative analysis of couples' experience with prostate cancer by age cohort. 2006 , 29, 367-77	48
1437	Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors. 2006 , 18, 258-65	4
1436	18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. 2006 , 27, 795-802	68
1435	Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases. 2006 , 30, 883-91	71
1434	Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. 2006 , 22, 231-8; discussion 239-40	115
1433	A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma. 2006 , 29, 555-61	5
1432	A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. 2006 , 17, 1067-73	12
1431	Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. 2006 , 107, 77-85	327
1430	What about chemoprevention for melanoma?. 2006 , 18, 180-4	8
1429	Signal transduction cross-talk during colorectal tumorigenesis. 2006 , 13, 270-4	19
1428	Oral contrast adherence to polyps on CT colonography. 2006 , 30, 51-7	40
1427	Cancer mortality among populations residing in counties near the Hanford site, 1950-2000. 2006 , 90, 431-45	12
1426	Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy. 2006 , 68, 555-62	49
1425	Is liver resection justified for patients with hepatic metastases from breast cancer?. 2006 , 244, 897-907; discussion 907-8	254
1424	Telephone outreach to increase colorectal cancer screening in an urban minority population. 2006 , 96, 2246-53	82
1423	BRAF mutation in thyroid carcinogenesis and its clinical implications. 2006 , 13, 455-459	2
1422	Microinvasive Carcinoma of the Cervix. 2006 , 11, 121-129	1

1421	Melanoma of the ear: treatment and survival probabilities based on 199 patients. 2006 , 57, 70-6	41
1420	Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. 2006 , 22, 587-600	64
1419	Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. 2006 , 17, 95-102	32
1418	Bladder cancer. 2006 , 18, 277-83	11
1417	Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?. 2006 , 29, 232-9	28
1416	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. 2006 , 16, 475-83	90
1415	The role of cholesterol in prostate cancer. 2006 , 9, 379-85	112
1414	Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. 2006 , 33, 246-9	17
1413	Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer?. 2006 , 107, 71-6	27
1412	Diagnosis and management of epithelial ovarian cancer. 2006 , 107, 1399-410	150
1411	A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. 2006 , 108, 1375-9	131
1410	Targeting angiogenesis for the treatment of sarcoma. 2006 , 18, 354-9	35
1409	Colorectal cancer in Hispanics: a population at risk for earlier onset, advanced disease, and decreased survival. 2006 , 29, 123-6	44
1408	The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. 2006 , 18, 29-34	55
1407	Breast reconstruction. 2006 , 49, 401-13	4
1406	Intraperitoneal chemotherapy for epithelial ovarian cancer. 2006 , 61, 529-34	1
1405	Molecular basis of pregnancy-induced breast cancer protection. 2006 , 15, 306-42	63
1404	Tissue pretreatment with formic acid might lower HercepTest scores in breast cancer. 2006 , 15, 237-42	2

1403	High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. 2006 , 243, 684-90; discussion 691-2	44
1402	Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus. 2006 , 243, 824-30; discussion 830-2	29
1401	Advances in chemotherapy of non-small cell lung cancer. 2006 , 130, 1211-9	139
1400	Intra- and inter-radiation therapist reproducibility of daily isocenter verification using prostatic fiducial markers. 2006 , 1, 2	20
1399	A prospective study of differences in duodenum compared to remaining small bowel motion between radiation treatments: implications for radiation dose escalation in carcinoma of the pancreas. 2006 , 1, 33	21
1398	Pool&am structure based microfluidic devices for filtering tumor cells from blood mixtures. 2006 , 38, 996-1003	21
1397	The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. 2006 , 208, 699-707	90
1396	Depressive symptoms, eating psychopathology, and physical activity in obese breast cancer survivors. 2006 , 15, 453-62	19
1395	Differential attenuation of oxidative/nitrosative injuries in early prostatic neoplastic lesions in TRAMP mice by dietary antioxidants. 2006 , 66, 57-69	44
1394	Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. 2006 , 66, 200-10	14
1393	Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. 2006 , 66, 591-603	41
1392	Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer. 2006 , 66, 294-304	40
1391	Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. 2006 , 66, 317-25	42
1390	Methylation of the ASC gene promoter is associated with aggressive prostate cancer. 2006 , 66, 687-95	41
1389	Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. 2006 , 66, 421-9	85
1388	Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers. 2006 , 66, 801-10	32
1387	Expression of prothymosin alpha is correlated with development and progression in human prostate cancers. 2006 , 66, 463-9	31
1386	Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. 2006 , 66, 811-21	100

1385	Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy. 2006 , 66, 1620-30	15
1384	Presence of prostate cancer metastasis correlates with lower lymph node reactivity. 2006 , 66, 1710-20	24
1383	Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer. 2006 , 66, 1487-97	13
1382	Quantitative multi-gene expression profiling of primary prostate cancer. 2006 , 66, 1521-34	91
1381	A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. 2006 , 66, 1556-64	43
1380	Control of prostate cancer spheroid growth using ²¹³ Bi-labeled multiple targeted alpha radioimmunoconjugates. 2006 , 66, 1753-67	12
1379	Identification of S-nitrosylated proteins after chronic exposure of colon epithelial cells to deoxycholate. 2006 , 6, 1654-62	40
1378	Expanding the protein catalogue in the proteome reference map of human breast cancer cells. 2006 , 6, 2609-25	35
1377	Breast cancer in limited-resource countries: health care systems and public policy. 2006 , 12 Suppl 1, S54-69	106
1376	Diagnosis, treatment, and management of breast cancer in previously augmented women. 2006 , 12, 343-8	35
1375	Follow-up recommendations for benign breast biopsies. 2006 , 12, 413-7	29
1374	Does butyrate protect from colorectal cancer?. 2006 , 21, 209-18	139
1373	In search of a familial cancer risk assessment tool. 2007 , 71, 76-83	15
1372	Mini-flank supra-11th rib incision for open partial or radical nephrectomy. 2006 , 97, 149-56	44
1371	Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. 2006 , 97, 997-1001	105
1370	Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. 2006 , 97, 1202-7	36
1369	Telomerase activity in disseminated prostate cancer cells. 2006 , 97, 1309-13	35
1368	Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. 2006 , 97, 1190-3	81

1367	Concurrent radical retropubic prostatectomy and Lichtenstein inguinal hernia repair through a single modified Pfannenstiel incision: a 3-year experience. 2006 , 98, 341-4	18
1366	Epigenetics of lung cancer. 2006 , 11, 355-65	46
1365	Early detection and chemoprevention of lung cancer. 2006 , 11, 366-72	12
1364	Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. 2006 , 13, 211-7	21
1363	Lack of association between the incidence of testicular germ cell tumors and Y-chromosome haplogroups in the Japanese population. 2006 , 13, 1212-7	4
1362	Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. 2006 , 19, 69-72	40
1361	Predictive and prognostic molecular markers in outcome of esophageal cancer. 2006 , 19, 425-32	62
1360	Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. 2006 , 32, 330-7	13
1359	The efficacy of oral lumenoscopy (ViziLite) in visualizing oral mucosal lesions. 2006 , 26, 171-4	43
1358	Colorectal cancer screening in the elderly population: disparities by dual Medicare-Medicaid enrollment status. 2006 , 41, 2136-54	33
1357	Fertility preservation in female oncology patients. 2006 , 46, 15-23	22
1356	Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. 2006 , 16, 210-8	53
1355	Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. 2006 , 16 Suppl 1, 152-65	41
1354	BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. 2006 , 16 Suppl 1, 166-71	65
1353	Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. 2006 , 16, 1668-72	18
1352	Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists. 2006 , 21, 678-82	89
1351	Cutaneous melanoma: family screening and genetic testing. 2006 , 19, 1-8	15
1350	Cutaneous melanoma: available therapy for metastatic disease. 2006 , 19, 19-25	106

1349	An overview of ethnicity and assessment of family history in primary care settings. 2006 , 18, 447-56	14
1348	Non-Hodgkin's lymphoma as an exemplar of the effects of genetics and genomics. 2006 , 38, 335-43	5
1347	Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter 2006, 155, 570-3	49
1346	Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. 2006 , 135, 174-83	67
1345	Urodilatin and four cardiac hormones decrease human renal carcinoma cell numbers. 2006 , 36, 810-9	29
1344	Expression patterns of polo-like kinase 1 in human gastric cancer. 2006 , 97, 271-6	40
1343	Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. 2006 , 23, 145-54	27
1342	The combination of millimetres of cancer and Gleason index in core biopsy is a predictor of extraprostatic disease. 2006 , 48, 663-7	17
1341	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. 2006 , 8, 1053-63	270
1340	Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. 2006 , 6, 360-8	188
1339	Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. 2006 , 94, 275-80	341
1338	Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa. 2006 , 94, 586-92	39
1337	Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. 2006 , 94, 642-6	465
1336	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. 2006 , 95, 289-97	37
1335	Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. 2006 , 95, 699-704	212
1334	Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. 2006 , 19, 581-7	48
1333	Prostate cancer detected by uPM3: radical prostatectomy findings. 2006 , 19, 630-3	14
1332	Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications. 2006 , 19, 797-803	30

1331	Enhanced expression of hedgehog signaling molecules in squamous cell carcinoma of uterine cervix and its precursor lesions. 2006 , 19, 1139-47	48
1330	Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. 2006 , 19, 1261-9	138
1329	Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). 2006 , 19, 1386-94	121
1328	Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. 2006 , 19, 1487-97	51
1327	Graft-versus-tumor effects on murine mammary carcinoma in a model of nonmyeloablative haploidentical stem cell transplantation. 2006 , 37, 1043-9	3
1326	Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. 2006 , 13, 658-63	19
1325	Papillomaviruses as targets for cancer gene therapy. 2006 , 13, 445-50	26
1324	siRNA-based approaches in cancer therapy. 2006 , 13, 819-29	254
1323	Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. 2006 , 13, 60-6	57
1322	MCM7 amplification and overexpression are associated with prostate cancer progression. 2006 , 25, 1090-8	142
1321	Mitochondrial DNA determines androgen dependence in prostate cancer cell lines. 2006 , 25, 1437-45	70
1320	MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. 2006 , 25, 2987-98	172
1319	Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. 2006 , 25, 3719-34	78
1318	An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. 2006 , 25, 3994-4008	431
1317	Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis. 2006 , 25, 4207-16	21
1316	Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. 2006 , 25, 6574-81	50
1315	Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid. 2006 , 25, 5315-25	23
1314	Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. 2006 , 25, 6997-7008	85

1313	Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. 2006 , 25, 7311-23	64
1312	Neck management in patients undergoing postradiotherapy salvage laryngeal surgery for recurrent/persistent laryngeal cancer. 2006 , 116, 1864-6	64
1311	Sexual function after external-beam radiotherapy for prostate cancer: what do we know?. 2006 , 57, 165-73	54
1310	Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). 2006 , 58, 221-30	15
1309	Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. 2006 , 59, 250-5	29
1308	Molecular predictors of response and outcome in ovarian cancer. 2006 , 60, 19-37	33
1307	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. 2006 , 60, 99-111	30
1306	The case for adjuvant chemoradiation for pancreatic cancer. 2006 , 20, 403-16	21
1305	Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment. 2006 , 36, 634-55	20
1304	Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen. 2006 , 14, 67-76	14
1303	Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. 2006 , 326, 174-81	146
1302	Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. 2006 , 64, 6-12	88
1301	Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. 2006 , 64, 1395-400	73
1300	Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years. 2006 , 65, 100-6	71
1299	Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. 2006 , 64, 1482-94	12
1298	Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. 2006 , 65, 412-25	305
1297	FDG-PET/CT in the evaluation of anal carcinoma. 2006 , 65, 720-5	151
1296	The potential for dose escalation in lung cancer as a result of systematically reducing margins used to generate planning target volume. 2006 , 65, 573-86	22

1295	Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. 2006 , 65, 1087-96	245
1294	Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck. 2006 , 65, 1051-62	62
1293	Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. 2006 , 65, 1106-11	102
1292	Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. 2006 , 66, 117-25	243
1291	A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. 2006 , 66, 439-44	55
1290	External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. 2006 , 66, 772-9	99
1289	Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center. 2006 , 10, 63-8	20
1288	Adjuvant treatment strategies for pancreatic cancer. 2006 , 10, 916-26	12
1287	Computer algorithm for analysing breast tumor angiogenesis using 3-D power Doppler ultrasound. 2006 , 32, 1499-508	14
1286	Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. 2006 , 8, 99-106	307
1285	Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. 2006 , 16, 109-42	1553
1284	Multicolor quantum dots for molecular diagnostics of cancer. 2006 , 6, 231-44	288
1283	A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. 2006 , 16, 927-38	74
1282	MR colonography: current status. 2006 , 16, 1519-26	20
1281	Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients. 2006 , 1075, 197-203	27
1280	Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. 2006 , 1075, 230-4	47
1279	Carcinogen exposure and epigenetic silencing in bladder cancer. 2006 , 1076, 810-21	44
1278	Molecular screening for hereditary nonpolyposis colorectal cancer in Bulgaria. 2006 , 1, 128-135	1

1277	Degradation and beyond: control of androgen receptor activity by the proteasome system. 2006 , 11, 109-31	30
1276	5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives. 2006 , 82, 994-1015	156
1275	A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. 2006 , 64, 455-60	33
1274	Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma. 2006 , 8, 22-8	13
1273	Genetics and pathology of pancreatic cancer. 2006 , 8, 324-36	30
1272	18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. 2006 , 13, 677-84	38
1271	Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. 2006 , 13, 353-62	52
1270	Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. 2006 , 13, 823-35	93
1269	Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. 2006 , 13, 933-9	103
1268	Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. 2006 , 13, 1021-34	44
1267	Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy. 2006 , 13, 1099-104	91
1266	Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. 2006 , 13, 1189-200	190
1265	The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. 2006 , 13, 1386-92	117
1264	Patient satisfaction with quality of life as a predictor of survival in pancreatic cancer. 2006 , 37, 35-44	23
1263	Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. 2006 , 37, 7-14	7
1262	Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. 2006 , 23, 507-13	11
1261	Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. 2006 , 194, 1119-26; discussion 1126-8	17
1260	Microscopic hematuria as a predictive factor for detecting bladder cancer at cystoscopy in women with irritative voiding symptoms. 2006 , 194, 1423-6	10

1259	Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. 2006 , 195, 568-74; discussion 574-6	48	
1258	Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. 2006 , 195, 1862-8	54	
1257	Current concepts in neuroendocrine cancer metabolism. 2006 , 9, 193-202	5	
1256	Measuring meaning in life following cancer. 2006 , 15, 1355-71	48	
1255	A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). 2006 , 24, 343-6	13	
1254	Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. 2006 , 24, 359-63	7	
1253	Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. 2006 , 24, 447-54	32	
1252	A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. 2007 , 25, 181-5	25	
1251	Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. 2007 , 25, 173-80	54	
1250	2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. 2006 , 8, 309-14	17	
1249	Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D: -glucose positron emission tomography: variations with age, breast density, and menopausal status. 2006 , 8, 355-62	43	
1248	Time spent in the United States and breast cancer screening behaviors among ethnically diverse immigrant women: evidence for acculturation?. 2006 , 8, 347-58	66	
1247	Inter- and intra-ethnic differences for female breast carcinoma incidence in the continental United States and in the state of Hawaii. 2006 , 97, 57-65	13	
1246	Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. 2006 , 98, 267-74	160	
1245	LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. 2006 , 99, 163-76	148	
1244	A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. 2006 , 99, 177-84	72	
1243	Relation of anthropometric measurements to ovarian cancer risk in a population-based case-control study (United States). <i>Cancer Causes and Control</i> , 2006 , 17, 459-67	2.8	19
1242	Do centralised skin screening clinics increase participation in melanoma screening (Australia)?. <i>Cancer Causes and Control</i> , 2006 , 17, 161-8	2.8	12

1241	Regular use of aspirin and prostate cancer risk (United States). <i>Cancer Causes and Control</i> , 2006 , 17, 251-6.8		29
1240	Recreational physical activity and prostate cancer risk (United States). <i>Cancer Causes and Control</i> , 2006 , 17, 831-41	2.8	47
1239	Mammography screening after breast cancer diagnosis in a first degree female relative: age group differences (United States). <i>Cancer Causes and Control</i> , 2006 , 17, 1053-65	2.8	9
1238	Molecular mechanisms of metastasis. 2006 , 25, 203-20		88
1237	Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. 2006 , 23, 209-22		35
1236	Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase. 2006 , 23, 269-78		25
1235	Shift of tumor features in patients with clinically localized prostate cancer undergoing radical prostatectomy since the beginning of the PSA era. 2006 , 118, 348-54		3
1234	The role of epigenetic alterations in pancreatic cancer. 2006 , 13, 286-95		68
1233	A patient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. 2006 , 49, 319-29		48
1232	Vascular endothelial growth factor-C expression and lymphangiogenesis in colorectal cancer. 2006 , 38, 149-154		
1231	Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. 2006 , 9, 101-10		42
1230	Clinical characteristics of a second small nodule(s) associated with cT1-2N0M0 non-small-cell lung cancer. 2006 , 184, 273-8		2
1229	ICAM gene cluster SNPs and prostate cancer risk in African Americans. 2006 , 120, 69-76		27
1228	Elevated male European and female African contributions to the genomes of African American individuals. 2007 , 120, 713-22		66
1227	Innovative Therapiekonzepte beim Ovarialkarzinom. 2006 , 39, 791-796		
1226	[Soft tissue carcinoma. Epidemiology, diagnostics and therapy]. 2006 , 35, 1269-76; quiz 1277		1
1225	Long-term outcomes of the surgical management of renal cell carcinoma. 2006 , 24, 255-66		41
1224	Improving outcomes with radical cystectomy for high-grade invasive bladder cancer. 2006 , 24, 509-16		19

1223	State-of-the-art management of metastatic disease at initial presentation or recurrence. 2006 , 24, 543-56	13
1222	Nodal staging in genitourinary cancers. 2006 , 31, 644-51	12
1221	Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. 2006 , 31, 490-9	23
1220	Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. 2006 , 55, 1294-8	134
1219	Tumor escape mechanisms in prostate cancer. 2007 , 56, 81-7	60
1218	A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. 2006 , 58, 570-6	20
1217	A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. 2006 , 58, 759-64	116
1216	The impact and role of EGFR gene mutation on non-small cell lung cancer. 2006 , 58, 25-31	7
1215	[Carcinomas of the distal bile duct]. 2006 , 77, 335-40	8
1214	[Proteome analysis--basis for individualized pancreatic carcinoma therapy?]. 2006 , 47 Suppl 1, S40-8	4
1213	[Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis]. 2006 , 45, 1293-4, 1296-9	4
1212	Diabetes mellitus and risk of bladder cancer: a meta-analysis. 2006 , 49, 2819-23	237
1211	Prophylactic oophorectomy for ovarian cancer. 2006 , 6, 12-19	
1210	Gene therapy developments for pancreatic cancer. 2006 , 20, 285-98	28
1209	What's new in pancreatic cancer treatment pipeline?. 2006 , 20, 315-26	9
1208	Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. 2006 , 60, 201-15	137
1207	Durability of portal venous reconstruction following resection during pancreaticoduodenectomy. 2006 , 10, 1371-5	96
1206	A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. 2006 , 10, 1338-45; discussion 1345-6	249

1205	Laparoscopic treatment of colorectal neoplasia. 2006 , 9, 256-64	3
1204	Four cardiac hormones eliminate up to 82% of human medullary thyroid carcinoma cells within 24 hours. 2006 , 30, 325-32	17
1203	The European organization for research and treatment of cancer quality of life questionnaire: implications for prognosis in pancreatic cancer. 2006 , 37, 65-73	12
1202	Present state of the Mini-Invasive Surgery (MIS) in esophageal and gastric cancer. 2006 , 8, 173-7	1
1201	Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer. 2006 , 8, 611-5	10
1200	Epidemiology and prevention of cutaneous melanoma. 2006 , 7, 181-6	29
1199	Chemotherapeutic options for primary brain tumors. 2006 , 7, 467-78	14
1198	Management of small cell lung cancer. 2006 , 7, 59-68	19
1197	Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E2 signaling: Recent advances in basic biology. 2006 , 2, 60-65	
1196	Neoadjuvant and adjuvant therapy combined with resection of hepatic colorectal cancer metastases. 2006 , 2, 81-84	
1195	Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. 2006 , 2, 85-93	2
1194	Chemoprophylaxis of colon cancer. 2006 , 2, 13-19	1
1193	Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. 2006 , 8, 111-20	4
1192	New aspects of the treatment of chronic lymphocytic leukemia. 2006 , 1, 251-7	
1191	Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. 2006 , 1, 171-9	13
1190	Turning cervix cancer into a "rare disease": is society prepared to do what is required to make this a reality?. 2006 , 8, 1-2	
1189	Adjuvant therapy for colon cancer. 2006 , 8, 161-6	1
1188	Preoperative and adjuvant treatment of localized rectal cancer. 2006 , 8, 167-73	8

1187	Gastric cancer: an update. 2006 , 8, 183-91	6
1186	New treatments for superficial bladder cancer. 2006 , 8, 201-5	0
1185	Targeted approaches for the management of metastatic prostate cancer. 2006 , 8, 206-12	3
1184	Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer. 2006 , 8, 213-20	7
1183	The role of bisphosphonates in the management of prostate cancer. 2006 , 8, 221-7	9
1182	Second-line treatment of small-cell lung cancer. 2006 , 8, 258-64	13
1181	The role of human papillomavirus in squamous carcinoma of the head and neck. 2006 , 8, 130-9	33
1180	Dealing with non-cancerous findings of prostate biopsy. 2006 , 4, 109-115	
1179	Prostate cancer detection strategies. 2006 , 7, 181-5	2
1178	Dealing with non-cancerous findings on prostate biopsy. 2006 , 7, 186-92	3
1177	Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools. 2006 , 7, 8-15	3
1176	Cell type-specific analyses for identifying prostate cancer biomarkers. 2006 , 7, 57-63	1
1175	Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes. 2006 , 45, 235-42	12
1174	Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. 2006 , 100, 133-8	51
1173	Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. 2006 , 100, 33-7	130
1172	Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. 2006 , 100, 283-7	126
1171	Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. 2006 , 100, 330-7	75
1170	Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. 2006 , 100, 349-54	80

1169	Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes. 2006 , 101, 24-7	24
1168	Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. 2006 , 101, 126-31	89
1167	Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. 2006 , 101, 140-2	62
1166	Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. 2006 , 101, 280-6	69
1165	Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. 2006 , 101, 296-304	41
1164	Gender of offspring and maternal ovarian cancer risk. 2006 , 101, 476-80	9
1163	The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. 2006 , 101, 470-5	100
1162	Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. 2006 , 101, 499-502	7
1161	Molecular profiling of endometrial cancers from African-American and Caucasian women. 2006 , 101, 209-13	31
1160	Advanced endometrial cancer with serous metastasis in a 17-year-old. 2006 , 101, 356-9	5
1159	Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. 2006 , 102, 270-7	29
1158	Surgical resection of recurrent endometrial carcinoma. 2006 , 102, 480-8	60
1157	Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. 2006 , 102, 134-9	87
1156	Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. 2006 , 101, 200-8	99
1155	The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. 2006 , 103, 87-93	62
1154	Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. 2006 , 103, 25-30	60
1153	Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. 2006 , 103, 120-6	65
1152	Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. 2006 , 103, 160-4	9

1151	CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. 2006 , 103, 212-8	18
1150	Conservative treatment of reproductive and sexual function in young woman with squamous carcinoma of the vagina. 2006 , 103, 234-7	15
1149	Is peritoneal cytology a prognostic factor of endometrial cancer confined to the uterus?. 2006 , 103, 277-80	41
1148	Endometrial cancer in Kentucky: the impact of age, smoking status, and rural residence. 2006 , 103, 300-6	31
1147	Salvage cytoreductive surgery for recurrent endometrial cancer. 2006 , 103, 281-7	51
1146	Paraneoplastic encephalomyelitis: a case report and review of the literature. 2006 , 102, 593-5	0
1145	Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell lines. 2006 , 103, 417-24	35
1144	Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. 2006 , 103, 518-22	17
1143	Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. 2006 , 103, 523-6	43
1142	What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. 2006 , 103, 559-64	466
1141	Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 2006 , 103, 405-16	90
1140	Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: a multi-institutional analysis of 608 women. 2006 , 103, 661-6	12
1139	Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus domesticus model of ovarian cancer. 2006 , 103, 673-8	35
1138	Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. 2006 , 103, 709-13	53
1137	The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. 2006 , 102, 425-8	104
1136	Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision. 2006 , 103, 749-51	7
1135	Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy. 2006 , 103, 985-9	3
1134	Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortality. 2006 , 103, 1043-7	29

1133	The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. 2006 , 103, 1083-90	256
1132	Reproduction beyond cancer: a message of hope for young women. 2006 , 103, 1109-21	74
1131	Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?. 2006 , 103, 797-801	62
1130	Functional sequelae of cavernous nerve injury in the rat: is there model dependency. 2006 , 3, 77-83	107
1129	Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. 2006 , 202, 284-90	47
1128	Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. 2006 , 203, 527-32	49
1127	Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. 2006 , 203, 521-6	56
1126	Vaccine therapy of malignant melanoma. 2006 , 6, 217-230	2
1125	The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. 2006 , 169, 33-8	14
1124	A (9;11)(q34;q13) translocation in a hibernoma. 2006 , 170, 163-6	12
1123	Clonality studies in sacral chordoma. 2006 , 171, 68-71	13
1122	Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. 2006 , 164, 1-14	95
1121	Connecting COX-2 and Wnt in cancer. 2006 , 9, 6-8	106
1120	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. 2006 , 10, 39-50	311
1119	Primary care patients' understanding of colorectal cancer screening. 2006 , 30, 67-74	31
1118	Risk factors for lung cancer in Iowa women: implications for prevention. 2006 , 30, 158-67	18
1117	The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy. 2006 , 30, 269-75	20
1116	Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. 2006 , 540, 24-33	42

1115	Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder. 2006 , 49, 71-5	23
1114	Prevention of bladder cancer: a review. 2006 , 49, 226-34	58
1113	Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal. 2006 , 49, 412-413	4
1112	For the motion. 2006 , 49, 396-398	5
1111	Screening for ovarian cancer in the general population. 2006 , 20, 307-20	33
1110	Screening and the prevention of gynecologic cancer: endometrial cancer. 2006 , 20, 363-77	46
1109	Effects of pharmacological concentrations of estrogens on growth of 3AO human ovarian cancer cells. 2006 , 33, 782-92	1
1108	Can single-patient investigational new drug studies hurry slow trains to the fast track?. 2006 , 11, 185-6	
1107	Fertility Preservation before Therapy for Cancer New Perspectives. 2006 , 3, 15-26	
1106	Imaging colorectal cancer. 2006 , 41, 113-20	2
1105	Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia. 2006 , 33, S15-22	7
1104	Bevacizumab in older patients and patients with poorer performance status. 2006 , 33, S19-25	5
1103	The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma. 2006 , 33, S50-6	161
1102	The management of head and neck melanoma. 2006 , 43, 781-835	15
1101	Microwave reflectometry as a novel diagnostic tool for detection of skin cancers. 2006 , 55, 1309-1316	69
1100	Stereotactic body radiation therapy for extracranial oligometastases: does the sword have a double edge?. 2006 , 16, 67-76	56
1099	The treatment of melanoma with an emphasis on immunotherapeutic strategies. 2006 , 15, 13-24	25
1098	Cervical cancer treatment with a locally insertable controlled release delivery system. 2006 , 115, 280-8	37

1097	Contemporary techniques and safety of cardiovascular procedures in the surgical management of renal cell carcinoma with tumor thrombus. 2006 , 131, 1289-95		23
1096	Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size. 2006 , 132, 1382-9		28
1095	Stent fabrication for graft immobilization following wide surgical excision of myofibroblastic sarcoma of the buccal mucosa: a clinical report. 2006 , 95, 280-5		14
1094	Analysis of the interaction of extracellular matrix and phenotype of bladder cancer cells. <i>BMC Cancer</i> , 2006 , 6, 12	4.8	22
1093	Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. <i>BMC Cancer</i> , 2006 , 6, 165	4.8	74
1092	Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. <i>BMC Cancer</i> , 2006 , 6, 211	4.8	63
1091	Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. <i>BMC Cancer</i> , 2006 , 6, 22	4.8	27
1090	A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. <i>BMC Cancer</i> , 2006 , 6, 285	4.8	91
1089	Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. <i>BMC Cancer</i> , 2006 , 6, 293	4.8	38
1088	Modest induction of phase 2 enzyme activity in the F-344 rat prostate. <i>BMC Cancer</i> , 2006 , 6, 62	4.8	29
1087	Single nucleotide polymorphisms of the APC gene and colorectal cancer risk: a case-control study in Taiwan. <i>BMC Cancer</i> , 2006 , 6, 83	4.8	24
1086	Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. 2006 , 26, 641-54		26
1085	Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive cancer network guidelines and the cooperative group studies. 2006 , 7, 33-41		8
1084	Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer. 2006 , 7, 42-50		13
1083	Chemotherapy for non-clear-cell renal cell carcinoma. 2006 , 4, 263-8		13
1082	Pathways of dysregulation in renal cell carcinoma: rational approaches to development of novel treatment. 2006 , 5 Suppl 1, S7-S18		1
1081	Lambert-eaton myasthenic syndrome in a patient with small-cell lung cancer. 2006 , 7, 282-4		4
1080	A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. 2006 , 7, 285-7		15

1079	Pulmonary dysfunction as a major cause of inoperability among patients with non-small-cell lung cancer. 2006 , 7, 344-9	28
1078	PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naïve women with advanced-stage non-small-cell lung cancer and performance status of 2. 2006 , 7, 417-9	46
1077	The effect of tamoxifen on the pharmacokinetics of letrozole in female rats. 2006 , 27, 335-44	3
1076	Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection. 2006 , 27, 1840-52	63
1075	Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. 2006 , 97, 18-32	90
1074	Roles of osteonectin in the migration of breast cancer cells into bone. 2006 , 97, 288-302	35
1073	Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. 2006 , 98, 36-53	26
1072	Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. 2006 , 98, 1408-23	69
1071	An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives. 2006 , 1, 196-211	24
1070	Clinical trial accrual among new cancer patients at a community-based cancer center. 2006 , 106, 426-33	89
1069	Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. 2006 , 106, 375-82	93
1068	Cutaneous melanoma in postmenopausal women after nonmelanoma skin carcinoma: the Women's Health Initiative Observational Study. 2006 , 106, 654-63	15
1067	A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma. 2006 , 106, 765-74	38
1066	Outcome of patients with fibrolamellar hepatocellular carcinoma. 2006 , 106, 1331-8	164
1065	Defining "success" in recruitment of underrepresented populations to cancer clinical trials: moving toward a more consistent approach. 2006 , 106, 1197-204	39
1064	Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. 2006 , 106, 1610-6	154
1063	Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. 2006 , 106, 1998-2004	107
1062	Effects of weight training on quality of life in recent breast cancer survivors: the Weight Training for Breast Cancer Survivors (WTBS) study. 2006 , 106, 2076-83	156

1061	Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. 2006 , 106, 1933-9	257
1060	Association between adiponectin, insulin resistance, and endometrial cancer. 2006 , 106, 2376-81	159
1059	Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. 2006 , 106, 2208-17	51
1058	Breast cancer incidence in U.S. radiologic technologists. 2006 , 106, 2707-15	66
1057	Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. 2006 , 106, 2459-65	16
1056	Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. 2006 , 106, 2428-36	120
1055	Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. 2006 , 106, 2503-13	216
1054	Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. 2006 , 106, 2445-51	39
1053	Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. 2006 , 107, 46-53	61
1052	High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. 2006 , 107, 37-45	76
1051	African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. 2006 , 107, 75-82	76
1050	Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. 2006 , 107, 83-9	120
1049	Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. 2006 , 107, 289-98	186
1048	A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015. 2006 , 107, 396-405	31
1047	Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. 2006 , 107, 299-308	84
1046	Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials. 2006 , 107, 849-53	12
1045	Late gastrointestinal toxicity after radiation for prostate cancer. 2006 , 107, 423-32	33
1044	Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia. 2006 , 107, 328-36	9

1043	A population-based study of colorectal cancer histology in the United States, 1998-2001. 2006 , 107, 1128-41	72
1042	Thapsigargin resistance in human prostate cancer cells. 2006 , 107, 649-59	9
1041	Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. 2006 , 107, 506-13	270
1040	Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. 2006 , 107, 530-5	40
1039	Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. 2006 , 107, 536-43	48
1038	What motivates men age > or =50 years to participate in a screening program for melanoma?. 2006 , 107, 815-23	34
1037	Variations in reconstruction after radical cystectomy. 2006 , 107, 729-37	105
1036	Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. 2006 , 107, 563-9	246
1035	Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. 2006 , 107, 738-45	31
1034	Bladder cancer risk as modified by family history and smoking. 2006 , 107, 705-11	29
1033	Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. 2006 , 107, 982-90	102
1032	Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. 2006 , 107, 1050-4	4
1031	Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. 2006 , 107, 1407-18	67
1030	Arkansas Special Populations Access Network perception versus reality--cancer screening in primary care clinics. 2006 , 107, 2052-60	9
1029	Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. 2006 , 107, 1475-82	34
1028	Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. 2006 , 107, 1823-30	330
1027	Long-term outcome of hematuria home screening for bladder cancer in men. 2006 , 107, 2173-9	131
1026	Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. 2006 , 107, 2197-205	82

1025	Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. 2006 , 107, 2160-6	69
1024	Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. 2006 , 107, 2361-7	74
1023	Hsp60 and Hsp10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. 2006 , 107, 2417-24	78
1022	Radiosurgery for the treatment of spinal lung metastases. 2006 , 107, 2653-61	49
1021	Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. 2006 , 107, 2462-7	73
1020	Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. 2006 , 107, 2637-46	164
1019	Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. 2006 , 107, 2786-91	155
1018	Mouse models for human head and neck squamous cell carcinomas. 2006 , 28, 945-54	42
1017	Differential tissue and subcellular expression of ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic significance for head and neck squamous cell carcinoma. 2006 , 28, 1018-27	43
1016	Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. 2006 , 24, 47-55	17
1015	PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. 2006 , 118, 1471-80	47
1014	Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. 2006 , 118, 2721-6	83
1013	The clinical significance of MAGEA3 expression in pancreatic cancer. 2006 , 118, 2269-75	56
1012	Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis. 2006 , 118, 2441-7	36
1011	Regular aspirin use and esophageal cancer risk. 2006 , 119, 202-7	30
1010	Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. 2006 , 119, 406-13	64
1009	Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients. 2006 , 119, 1455-61	16
1008	Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. 2006 , 119, 1403-11	109

1007	Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. 2006 , 119, 1586-98	32
1006	Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. 2006 , 119, 1761-6	101
1005	BRAF and KRAS mutations in prostatic adenocarcinoma. 2006 , 119, 1858-62	81
1004	M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. 2006 , 119, 1920-6	71
1003	Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. 2006 , 119, 2428-34	70
1002	Beta-cryptoxanthin suppresses the growth of immortalized human bronchial epithelial cells and non-small-cell lung cancer cells and up-regulates retinoic acid receptor beta expression. 2006 , 119, 2084-9	57
1001	Alcohol consumption and ovarian cancer risk in a population-based case-control study. 2006 , 119, 2423-7	23
1000	Gleason score, age and screening: modeling dedifferentiation in prostate cancer. 2006 , 119, 2366-71	58
999	Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. 2006 , 119, 2958-69	45
998	Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. 2006 , 119, 2651-6	39
997	Expression profiling identifies microRNA signature in pancreatic cancer. 2007 , 120, 1046-54	703
996	Beneficial effects of tea and its polyphenols against prostate cancer. 2006 , 50, 130-43	97
995	Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. 2006 , 38, 427-34	88
994	Endobronchial photodynamic therapy for lung cancer. 2006 , 38, 364-70	81
993	Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland. 2006 , 38, 672-81	54
992	In situ analysis of breast cancer progression in murine models using a macroscopic fluorescence imaging system. 2006 , 38, 928-38	9
991	The role of surgery in treatment of stage IV melanoma. 2006 , 94, 344-51	49
990	Re: safety and feasibility of breast conserving therapy in Indian women: two decades of experience at Tata Memorial Hospital, by Dinshaw KA, Sarin R, Budrikkar AN, et al. 2006 , 94, 89-90	2

989	Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?. 2006 , 93, 485-90	10
988	Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. 2006 , 94, 264-5	7
987	The role of reoperation in the management of endometrial carcinoma found in simple hysterectomy. 2006 , 93, 373-8	5
986	Retroperitoneal sarcomas: Combined-modality treatment approaches. 2006 , 94, 81-7	92
985	Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. 2006 , 94, 316-24	92
984	Total thyroidectomy for differentiated thyroid cancer. 2006 , 94, 701-7	46
983	Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. 2006 , 45, 506-17	12
982	Differential expression of insulin-like growth factor binding protein-5 in pancreatic adenocarcinomas: identification using DNA microarray. 2006 , 45, 814-27	19
981	Strain-specific induction of murine lung tumors following in utero exposure to 3-methylcholanthrene. 2006 , 45, 676-84	8
980	Prostate cancer chemoprevention by silibinin: bench to bedside. 2006 , 45, 436-42	109
979	Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III. 2006 , 45, 851-60	25
978	Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. 2006 , 79, 497-503	71
977	Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. 2006 , 66, 7136-42	127
976	Positron emission tomography in gynecological malignancies. 2006 , 6, 1033-44	22
975	Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. 2006 , 70, 265-72	15
974	Short schedule of cisplatin and vinorelbine: a dose-finding study in non-small-cell lung cancer. 2006 , 71, 229-36	1
973	Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. 2006 , 98, 441-50	188
972	Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. 2006 , 66, 9762-70	17

971	Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. 2006 , 66, 4542-6	92
970	Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. 2006 , 66, 6387-94	49
969	Association of activated transcription factor nuclear factor kappaB with chemoradiation resistance and poor outcome in esophageal carcinoma. 2006 , 24, 748-54	124
968	Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. 2006 , 15, 293-305	21
967	Arzoxifene: the development and clinical outcome of an ideal SERM. 2006 , 15, 317-26	26
966	The second annual symposium on the future of lung cancer: a translational focus. 11-12 November 2005, Washington D.C., USA. 2006 , 10, 475-80	
965	Robotic prostatectomy: a pooled analysis of published literature. 2006 , 6, 11-20	51
964	Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer. 2006 , 6, 141-52	4
963	Fertility-sparing therapy for young women with endometrial cancer. 2006 , 6, 27-32	13
962	An overview of uterine cancer and its management. 2006 , 6, 33-42	14
961	Developing innovative strategies for advanced transitional cell carcinoma of the bladder. 2006 , 6, 83-92	1
960	Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. 2006 , 6, 281-91	7
959	Capecitabine in carcinoma of the pancreas. 2006 , 7, 1633-9	7
958	The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. 2006 , 66, 2264-70	97
957	Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. 2006 , 147, 4505-16	148
956	Evaluation of benign and malignant rectal lesions with CT colonography and endoscopic correlation. 2006 , 26, 1085-99	27
955	Thalidomide in multiple myeloma. 2006 , 7, 195-213	11
954	Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. 2006 , 238, 597-603	205

953	Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. 2006 , 91, 3662-6	53
952	Screening for colorectal neoplasia with CT colonography: initial experience from the 1st year of coverage by third-party payers. 2006 , 241, 417-25	135
951	Mechanisms underlying the development of androgen-independent prostate cancer. 2006 , 12, 1665-71	338
950	Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. 2006 , 147, 4883-92	61
949	A gene expression signature that can predict green tea exposure and chemopreventive efficacy of lung cancer in mice. 2006 , 66, 1956-63	33
948	Chemoradiation paradigm for the treatment of lung cancer. 2006 , 3, 188-99	28
947	Management of panurothelial disease in superficial bladder cancer. 2006 , 3, 284-8	1
946	Breast masses: computer-aided diagnosis with serial mammograms. 2006 , 240, 343-56	35
945	Colorectal cancer: screening double-contrast barium enema examination in average-risk adults older than 50 years. 2006 , 240, 725-35	28
944	Epidermoid carcinoma of the anal canal. 2006 , 19, 54-60	10
943	Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. 2006 , 238, 176-83	113
942	Lung cancer screening: radiology's opportunity here and now. 2006 , 238, 395-7	7
941	Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. 2006 , 91, 4013-21	107
940	Paclitaxel in breast cancer. 2006 , 2, 11-21	7
939	BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance. 2006 , 6, 187-96	8
938	Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: early experience. 2006 , 239, 481-7	58
937	Reducing the risk of gynecologic cancer in the Lynch syndrome. 2006 , 354, 293-5	27
936	Significance of gene expression analysis of renal cell carcinoma. 2006 , 6, 293-9	3

935	Effectiveness of radiation therapy for older women with early breast cancer. 2006 , 98, 681-90	145
934	Abstracts from the Chemotherapy Foundation Symposium XXIV: Innovative Cancer Therapy for Tomorrow, November 8-11, 2006, New York, New York, USA. 2006 , 24 Suppl 1, 1-59	
933	Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. 2006 , 27, 833-9	66
932	Interstitial brachytherapy dosimetry update. 2006 , 120, 64-9	3
931	Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. 2006 , 66, 7341-7	151
930	Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. 2006 , 15, 1668-73	93
929	Mining methylation for early detection of common cancers. 2006 , 3, e479	16
928	Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. 2006 , 12, 6049-55	173
927	Prostate cancer in US Air Force veterans of the Vietnam war. 2006 , 16, 184-90	28
926	Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. 2006 , 12, 3003-9	122
925	Intrathecal topotecan in adult patients with neoplastic meningitis. 2006 , 63, 2083-6	21
924	Ultraviolet a Radiation and The Need for Protection. 2006 , 10, S1-S7	2
923	Prostate activity and prostate cancer in spinal cord injury. 2006 , 9, 115-20	14
922	Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. 2006 , 98, 1494-500	39
921	Monitoring the physical health of cancer survivors: a survivorship-focused medical history. 2006 , 24, 5105-11	97
920	Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men. 2006 , 9, 50-5	9
919	Ultrasound imaging and contrast agents: a safe alternative to MRI?. 2006 , 15, 93-100	31
918	Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States?. 2006 , 24, 626-34	247

917	Testosterone replacement therapy for late-onset hypogonadism. 2006 , 3, 260-7	29
916	Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. 2006 , 24, 4895-900	118
915	Grape seed extract induces anoikis and caspase-mediated apoptosis in human prostate carcinoma LNCaP cells: possible role of ataxia telangiectasia mutated-p53 activation. 2006 , 5, 1265-74	65
914	High-throughput mutational analysis of the human cancer genome. 2006 , 7, 597-612	13
913	Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead. 2006 , 17, 1360-9	8
912	Aberrant expression of PDGF ligands and receptors in the tumor prone ovary of follitropin receptor knockout (FORKO) mouse. 2006 , 27, 903-15	17
911	Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. 2006 , 17, 813-7	99
910	Medical treatments for hepatocellular carcinoma (HCC): what's next?. 2006 , 17 Suppl 10, x308-14	23
909	Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. 2006 , 24, 587-92	158
908	Survivorship. 2006 , 10, 407-422	14
907	Sunscreens: Past, Present, and Future. 2006 , 10, S14-S21	1
906	Suppression of the tumorigenic phenotype in human oral squamous cell carcinoma cells by an ethanol extract derived from freeze-dried black raspberries. 2006 , 54, 58-68	94
905	A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. 2006 , 12, 3381-8	101
904	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. 2006 , 12, 3661-97	235
903	Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. 2006 , 24, 1898-903	332
902	Ectopic doublecortin gene expression suppresses the malignant phenotype in glioblastoma cells. 2006 , 66, 11726-35	34
901	Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. 2006 , 24, 1415-20	267
900	The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. 2006 , 17, 189-99	76

899	Screening in women's health, with emphasis on fetal Down's syndrome, breast cancer and osteoporosis. 2006 , 12, 499-512	7
898	Lung cancer death rates in lifelong nonsmokers. 2006 , 98, 691-9	206
897	The role of perioperative chemotherapy in the treatment of urothelial cancer. 2006 , 11, 630-40	12
896	Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. 2006 , 66, 7032-40	71
895	Influence of the microenvironment on melanoma cell fate determination and phenotype. 2006 , 66, 7833-6	97
894	Targeted therapy for renal cell carcinoma: a new therapeutic paradigm. 2006 , 24, 640-56	7
893	DNA damage levels in prostate cancer cases and controls. 2006 , 27, 1187-93	41
892	Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. 2006 , 5, 2234-40	51
891	Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. 2006 , 12, 6444-51	53
890	Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. 2006 , 5, 2977-90	35
889	Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. 2006 , 4, 521-8	119
888	Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. 2006 , 66, 1025-32	46
887	A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. 2006 , 15, 1115-9	63
886	Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. 2006 , 12, 2689-97	143
885	Hormone replacement therapy is associated with decreased survival in women with lung cancer. 2006 , 24, 59-63	151
884	Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. 2006 , 12, 442-6	179
883	Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. 2006 , 12, 4916-24	260
882	Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. 2006 , 12, 2869-78	23

881	Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. 2006 , 63, 527-33	8
880	PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. 2006 , 12, 2928-36	85
879	Prognostic significance of nuclear factor-kappaB p105/p50 in human melanoma and its role in cell migration. 2006 , 66, 8382-8	37
878	Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. 2006 , 12, 1487-93	47
877	Physiological and functional interactions between Tcf4 and Daxx in colon cancer cells. 2006 , 281, 15405-11	29
876	Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. 2006 , 12, 791-9	68
875	Challenges of chemosensitivity testing. 2006 , 12, 5258-9	8
874	Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. 2006 , 15, 1226-8	44
873	Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. 2006 , 24, 3789-98	153
872	Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. 2006 , 24, 306-14	138
871	The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer. 2006 , 13, 304-11	18
870	DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. 2006 , 66, 1208-17	181
869	Fenretinide activity in retinoid-resistant oral leukoplakia. 2006 , 12, 3109-14	43
868	Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. 2006 , 11, 336-41	14
867	The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. 2006 , 12, 6170-8	80
866	Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. 2006 , 66, 8250-7	151
865	CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. 2006 , 177, 7398-405	322
864	Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. 2006 , 5, 2844-50	54

863	Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. 2006 , 24, 878-83	54
862	Hypoxia increases androgen receptor activity in prostate cancer cells. 2006 , 66, 5121-9	66
861	Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector. 2006 , 12, 7108-16	25
860	Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer. 2006 , 12, 392-7	42
859	Effect of silibinin on the growth and progression of primary lung tumors in mice. 2006 , 98, 846-55	137
858	Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. 2006 , 24, 2723-8	114
857	A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. 2006 , 12, 7046-53	87
856	Development of quality indicators for patients undergoing colorectal cancer surgery. 2006 , 98, 1623-33	112
855	Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. 2006 , 11, 857-67	73
854	Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. 2006 , 15, 935-8	44
853	Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. 2006 , 66, 2592-9	83
852	Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. 2006 , 5, 1216-26	26
851	Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. 2006 , 66, 5867-74	116
850	Unconventional anticancer agents: a systematic review of clinical trials. 2006 , 24, 136-40	23
849	Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. 2006 , 24, 1892-7	81
848	Cast Nephropathy in Myeloma Does PACAP38, a New Member of the Vasoactive Intestinal Peptide Family, Open a Therapeutic Window?. 2006 , 17, 911-919	4
847	Soy and breast cancer: the controversy continues. 2006 , 98, 430-1	15
846	The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. 2006 , 5, 1744-53	41

845	Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. 2006 , 12, 5944-50	89
844	Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. 2006 , 55, 1598-605	75
843	Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. 2006 , 66, 7653-60	46
842	RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. 2006 , 66, 1062-9	38
841	Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma. 2006 , 66, 8581-9	54
840	Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. 2006 , 66, 10613-20	110
839	Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. 2006 , 11, 358-73	54
838	Therapeutic vaccines for prostate cancer. 2006 , 11, 451-62	32
837	Rising incidence of small renal masses: a need to reassess treatment effect. 2006 , 98, 1331-4	874
836	Endocan expression and relationship with survival in human non-small cell lung cancer. 2006 , 12, 4575-82	136
835	Cancer and leukemia group B gastrointestinal cancer committee. 2006 , 12, 3589s-95s	1
834	Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. 2006 , 12, 2281-8	65
833	Hyperplastic and neoplastic lesions of the mammary gland in macaques. 2006 , 43, 471-83	40
832	Exercise for women with or at risk for breast cancer-related lymphedema. 2006 , 86, 1398-405	57
831	Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. 2006 , 15, 2332-5	40
830	Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. 2006 , 12, 2919-27	35
829	Risk stratification of colon carcinogenesis through enhanced backscattering spectroscopy analysis of the uninvolved colonic mucosa. 2006 , 12, 961-8	31
828	HsulF-1 regulates growth and invasion of pancreatic cancer cells. 2006 , 59, 1052-8	29

827	Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. 2006 , 24, 4069-77	89
826	Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. 2006 , 66, 1354-62	219
825	High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. 2006 , 24, 3438-44	16
824	Identifying and screening patients at risk of second cancers. 2006 , 15, 2027-32	26
823	Folate nutrition and prostate cancer incidence in a large cohort of US men. 2006 , 163, 989-96	59
822	Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. 2006 , 24, 1910-6	112
821	Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. 2006 , 66, 10188-98	34
820	Genetic alterations in cancer knowledge system: analysis of gene mutations in mouse and human liver and lung tumors. 2006 , 90, 400-18	35
819	Technology insight: Photodynamic therapy for cholangiocarcinoma. 2006 , 3, 459-67	27
818	Dietary factors of one-carbon metabolism in relation to non-Hodgkin lymphoma and multiple myeloma in a cohort of male smokers. 2006 , 15, 1109-14	24
817	Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. 2006 , 12, 5423-34	586
816	Computational methods for analysis of human breast tumor tissue in optical coherence tomography images. 2006 , 11, 054015	83
815	Cancer incidence and mortality and vitamin D in black and white male health professionals. 2006 , 15, 2467-72	75
814	Overview of genetic testing in cancer. 2006 , 3, 325-333	
813	Pancreatic cancer in mice and man: the Penn Workshop 2004. 2006 , 66, 14-7	42
812	Targeting the ubiquitin-proteasome pathway in breast cancer therapy. 2006 , 2, 121-35	20
811	Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. 2006 , 59, 403-9	90
810	New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. 2006 , 24, 252-8	108

809	Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from <i>Kaempferia pandurata</i> in androgen-independent human prostate cancer cells PC3 and DU145. 2006 , 27, 1454-64	90
808	Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. 2006 , 24, 4485-91	95
807	The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. 2006 , 387, 707-14	29
806	Activin receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines. 2006 , 4, 235-46	38
805	Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. 2006 , 5, 3181-90	66
804	Hormonal and reproductive factors and the risk of bladder cancer in women. 2006 , 163, 236-44	111
803	The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. 2006 , 12, 759-63	41
802	Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. 2006 , 12, 2492-7	127
801	Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway. 2006 , 70, 869-77	60
800	Progress in SPECT/CT imaging of prostate cancer. 2006 , 5, 329-36	17
799	Analysis of protein redox modification by hypoxia. 2006 , 36, 65-79	10
798	Lung cancer screening. 2006 , 11, 481-7	30
797	Challenges for chemotherapy in ovarian cancer. 2006 , 17 Suppl 5, v181-7	78
796	The future in diagnosis and staging of lung cancer. Molecular techniques. 2006 , 73, 575-80	9
795	Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in ApcMin/+ mice. 2006 , 66, 6955-63	93
794	Innovative strategies for image-guided proton treatment of prostate cancer. 2006 , 5, 91-100	4
793	Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. 2006 , 12, 2109-16	155
792	Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. 2006 , 387, 801-5	14

791	Locally advanced pancreatic cancer: current therapeutic approach. 2006 , 11, 612-23	79
790	Multiple myeloma. 2006 , 17, 2533-45	124
789	Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers. 2006 , 33, E27-35	14
788	Prospective changes in quality of life after ductal carcinoma-in-situ: results from the Nurses' Health Study. 2006 , 24, 2822-7	20
787	Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. 2006 , 24, 5010-6	81
786	Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting. 2006 , 52, 782-4	11
785	Efficient interval estimation for age-adjusted cancer rates. 2006 , 15, 547-69	332
784	Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. 2006 , 66, 3802-12	51
783	The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. 2006 , 66, 1917-22	118
782	Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. 2006 , 66, 9722-30	49
781	Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. 2006 , 66, 7414-9	49
780	A systems approach to model metastatic progression. 2006 , 66, 5537-9	8
779	Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells. 2006 , 66, 8439-47	30
778	Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. 2006 , 66, 11085-8	68
777	Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. 2006 , 12, 690-700	58
776	The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. 2006 , 12, 1707-14	136
775	Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. 2006 , 12, 3152-7	37
774	The use of targeted mouse models for preclinical testing of novel cancer therapeutics. 2006 , 12, 5277-87	197

773	Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. 2006 , 12, 6012-7	48
772	Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression. 2006 , 12, 6637-42	47
771	When in doubt should we cut it out? The role of surgery in non-small cell lung cancer. 2006 , 61, 554-6	4
770	Effectiveness of radiation therapy in older women with ductal carcinoma in situ. 2006 , 98, 1302-10	69
769	Population-based assessment of the surgical management of locally advanced colorectal cancer. 2006 , 98, 1474-81	74
768	Biomarkers and screening for prostate cancer. 2006 , 17 Suppl 10, x201-6	2
767	Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. 2006 , 281, 18973-82	63
766	Oncogenic role of microRNA-20a in human multiple myeloma. 2017 , 10, 4465-4474	10
765	Parameters sensitivity assessment and heat source localization using infrared imaging techniques. 2017 , 16, 113	6
764	Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition. 2017 , 7, 9814	14
763	Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. 2017 , 8, 408-417	7
762	Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity. 2017 , 16, 2868-2874	11
761	Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. 2017 , 24, e261-e268	7
760	T cells in cancer immunotherapy. 2017 , 8, 8900-8909	58
759	Endoscopic ultrasound-guided radiofrequency ablation in gastroenterology: New horizons in search. 2017 , 23, 4892-4896	7
758	Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial. 2018 , 15, 3646-3652	5
757	EGlutamylcysteine synthetase (EGCS) as a target for overcoming chemo- and radio-resistance of human hepatocellular carcinoma cells. 2018 , 198, 25-31	14
756	Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation. 2018 , 288, 300-307	23

755	A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells. 2018 , 15, 6147-6160	16
754	F-FDG PET/CT in Local Ablative Therapies: A Systematic Review. 2018 , 59, 551-556	9
753	Synthesis and bioevaluation and docking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors. 2018 , 145, 315-327	12
752	Combination of 247 Genome-Wide Association Studies Reveals High Cancer Risk as a Result of Evolutionary Adaptation. 2018 , 35, 473-485	31
751	A simple test procedure in standardizing the power of Hosmer Lemeshow test in large data sets. 2018 , 88, 2463-2472	7
750	The role of intraoperative radiotherapy (IORT) in the management of patients with pancreatic and periampullary cancer: A single center experience. 2018 , 30, 77-79	4
749	EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma. 2018 , 52, 1443-1454	12
748	Body composition predictors of therapy response in patients with primary extremity soft tissue sarcomas. 2018 , 59, 478-484	8
747	Cytology and high risk HPV testing in cervical cancer screening program: Outcome of 3-year follow-up in an academic institute. 2018 , 46, 22-27	5
746	Comparison of SFRP2 promoter methylation in stool sample and cfDNA regarding patients with colorectal cancer. 2018 , 27, 155-159	1
745	MRI/US fusion-guided biopsy: performing exclusively targeted biopsies for the early detection of prostate cancer. 2018 , 123, 227-234	15
744	Herbal remedies for liver fibrosis: A review on the mode of action of fifty herbs. 2018 , 8, 352-360	38
743	The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. 2018 , 41, 269-283	46
742	Radiomics of the primary tumour as a tool to improve F-FDG-PET sensitivity in detecting nodal metastases in endometrial cancer. 2018 , 8, 86	29
741	Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts. 2018 , 25, e444-e453	6
740	Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide. 2018 , 9, 1271	18
739	Transitions From Heart Disease to Cancer as the Leading Cause of Death in US States, 1999-2016. 2018 , 15, E158	16
738	High expression of uPA related to p38MAPK in esophageal cancer indicates poor prognosis. 2018 , 11, 8427-8434	5

737	Second primary colorectal cancer after the initial primary colorectal cancer. <i>BMC Cancer</i> , 2018 , 18, 931	4.8	6
736	Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models. 2018 , 11, 5133-5142		1
735	lncRNA LOC100132354 promotes angiogenesis through VEGFA/VEGFR2 signaling pathway in lung adenocarcinoma. 2018 , 10, 4257-4266		24
734	Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K/AKT/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B. 2018 , 11, 6351-6360		14
733	MicroRNA-23a promotes colorectal cancer cell survival by targeting PDK4. 2018 , 373, 171-179		23
732	Trend in relative survival in squamous cervical cancer by decade from 1983 to 2012: a period analysis. 2018 , 10, 3177-3191		2
731	Pre-diagnostic delays caused by gastrointestinal investigations do not affect outcomes in pancreatic cancer. 2018 , 34, 66-70		8
730	Effects of zerumbone on proliferation and apoptosis of esophageal cancer cells and on P53 and Bcl-2 expression levels. 2018 , 16, 4379-4383		5
729	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer-From Cell Line Models to Liquid Biopsies. 2018 , 8,		12
728	Potential role of LINC00996 in colorectal cancer: a study based on data mining and bioinformatics. 2018 , 11, 4845-4855		18
727	Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis. 2018 , 485, 67-73		10
726	The impact of psychosocial characteristics in predicting smoking cessation in long-term cancer survivors: A time-to-event analysis. 2018 , 27, 2458-2465		5
725	Special Considerations in Big Data Analysis. 2018 , 303-319		
724	Exploring Associations of Sedentary Behavior and Physical Activity with Quality of Life in Young Adult Cancer Survivors. 2018 , 7, 643-651		3
723	The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. 2018 , 9, 10164-10174		53
722	Hyperspectral Imaging and K-Means Classification for Histologic Evaluation of Ductal Carcinoma. <i>Frontiers in Oncology</i> , 2018 , 8, 17	5.3	29
721	Extraction method and anti-cancer evaluation of two lignans from <i>Phyllanthus Niruri</i> L.. 2018 , 27, 2034-2041		1
720	Managing Synchronous Liver Metastases in Colorectal Cancer. 2018 , 9, 461-471		2

719	Conventional Ultrasound, Immunohistochemical Factors and BRAF Mutation in Predicting Central Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma. 2018 , 44, 2296-2306		20
718	MiRNA-206 suppresses PGE2-induced colorectal cancer cell proliferation, migration, and invasion by targetting TM4SF1. 2018 , 38,		36
717	Antiproliferative potential of miR-33a in laryngeal cancer Hep-2 cells via targetting PIM1. 2018 , 40, 2455-2461		11
716	Decoding methylation patterns in ovarian cancer using publicly available Next-Gen sequencing data. 2018 , 7, 1		0
715	Stem cell-based Lung-on-Chips: The best of both worlds?. 2019 , 140, 12-32		33
714	Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015. 2019 , 37, 166-174		4
713	IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer. 2019 , 105, 84-91		18
712	The effects of physics-based data augmentation on the generalizability of deep neural networks: Demonstration on nodule false-positive reduction. 2019 , 46, 4563-4574		6
711	PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. <i>Cancer Medicine</i> , 2019 , 8, 6036-6048	4.8	16
710	An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. 2019 , 9, 12070		32
709	Biophysical Psychiatry-How Computational Neuroscience Can Help to Understand the Complex Mechanisms of Mental Disorders. 2019 , 10, 534		10
708	Intestinal probiotics Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. 2019 , 13, 58		45
707	Resveratrol-Induced Temporal Variation in the Mechanical Properties of MCF-7 Breast Cancer Cells Investigated by Atomic Force Microscopy. 2019 , 20,		9
706	Esophageal Cancer Diagnosis and Staging. 2019 , 368-381		1
705	Gallbladder Polyps Are Associated with Proximal Colon Polyps. 2019 , 2019, 9832482		4
704	Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 986	5.3	4
703	Hormone replacement therapy following treatment of gynaecological malignancies. 2019 , 21, 291-298		
702	A Survey of Deep-Learning Applications in Ultrasound: Artificial Intelligence-Powered Ultrasound for Improving Clinical Workflow. 2019 , 16, 1318-1328		63

701	CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach. 2019 , 145, 2649-2661	15
700	Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis. 2019 , 41, 2252-2262	1
699	Anti-tumor efficacy of folate modified PLGA-based nanoparticles for the co-delivery of drugs in ovarian cancer. 2019 , 13, 1271-1280	11
698	Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer. 2019 , 24, 524-529	2
697	Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection. 2019 , 11, 1106-1116	4
696	Mutational landscape of head and neck squamous cell carcinomas in a South Asian population. 2019 , 4242, 526-542	1
695	Benzo[a]phenoselenazine-based NIR photosensitizer for tumor-targeting photodynamic therapy via lysosomal-disruption pathway. 2019 , 170, 107617	8
694	Evaluation of incidence and histopathological findings of soft tissue sarcomas in genitourinary tract: Uludag university experience. 2019 , 45, 68-73	2
693	General Laboratory Tests. 2019 , 151-153	
692	Identification of Cancer Hallmarks Based on the Gene Co-expression Networks of Seven Cancers. 2019 , 10, 99	4
691	The "cancer-cold" hypothesis and possible extensions for the Nordic populations. 2019 , 47, 477-481	8
690	Flavonoids from the Amazon plant Brosimum acutifolium induce C6 glioma cell line apoptosis by disrupting mitochondrial membrane potential and reducing AKT phosphorylation. 2019 , 113, 108728	7
689	Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer. 2019 , 153, 320-325	7
688	A phase II study of intraoperative radiotherapy using a low-energy x-ray source for resectable pancreatic cancer: a study protocol. 2019 , 19, 31	2
687	Hormonal contraception and risk of breast cancer: a critical look. 2019 , 35, 460-462	2
686	Antarctic Krill (<i>Euphausia superba</i>) Oil: A Comprehensive Review of Chemical Composition, Extraction Technologies, Health Benefits, and Current Applications. 2019 , 18, 514-534	57
685	Optical Diagnosis of Prostate Cancer. 2019 , 571, 012123	1
684	YPLL: A Comprehensive Quantitative Tool to Evaluate Worker Risk Under Green and Sustainable Remediation. 2019 , 468-477	

683	Detection of inhomogeneity by the observation of the surface of the material simulating biological tissues. 2019 , 15,	
682	Radical Cystectomy in Female Patients - Improving Outcomes. 2019 , 20, 83	0
681	A sub-Saharan African experience in the surgical management of soft tissue sarcomas in an oncology unit in: a retrospective cohort study. 2019 , 33, 207	1
680	Enhanced ultrasound imaging and anti-tumor properties of Span-polyethylene glycol with folic acid-carbon nanotube-paclitaxel multifunctional microbubbles.. 2019 , 9, 35345-35355	5
679	The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. 2019 , 6, 274-282	5
678	Thyroid Nodule: Current Evaluation and Management. 2019 , 493-516	1
677	Popliteal Angiosarcoma after Bypass with Autologous Saphenous Vein. 2019 , 55, 308.e1-308.e4	3
676	Pancreatic Metastases of Rectal Cancer-Case Report and Literature Review. 2019 , 50, 338-341	2
675	An intelligent lung cancer diagnosis system using cuckoo search optimization and support vector machine classifier. 2019 , 10, 267-293	38
674	Adenoviral transduction of EGFR into pregnancy-adapted uterine artery endothelial cells remaps growth factor induction of endothelial dysfunction. 2020 , 499, 110590	11
673	Pancreatic Cancer in Iran: an Epidemiological Review. 2020 , 51, 418-424	7
672	In-vivo antiproliferative activity of leaf and bark extracts against Ehrlich's ascites carcinoma. 2020 , 36, 79-88	4
671	Progress in cancer biomarkers monitoring strategies using graphene modified support materials. 2020 , 210, 120669	27
670	Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1 mediated pathways. 2020 , 66, 109435	6
669	Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening. 2020 , 31, 101-109	3
668	MRI for Rectal Cancer Primary Staging and Restaging After Neoadjuvant Chemoradiation Therapy: How to Do It During Daily Clinical Practice. 2020 , 131, 109238	7
667	The Importance of Cancer Screening. 2020 , 104, 919-938	5
666	Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes multiple myeloma resistance through the JAK2/STAT3 pathway. 2020 , 257, 118088	2

665	Utility of Ultrasound for Evaluating Masses in the Pediatric Population. 2020 , 2, 235-245	
664	Formulation Design, Statistical Optimization, and In Vitro Evaluation of a Naringenin Nanoemulsion to Enhance Apoptotic Activity in A549 Lung Cancer Cells. 2020 , 13,	34
663	Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis. 2020 ,	2
662	Green synthesis of silver and iron nanoparticles of isolated proanthocyanidin: its characterization, antioxidant, antimicrobial, and cytotoxic activities against COLO320DM and HT29. 2020 , 18, 43	15
661	Higher dietary soy intake appears inversely related to breast cancer risk independent of estrogen receptor breast cancer phenotypes. 2020 , 6, e04228	2
660	Dielectric spectroscopy signature for cancer diagnosis: A review. 2020 , 62, 3739-3753	6
659	Advanced clinical trials of dendritic cell vaccines in ovarian cancer. 2020 , 68, 1223-1227	2
658	Green chemistry assisted synthesis of natural and synthetic compounds as anticancer agents. 2020 , 3-14	
657	Flexible ultrasonic array for breast-cancer diagnosis based on a self-shape-estimation algorithm. 2020 , 108, 106199	5
656	Adolescent overweight and obesity and the risk of papillary thyroid cancer in adulthood: a large-scale case-control study. 2020 , 10, 5000	4
655	Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. 2020 , 126, 2956-2964	7
654	Lymphadenectomy in Ovarian Cancer: Is It Still Justified?. 2020 , 22, 22	4
653	Ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma: a retrospective analysis of 198 patients. 2020 , 37, 168-174	24
652	Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression. 2020 , 22, 1491-1498	6
651	Quantitative Framework for Risk Stratification of Thyroid Nodules With Ultrasound: A Step Toward Automated Triage of Thyroid Cancer. 2020 , 214, 885-892	2
650	Involvement of Nrf2 and Keap1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent peptides from soft-shelled turtle. 2020 , 92, 174-181	14
649	The Remarkable Pharmacological Efficacy of Saffron Spice via Antioxidant, Immunomodulatory, and Antitumor Activities. 2020 , 245-262	
648	Prognostic performance of magnetic resonance imaging-guided biopsy in defining prostate cancer anterior lesions. 2021 , 39, 1473-1479	2

647	Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors. 2021 , 354, e2000237	21
646	Application of Rough Sets to Predict the Breast Cancer Risk Association with Routine Blood Analyses. 2021 , 10, 67-72	
645	Research Progress of Biological Characteristics and Anti-Tumor Immunotherapy of T Cells. 2021 , 11, 83-90	
644	Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial. 2021 , 22, 134	3
643	TGF- β signaling suppresses TCA cycle metabolism in renal cancer.	0
642	Circular RNAs: A Promising Biomarker for Endometrial Cancer. 2021 , 13, 1651-1665	4
641	Engineering confining microenvironment for studying cancer metastasis. 2021 , 24, 102098	3
640	Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. 2021 , 6, 100037	1
639	Is there a PSA cut-off value indicating incidental prostate cancer in patients undergoing surgery for benign prostatic hyperplasia?. 2021 , 93, 31-34	1
638	Unmet needs in the diagnosis and treatment of Romanian patients with bilio-pancreatic tumors: results of a prospective observational multicentric study. 2021 , 59, 286-295	
637	Esophageal squamous cell carcinoma metachronous to head and neck cancers. 2021 , 219, 153346	2
636	Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study. 2021 , 9, e25635	2
635	Imaging of ureter: a primer for the emergency radiologist. 2021 , 28, 815-837	
634	ROLE OF ULTRASONOGRAPHIC ELASTOGRAPHY IN THE DIFFERENTIAL DIAGNOSIS OF BREAST MASSES AND ITS CONTRIBUTION TO CLASSICAL ULTRASONOGRAPHIC EVALUATION. 2021 , 48-50	
633	Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives. <i>Cancers</i> , 2021 , 13,	6.6 1
632	Application-specific nuclear medical imaging devices. 2021 , 66,	0
631	Decreased expression of Dlg5 is associated with a poor prognosis and epithelial-mesenchymal transition in squamous cell lung cancer. 2021 , 13, 3115-3125	2
630	Nanocarrier-based drug delivery systems for bone cancer therapy: a review. 2021 , 16,	1

629	Trends in Breast Cancer Survival by Race-Ethnicity in Florida, 1990-2015. 2021 , 30, 1408-1415			1
628	Water-Soluble Total Flavonoids Isolated from var (Benth.) H. Hara Promote Hepatocellular Carcinoma Sensitivity to 5-Fluorouracil. 2021 , 2021, 6623212			0
627	Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells. <i>Frontiers in Oncology</i> , 2021 , 11, 645732	5:3		0
626	Pancreatic cancer: A review of epidemiology, trend, and risk factors. 2021 , 27, 4298-4321			17
625	CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies. 2021 , 22,			7
624	Data Mining and Systems Pharmacology to Elucidate Effectiveness and Mechanisms of Chinese Medicine in Treating Primary Liver Cancer. 2021 , 1			0
623	Immunohistochemical Expression of Retinoblastoma Gene Product and p53 Protein in Transitional Cell Carcinoma of the Urinary Bladder and its Relationship to Different Clinicopathological Parameters. 2021 , 9, 595-609			
622	Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab). 2021 , 12, 104-110			1
621	A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment. <i>Frontiers in Oncology</i> , 2021 , 11, 703465	5:3		5
620	Pathology findings among women with alterations in uterine bleeding patterns in cameroon. 2021 , 37, 100821			
619	Male breast cancer: an update. 2021 , 1			1
618	Lung Cancer Detection in Radiographs Using Image Processing Techniques. 2022 , 485-495			
617	Physiological and Disease Models of Respiratory System Based on Organ-on-a-Chip Technology. 2021 , 12,			3
616	TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer. 2021 , 12, 6356-6362			1
615	Risk Prediction-Based Breast Cancer Diagnosis Using Personal Health Records and Machine Learning Models. 2021 , 445-460			0
614	Effect of Medicinal Plants against Lung Cancer. 2021 , 285-302			0
613	Isolated hepatic perfusion: treating unresectable liver metastases. 2006 , 574, 1-16			5
612	Melanoma of the Skin. 2006 , 207-216			4

611	Possible immunoprotective and angiogenesis-promoting roles for malignant cell-derived prostasomes: a new paradigm for prostatic cancer?. 2006 , 586, 107-19	4
610	Strategies for colon cancer prevention: combination of chemopreventive agents. 2007 , 42, 213-25	19
609	High Frequency Quantitative Ultrasound Imaging of Solid Tumors in Mice. 2007 , 301-306	2
608	A Multiclassifier Approach for Lung Nodule Classification. 2006 , 612-623	5
607	Breast Cancer Diagnosis Using Neural-Based Linear Fusion Strategies. 2006 , 165-175	7
606	Thermal ablation in bone tumors. 2006 , 167, 135-46	5
605	Cancer and Sexual Minority Women. 2007 , 523-538	8
604	The Burden of Cancer Survivorship. 2007 , 7-18	12
603	Colorectal Cancer: Metastatic (Palliation). 2007 , 462-481	1
602	Lung Neoplasms. 2008 , 1491-1523	2
601	Classification of ovarian cancer: a genomic analysis. 2008 , 622, 23-33	5
600	Risk of waterborne illness via drinking water in the United States. 2008 , 192, 117-58	220
599	Common Non-Small-Cell Carcinomas and Their Variants. 2008 , 216-307	4
598	Apoptosis in Carcinogenesis and Chemotherapy [Esophageal Cancer]. 2009 , 127-156	1
597	Papillary Carcinoma. 2006 , 253-260	2
596	Taxane-Based Chemotherapy for Prostate Cancer. 2007 , 445-462	1
595	Lifestyle, genes, and cancer. 2009 , 472, 25-56	31
594	Animal Models of Cancer Pain. 2011 , 117-145	1

593	Cross-Sectional Imaging of Renal Cell Carcinoma. 2009 , 61-83	1
592	Epidemiology of Renal Cell Carcinoma. 2008 , 1-8	1
591	Epidemiology of Skin Cancer: Update 2019. 2020 , 1268, 123-139	58
590	Skin Cancer. 2017 , 257-284	1
589	Breast Imaging with Scintimammography. 2008 , 57-70	1
588	Primary dietary prevention: is the fiber story over?. 2007 , 174, 171-7	15
587	Prostate cancer treatment and quality of life. 2007 , 175, 251-65	8
586	Introduction. 2007 , 1-26	4
585	Hodgkin and non-Hodgkin lymphomas during pregnancy. 2008 , 178, 111-21	3
584	Counseling young cancer patients about reproductive issues. 2008 , 178, 237-45	2
583	Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. 2008 , 177, 137-50	69
582	OCT in Gynecology. 2008 , 1211-1240	2
581	Natural Products in Cancer Chemoprevention and Chemotherapy. 2009 , 153-171	9
580	The Performance of CTC. 2010 , 17-28	1
579	Liver Cancer. 2011 , 225-249	1
578	Recent Advances in Reduction of False Positives in Computerized Detection of Polyps in CT Colonography. 2011 , 32-39	1
577	Breast Cancer Liver Metastasis. 2011 , 273-303	2
576	Mouse Models of Pancreatic Cancer. 2013 , 57-91	1

575	Methylation in Colorectal Cancer. 2015 , 373-455	1
574	A Decision Model to Predict Clinical Stage of Bladder Cancer. 2018 , 829-838	2
573	Fuzzy Inference System for Efficient Lung Cancer Detection. 2020 , 33-41	4
572	Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. 2006 , 31, 490	2
571	Cancer of the Breast. 2008 , 1875-1943	8
570	Acute Myeloid Leukemia in Adults. 2008 , 2215-2234	1
569	Ovarian neoplasia: epidemiology and etiology. 2009 , 601-610	10
568	Early Treatment with Radiation and Chemotherapy. 2010 , 129-165	1
567	Colorectal Cancer. 2014 , 1278-1335.e14	1
566	Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro. 2010 , 12, 697-708	29
565	Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data. 2012 , 14, 385-92	3
564	Evaluation of serum phosphopeptides as potential biomarkers of gastric cancer. 2017 , 7, 21630-21637	6
563	Computer aided detection system for lung cancer using computer tomography scans. 2018 ,	3
562	Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. 2006 , 060118075408001	7
561	Cancer of the Lung. 2006 , 638-658	29
560	Cancer of the Pancreas. 2006 , 721-762	71
559	Colorectal cancer screening: today and tomorrow. 2006 , 99, 240-6; quiz 247-9	6
558	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. 2006 , 1, 52-60	11

557	Prognostic Value of Fluorodeoxyglucose Positron Emission Tomography in Non-small Cell Lung Cancer: A Review. 2006 , 1, 152-159	30
556	Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594. 2006 , 1, 441-446	91
555	Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer. 2006 , 1, 635-647	26
554	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. 2006 , 1, 1010-1019	16
553	Diagnosis of marginal cell lymphoma of small intestine by double balloon enteroscopy. 2008 , 101, 561-4	4
552	Palliation of malignant rectal obstruction from invasive prostate cancer with multiple overlapping self-expanding metal stents. 2009 , 102, 1257-9	7
551	Study of the role of telomerase in colorectal cancer: preliminary report and literature review. 2017 , 38, 213-218	6
550	Reduction of unnecessary thyroid biopsies using deep learning. 2019 ,	4
549	Chemotherapy for elderly colorectal cancer patients at a tertiary hospital in South Africa. 2020 , 37, 100	2
548	Are you sure this is Waldenström macroglobulinemia?. 2012 , 2012, 586-594	27
547	Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer. 2015 , 25, 8	8
546	Delayed post-diuretic 18F-FDG PET/CT: can it help in determination of the best clinical decision for muscle invasive UB cancer patients?. 2019 , 50,	3
545	Atomic Force Microscopy for Medicine. 2011 , 421-436	2
544	Cancer education for home health care workers: a process evaluation. 2005 , 20, 229-34	1
543	Cancer research training: the Southwest Oncology Group young investigator training program (YITP). 2006 , 21, 77-9	1
542	Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. 2016 , 22, 276-83	12
541	Diagnostic Value of Conventional Ultrasonography Combined with Contrast-Enhanced Ultrasonography in Thyroid Imaging Reporting and Data System (TI-RADS) 3 and 4 Thyroid Micronodules. 2016 , 22, 3086-94	12
540	Advances in the management of basal cell carcinoma. 2015 , 7, 53	25

539	Complete remission of primary hepatic lymphoma in a patient with human immunodeficiency virus. 2015 , 3, 186-90	2
538	Human Breast Cancer Identification by K-Space Analysis of Optical Coherence Tomography Images. 2006 ,	2
537	Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. 2006 , 3, e232	63
536	Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. 2008 , 3, e1592	45
535	Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. 2008 , 3, e2079	97
534	Mitochondrial DNA haplogroup analysis reveals no association between the common genetic lineages and prostate cancer in the Korean population. 2008 , 3, e2211	28
533	The intracellular localization of ID2 expression has a predictive value in non small cell lung cancer. 2009 , 4, e4158	23
532	CTIP2 expression in human head and neck squamous cell carcinoma is linked to poorly differentiated tumor status. 2009 , 4, e5367	24
531	Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. 2009 , 4, e6555	71
530	Repressive effects of resveratrol on androgen receptor transcriptional activity. 2009 , 4, e7398	30
529	GLUT 5 is not over-expressed in breast cancer cells and patient breast cancer tissues. 2011 , 6, e26902	23
528	Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas. 2012 , 7, e41746	25
527	Detection of rib metastases in patients with lung cancer: a comparative study of MRI, CT and bone scintigraphy. 2012 , 7, e52213	8
526	Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. 2013 , 8, e59083	67
525	Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris. 2013 , 8, e61088	41
524	Transcript profiling identifies iqgap2(-/-) mouse as a model for advanced human hepatocellular carcinoma. 2013 , 8, e71826	15
523	Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. 2014 , 9, e87703	53
522	The Anti-Proliferative Effect of Boron Neutron Capture Therapy in a Prostate Cancer Xenograft Model. 2015 , 10, e0136981	7

521	The treatment of brain metastasis from breast cancer, role of blood-brain barrier disruption and early experience with trastuzumab. 2006 , 3, 97-112	2
520	Molecular markers in lung cancer: prognostic role and relationship to smoking. 2006 , 32, 56-65	22
519	Psychological Predictors of Prostate Cancer Screening Behaviors Among Men Over 50 Years of Age in Hamadan: Perceived Threat and Efficacy. 2016 , 9, e4144	8
518	Current cancer stem cell biomarkers in laryngeal cancer.	1
517	Musashi1 as a potential therapeutic target and diagnostic marker for lung cancer. 2013 , 4, 739-50	35
516	Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue. 2013 , 4, 1472-83	14
515	A polysaccharide from <i>Lentinus edodes</i> inhibits human colon cancer cell proliferation and suppresses tumor growth in athymic nude mice. 2017 , 8, 610-623	38
514	Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. 2014 , 5, 7917-35	50
513	Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition. 2014 , 5, 716-25	28
512	A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. 2014 , 5, 2487-98	31
511	Hydrogen peroxide/ATR-Chk2 activation mediates p53 protein stabilization and anti-cancer activity of cheliensisin A in human cancer cells. 2014 , 5, 841-52	18
510	CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. 2014 , 5, 1969-86	48
509	CTCF promotes epithelial ovarian cancer metastasis by broadly controlling the expression of metastasis-associated genes. 2017 , 8, 62217-62230	12
508	Hepatocyte growth factor-like protein is required for prostate tumor growth in the TRAMP mouse model. 2014 , 5, 5547-58	9
507	The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. 2014 , 5, 6896-908	24
506	A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. 2014 , 5, 9007-21	5
505	Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. 2014 , 5, 8703-15	21
504	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. 2014 , 5, 8147-60	64

503	The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer. 2014 , 5, 9362-81	95
502	GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. 2014 , 5, 9460-71	21
501	C-X-C Motif Ligand 1 (CXCL1) from melanoma cells down-regulates the invasion of their metastatic melanoma cells. 2018 , 9, 31090-31097	2
500	Targeting cytosolic phospholipase A2 in colorectal cancer cells inhibits constitutively activated protein kinase B (AKT) and cell proliferation. 2014 , 5, 12304-16	13
499	Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. 2015 , 6, 2812-26	39
498	Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. 2015 , 6, 5832-45	27
497	A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells. 2015 , 6, 7686-700	35
496	Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]. 2012 , 3, 686-99	29
495	DNA damage-induced activation of ATM promotes TRCP-mediated Mdm2 ubiquitination and destruction. 2012 , 3, 1026-35	25
494	Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. 2016 , 7, 5877-91	21
493	Gene expression-based risk score in diffuse large B-cell lymphoma. 2012 , 3, 1700-10	18
492	Assessment of Two-Years Bladder Biopsy and Cystectomy Outcomes. 2017 , 3, 11-11	0
491	Secondary metastatic lesions to colon and rectum. 2018 , 31, 282-287	20
490	Angiogenesis in cancer. 2006 , 2, 213-9	772
489	Clinical and Translational Research Challenges in Biliary Tract Cancers. 2020 , 27, 4756-4777	10
488	Thymoquinone, an Active Compound of Nigella sativa: Role in Prevention and Treatment of Cancer. 2020 , 21, 1028-1041	11
487	Phytochemicals: Key to Effective Anticancer Drugs. 2019 , 16, 141-158	4
486	Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans. 2018 , 15, 185-191	3

485	Cancer patients' self-reported attitudes about the Internet. 2005 , 7, e22	32
484	Evaluation of Therapeutic Potential of Eugenol-A Natural Derivative of Syzygium aromaticum on Cervical Cancer. 2018 , 19, 1977-1985	11
483	Radiation therapy for older cancer patients. 2006 , 2, 919-930	3
482	Chemotherapy in the elderly. 2007 , 3, 165-175	2
481	Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. 2007 , 12, 2279-90	45
480	Type 2 diabetes and cancer. 2020 , 4, 001-006	1
479	Single Nucleotide Polymorphism in Adiponectin Gene and Risk of Pancreatic Adenocarcinoma. 2019 , 20, 139-143	2
478	Opinions of the Urban Women on Pap test: Evidence from Bangladesh. 2019 , 20, 1613-1620	3
477	Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass. 2018 , 21, 505-511	17
476	Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. 2007 , 14, 154-61	31
475	Relationship between expression of gastrin, somatostatin, Fas/FasL and caspases in large intestinal carcinoma. 2008 , 14, 2802-9	3
474	Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. 2008 , 14, 3681-92	25
473	Tumor suppress genes screening analysis on 4q in sporadic colorectal carcinoma. 2008 , 14, 5606-11; discussion 5609-10	8
472	Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. 2007 , 13, 1947-52	24
471	Metastatic colorectal cancer-past, progress and future. 2007 , 13, 3806-15	51
470	DNA polymorphism and risk of esophageal squamous cell carcinoma in a population of North Xinjiang, China. 2010 , 16, 641-7	24
469	Clinicopathologic significance of GLUT1 expression and its correlation with Apaf-1 in colorectal adenocarcinomas. 2011 , 17, 1866-73	20
468	Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. 2011 , 17, 3126-32	4

467	Prognostic analysis and comparison of colon cancer in Han and Hui patients. 2014 , 20, 5082-6	8
466	Post-cancer Treatment with Condurango 30C Shows Amelioration of Benzo[a]pyrene-induced Lung Cancer in Rats Through the Molecular Pathway of Caspa- se-3-mediated Apoptosis Induction: -Anti-lung cancer potential of Condurango 30C in rats. 2013 , 16, 11-22	9
465	Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model. 2017 , 13, 3767-3773	4
464	Function of miR-200a in proliferation and apoptosis of non-small cell lung cancer cells. 2020 , 20, 1256-1262	5
463	Prevalence of Oral and Pharyngeal Cancers in Kermanshah Province, Iran: A Ten-year Period. 2016 , 12, 169-175	9
462	Efficacy of Emodin/Paclitaxel Versus Paclitaxel for the Treatment of Ovarian Cancer in vivo. 2016 , 12, 743-748	2
461	Targeted therapies in the treatment of cancer. 2005 , 36, 193-4	1
460	Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of BCG treatment of bladder cancer. 2011 , 8, 529-47	10
459	Endoscopic ultrasonography for pancreatic cancer: current and future perspectives. 2013 , 4, 220-30	24
458	Delayed diagnosis of pancreatic cancer reported as more common in a population of North African young adults. 2015 , 6, 505-10	7
457	A review of computer-aided diagnosis in thoracic and colonic imaging. 2012 , 2, 163-76	38
456	"Vanishing liver metastases"-A real challenge for liver surgeons. 2014 , 3, 295-302	5
455	Endometrial Assessment: When is it Necessary?. 2014 , 6, 21-5	7
454	Tumor doubling time of renal cell carcinoma measured by CT. 2014 , 30, 153-7	6
453	Impact of age and gender on the clinicopathological characteristics of bladder cancer. 2009 , 25, 207-10	51
452	Role of human papillomavirus and tumor suppressor genes in oral cancer. <i>Journal of Oral and Maxillofacial Pathology</i> , 2016 , 20, 106-10	1.2 3
451	The influence of urine cytology on our practice. 2012 , 4, 80-3	8
450	Multimodality Imaging Characteristics of the Common Renal Cell Carcinoma Subtypes: An Analysis of 544 Pathologically Proven Tumors. 2016 , 6, 50	8

449	Methylation pattern of ALX4 gene promoter as a potential biomarker for blood-based early detection of colorectal cancer. 2015 , 4, 252	15
448	Evaluation of Cytotoxicity Effects of Oleo-Gum-Resin and Its Essential Oil of and Ferulic Acid on 4T1 Breast Cancer Cells. 2017 , 38, 116-120	12
447	Role of MRI in staging and surgical planning and its clinicopathological correlation in patients with renal cell carcinoma. 2019 , 29, 277-283	1
446	Efficacy of Color Doppler Ultrasonography in Differentiation of Ovarian Masses. 2019 , 10, 22-28	4
445	Patterns of failure after postoperative radiation therapy for endometrial carcinoma. 2006 , 38, 133-8	2
444	Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -. 2006 , 38, 189-97	17
443	Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. 2009 , 41, 67-72	57
442	Cytoplasmic expression of HuR is related to cyclooxygenase-2 expression in colon cancer. 2009 , 41, 87-92	36
441	Management of Breast Cancer in Visceral Surgery of CNHU-HKM of Cotonou in Benin. 2016 , 07, 170-176	3
440	Radiofrequency ablation of pancreatic ductal adenocarcinoma: The past, the present and the future. 2015 , 7, 6-11	23
439	Prediction of tumor grade and stage in endometrial carcinoma by preoperative assessment of sonographic endometrial thickness: Is it possible?. 2014 , 11, 211-214	2
438	The role of the CpG island methylator phenotype on survival outcome in colon cancer. 2015 , 9, 202-7	12
437	Comparison of power Doppler ultrasound with gray scale transrectal ultrasound in predicting cancer positive prostate biopsy cores. 2010 , 42, 81-5	5
436	Effects of Anti-ecotoxicological Curcumin Nanospheres on Feed Efficiency and Fecal Odor in Mice. 2019 , 28, 183-189	2
435	Screening and Purification of an Anti-Prostate Cancer Compound, Deoxypodophyllotoxin, from <i>Anthriscus sylvestris</i> Hoffm. 2009 , 19, 9-14	3
434	Protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9. 2013 , 46, 533-8	15
433	Sulforaphane controls TPA-induced MMP-9 expression through the NF- κ B signaling pathway, but not AP-1, in MCF-7 breast cancer cells. 2013 , 46, 201-6	45
432	The value of 18 F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy. 2012 , 156, 171-9	14

431	Methylation status as a predictor of intravesical Bacillus Calmette-Guérin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor. 2017 , 161, 210-216	11
430	Ethanollic extract of Condurango (<i>Marsdenia condurango</i>) used in traditional systems of medicine including homeopathy against cancer can induce DNA damage and apoptosis in non small lung cancer cells, A549 and H522, in vitro. 2013 , 3, 9.1-9.10	4
429	Stage T1N0M0 renal cell carcinoma: the prognosis in Asian patients. 2011 , 30, 772-8	7
428	Limited sampling of radical prostatectomy specimens with excellent preservation of prognostic parameters of prostate cancer. 2009 , 133, 1278-84	16
427	Papillary thyroid carcinoma: an overview. 2006 , 130, 1057-62	53
426	Key issues in handling and reporting radical prostatectomy specimens. 2006 , 130, 303-17	72
425	Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry. 2007 , 131, 599-603	30
424	Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. 2007 , 131, 902-8	39
423	Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. 2012 , 67, 419-24	34
422	Association between EGF, TGF- β and TNF- α gene polymorphisms and hepatocellular carcinoma. 2012 , 13, 6217-20	15
421	Perioperative comprehensive supportive care interventions for chinese patients with esophageal carcinoma: a prospective study. 2013 , 14, 7359-66	18
420	Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. 2013 , 14, 691-4	10
419	Incidence and trends of malignant and benign pancreatic lesions in Yazd, Iran between 2001 and 2011. 2013 , 14, 2631-5	12
418	Cyclin D1, retinoblastoma and p16 protein expression in carcinoma of the gallbladder. 2013 , 14, 2711-5	20
417	Use of an artificial neural network to predict risk factors of nosocomial infection in lung cancer patients. 2014 , 15, 5349-53	7
416	Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. 2014 , 15, 2591-6	18
415	ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. 2014 , 15, 2777-83	32
414	P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience. 2015 , 16, 5043-7	7

413	Use of an Artificial Neural Network to Construct a Model of Predicting Deep Fungal Infection in Lung Cancer Patients. 2015 , 16, 5095-9	12
412	Trends and Analysis of Cancer Incidence for Common Male and Female Cancers in the Population of Punjab Province of Pakistan during 1984 to 2014. 2015 , 16, 5297-304	9
411	Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. 2015 , 16, 6001-6	5
410	Update knowledge on cervical cancer incidence and prevalence in Asia. 2015 , 16, 3617-20	24
409	The Value of Preoperative CA 125 Levels in Prediction of Myometrial Invasion in Patients with Early-stage Endometrioid- type Endometrial Cancer. 2016 , 17, 497-501	4
408	Emerging targets for glioblastoma stem cell therapy. 2016 , 30, 19-31	26
407	Treating hepatocellular carcinoma with Y-bearing microspheres: a review. 2016 , 6, 19	14
406	The TGF- β /HDAC7 axis suppresses TCA cycle metabolism in renal cancer. 2021 , 6,	1
405	Chronische pijn chronische pijn na borstkankerchirurgie borstkankerchirurgie. 2004 , 1317-1322	
404	Docetaxel-based therapy for prostate cancer. 2005 , 1, 231-240	
403	Androgens, DHEA and breast cancer. 2005 , 113-135	
402	Management of early-stage ovarian cancer. 2005 , 57-86	1
401	Cancer. 2006 , 448-462	
400	Genitourinary Oncology. 2006 , 123-130	
399	Confocal Mosaicing of Basal Cell Carcinomas in Mohs Micrographic Surgical Skin Excisions. 2006 ,	
398	Colorectal cancer screening: cost-effectiveness and adverse events. 2006 , 91-103	
397	Follicular Thyroid Carcinoma. 2006 , 517-522	
396	Peptide Vaccines for Cancer Treatment. 2006 , 499-505	

395 The Thyroid Nodule. **2006**, 201-210

394 PET in Melanoma. **2006**, 75-88

393 The treatment of brain metastasis from breast cancer, role of bloodBrain barrier disruption and early experience with trastuzumab. **2006**, 3, 97-112 1

392 Clinical Protocol: Phase I Study of an Adenovirus/Prostate-Specific Antigen Vaccine in Men with Metastatic Prostate Cancer. **2006**, 060123080936010

391 Image-Guided Ablation of Renal Tumors. **2006**, 381-408

390 Nuclear Medicine in Nephrourology. **2006**, 317-324

389 Adenovirus-Mediated and Targeted Expression of the Sodium-Iodide Symporter Permits In Vivo Radioiodide Imaging and Therapy of Pancreatic Tumors. **2006**, 060801084750017

388 Lycopene Dietary Supplements and Prostate Cancer Treatment. **2006**, 2, 72-75

387 Uterine Cervix Cancer.

386 Bladder Cancer.

385 Molecular Mechanisms of Chemoprevention of Cancer by Pomegranate. **2006**, 135-150

384 Combination ofPTENGene Therapy and Radiation Inhibits the Growth of Human Prostate Cancer Xenografts. **2006**, 060919113707002 1

383 The Multifactorial Model of Cardiovascular Pathology. **2006**, 93-131

382 Novel Biomarkers for Disease Diagnosis, Prognosis, and Prediction. **2006**, 39-57

381 Cancer Chemoprevention. **2006**, 1318-1340 1

380 Expanding the Role of EGFR Inhibitors in Prostate Cancer. **2006**, 209-221

379 The Molecular Pathogenesis and Pathophysiology of Prostate Cancer. **2006**, 1-25

378 Gastrointestinal Malignancies. **2007**, 370-381

377 Aging, Cancer, and Translational Research. **2007**, 57-68

376 Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: Long-term maspin expression efficiently suppresses tumor growth. **2007**, 119, 1-5

375 A Comparative Study of Operated and Non-operated Groups in Patients with Hepatic Metastasis from Colorectal Cancer. **2007**, 23, 477

374 Preinvasive Disease of the Vagina and Vulva and Related Disorders. **2007**, 37-54

373 Gastric and colon neoplasms. **2007**, 237-239

372 Neoplasms of the prostate. **2007**, 245-247

371 Neoplasms of the breast. **2007**, 233-236

370 Oral Cancer: Prevention, Management, and Treatment. **2007**, 273-310

369 Breast Cancer. **2007**, 821-840

1

368 The Role of Targeted Therapy in the Treatment of Metastatic Colorectal Cancer. **2007**, 23, 524

1

367 Neoplasms of the brain. **2007**, 229-231

366 Oncologic Emergencies. **2007**, 142-171

365 Endometrial Cancer and Hormonal Replacement Therapy. **2007**, 585-591

364 Stereotactic Radiosurgery for Liver Malignancies Using the CyberKnife. **2007**, 217-225

1

363 Postmenopausal Breast Surveillance. **2007**, 579-584

362 Flexible Sigmoidoscopy. **2007**, 433-444

361 Laparoscopy Assisted Minilaparotomy Radical Retropubic Prostatectomy (LaMRRP) for Localized Prostate Cancer. **2007**, 48, 579

360 Neoplasms of the skin. **2007**, 241-244

- 359 Principles of Surgical Therapy. **2007**, 39-52
- 358 Prevalence of Diet-Related Chronic Diseases. **2007**, 119-157
- 357 Antiangiogenic Therapy for Prostate Cancer. **2007**, 645-672
- 356 Topotecan for advanced non-small cell lung cancer.
- 355 Mucormycosis. **2007**, 215-230
- 354 Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma. **2007**, 223-254
- 353 Novel Options of Therapy in Waldenström Macroglobulinemia. **2007**, 277-297
- 352 Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma. **2007**, 211-242
- 351 Vitrification of ovarian tissues. **2007**, 273-292
- 350 Parathyroid carcinoma/malignancy. **2007**, 377-386
- 349 Skeletal malignancies. **2007**, 403-416
- 348 Cancer of the colon, rectum and anus. **2007**, 189-212
- 347 Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs. **2008**, 383-390
- 346 Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma. **2008**, 279-288
- 345 Chemotherapy for Tumors of the Spine. **2008**, 317-326
- 344 ?????????????? REIC/Dkk-3?????????????????????????????. **2008**, 120, 135-141
- 343 Colon, Rectum, and Anus. **2008**, 1011-1110
- 342 Loss of Heterozygosity in Lung Diseases. **2008**, 108-116

341 Potential New Staging Perspectives in Colorectal Cancer. **2008**, 365-372

340 Melanoma and Other Cutaneous Malignancies. **2008**, 2037-2059

339 Molecular Genetics in Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes. **2008**, 97-114

338 BIOLOGY AND EPIDEMIOLOGY OF LUNG CANCER. **2008**, 708-728

0

337 Incidental Extracolonic Lesions. **2008**, 339-354

336 FDG-PET and FDG-PET/CT in breast cancer. **2008**, 170, 125-40

1

335 Estudio mediante ecografía Doppler de la próstata. **2008**, 245-249

334 Melanoma. **2008**, 204-215

333 Renal Cell Carcinoma: Overview. **2008**, 263-280

4

332 Epidemiology of Renal Tumors. **2008**, 73-96

331 Vagina. **2008**, 311-339

330 Bortezomib as Induction Therapy in Patients with Multiple Myeloma. **2008**, 253-263

329 Protein microarrays in molecular oncology. **2008**, 21, 85-89

328 In Vivo Assessment of Microvascular Blood Content in the Rectal Mucosa Using Polarization-Gated Spectroscopy: Applications for Colon Cancer Screening. **2008**,

327 Role of Radiation Therapy in Advanced Renal Cell Carcinoma. **2008**, 497-505

326 Detection of Breast Cancer: Screening of Asymptomatic Patients. **2008**, 1-37

325 Gynecologic Cancer. **2008**, 160-173

324 Antisense Oligonucleotides and siRNA as Specific Inhibitors of Gene Expression: Mechanisms of Action and Therapeutic Potential. **2008**, 337-362

323 Liver. **2008**, 943-961

322 Cancer. **2008**, 103-129

321 Chemopreventive Potential of Cranberries on Azoxymethane Induced Aberrant Crypt Foci in Fisher 344 Male Rats. **2008**, 4, 52-60 3

320 Avaliaçã da expressã da caspase-3 no adenocarcinoma colorretal atravẽ de um sistema computadorizado de anãlise de imagem. **2008**, 21, 33-37 0

319 Melanoma in Hispanics. **2008**, 3, 279-285

318 Inhibitory Effects of Feeding Selected Levels of Peanuts on Azoxymethane-Induced Aberrant Crypt Foci in Male Fisher 344 Rats. **2008**, 4, 146-153 1

317 Adjuvant Chemotherapy. **2009**, 1-7

316 Protective Effect of Green Algae Against 7,12-Dimethylbenzanthracene (DMBA)-Induced Breast Cancer in Rats. **2008**, 5, 12-24 6

315 Expressã citofotomãtrica do marcador CD-34 no adenocarcinoma de cãbn. **2008**, 28, 409-413

314 Molecular Genetics in Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes. **2009**, 13-33

313 Adjuvant Therapy for Renal Cell Carcinoma: Targeted Approaches. **2009**, 473-495

312 A Novel Approach in Melanoma Identification. **2009**, 1438-1441

311 Identification of Lung Cancer Metastasis Related Gene Expression Profile Using Combined Transcriptome Analysis. **2009**, 49, 902-909

310 The Relationship between Prognostic Factors and the Expression Pattern of Fascin and E-cadherin in Renal Cell Carcinoma. **2009**, 43, 139

309 Clinical Follow-Up Study for Brain Metastases of Renal Cell Carcinoma. **2009**, 50, 224

308 Well-Differentiated Thyroid Cancer: An Overview and the Chernobyl Effect. **2009**, 111-120

307 Clinical Approach. **2009**, 281-285

306 On Data Quality and Risk in Guideline Based Clinical Decision Support.

- 305 Percutaneous Interventional Technique for Intra-arterial Chemoembolization. **2009**, 569-588
- 304 Maligne Hodentumoren. **2009**, 637-738
- 303 Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. **2009**, 133, 470-7 36
- 302 Hypofractionated radiotherapy in the elderly: sometimes less is more. **2009**, 5, 359-367
- 301 Renal Cell Carcinoma: Follow-Up with Magnetic Resonance Imaging After Percutaneous Radiofrequency Ablation. **2010**, 108-113 1
- 300 Malignant Lymphoma of the Ileum Treated by Laparoscopically Assisted Bowel Resection : A Case Report. **2010**, 60, 367-370
- 299 Ruolo della RM con USPIO nella valutazione del parametro N. **2010**, 139-144
- 298 Radiofrequency Ablation of Lung Tumors. **2010**, 266-274
- 297 Tumorbiologische und molekulargenetische Aspekte. **2010**, 38-51
- 296 Skin Cancer Under Special Circumstances. **2010**, 149-210
- 295 Geographic Disparities in Cancer Survival and Access to Care. **2010**, 1, 67-79
- 294 GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX. **2010**, 329-342
- 293 Strategies for Oral Cancer Detection. **2010**, 45-58 2
- 292 Invasiveness of and Drug Sensitivity to Various Anti-cancer Regimens in Five Colorectal Cancer Cell Lines. **2010**, 26, 98
- 291 Topotecan for advanced non-small cell lung cancer.
- 290 hTERT Expression in Thyroid Nodule. **2010**, 78, 277
- 289 Evaluation of Malignant and Premalignant Skin Lesions. **2010**, 159-169
- 288 MUTYH-Associated Polyposis. **2010**, 349-362

- 287 Substance Addiction and Gastrointestinal Malignancy. 347-360
- 286 Bortezomib in Waldenström Macroglobulinemia. **2011**, 123-133
- 285 PET-CT in Breast Cancer. **2011**, 227-243
- 284 Surgery for metastatic colorectal cancer. **2010**, 130-146
- 283 [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy]. **2010**, 151, 1956-60 ○
- 282 Tumorigenesis after Injection of Lung Cancer Cell Line (SW-900 G IV) into the Pleural Cavity of Nude Mice. **2010**, 43, 588-595
- 281 Urologie. **2011**, 505-631
- 280 Kopf-Hals-Region. **2011**, 633-728
- 279 Pneumologie. **2011**, 89-189
- 278 Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma with Sorafenib in a Reference Center in Mexico. **2011**, 02, 356-359
- 277 Lymphome. **2011**, 755-817
- 276 Colorectal Cancer: Metastatic (Palliation). **2011**, 783-802
- 275 Gynäkologie. **2011**, 367-503
- 274 Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder. **2011**, 27, 262-8
- 273 Variant angina pectoris associated with FOLFOX4 therapy. **2011**, 3, 165-8
- 272 A Case of Simultaneous Histiocytic Sarcoma and Ileus. **2011**, 44, 178-185 ○
- 271 Cruciferous Vegetable-Derived Isothiocyanates and Cancer Prevention. 147-170
- 270 Malignant Thyroid Conditions. **2012**, 107-149

- 269 Prospective Single-Arm Study of Radioprotection by Amifostine in High Dose Radioactive Iodine Therapy for Thyroid Cancer. **2012**, 46, 90-94
- 268 Prostate cancer presenting as cervical lymphadenopathy. **2012**, 13, 206-8 6
- 267 Cancer of the Esophagus. **2012**, 839-858
- 266 Prostate Cancer. **2012**, e51-1-e51-85
- 265 Breast Cancer. **2012**, 692-703.e4
- 264 Smoking Cause Specific Lung Cancer Evidence from Non-Smoking Lung Adenocarcinoma. **2012**, 03, 435-441
- 263 A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus. **2012**, 15, 31-5 3
- 262 Benign and Malignant Tumors of the Esophagus. **2013**, 579-598
- 261 Effects of Green Pepper (*Capsicum annum* var.) on Antioxidant Activity and Induction of Apoptosis in Human Breast Cancer Cell Lines. **2012**, 44, 750-758 6
- 260 Breast Imaging. **2013**, 23-44
- 259 Locally Advanced Non-Small Cell Lung Cancer in the Elderly: What Combination of Therapy Is Best?. **2013**, 173-183
- 258 Adjuvant Chemotherapy of Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with Resected Non-Small Cell Lung Cancer. **2013**, 04, 15-23 1
- 257 Kopf-Hals-Tumoren. **2013**, 431-515
- 256 The Role of MicroRNA in Head and Neck Cancer. **2013**, 1019-1048
- 255 Evaluation of Glutathione, Albumin and Ascorbic Acid Levels in Breast Cancer Patients. **2013**, 04, 405-408
- 254 Percutaneous Interventional Radiology: The Lung. **2013**, 535-558
- 253 PATHOLOGIE TUMORALE DU PARENCHYME PULMONAIRE. **2013**, 277-451
- 252 Colon Cancer. 269-282

- 251 References. **2013**, 247-255
- 250 Ovarian Cancer. 335-345
- 249 Lung and Airway Segmentation using Morphology Information and Spline Interpolation in Lung CT Image. **2013**, 18, 702-712
- 248 Maligne Hodentumoren. **2014**, 677-782 0
- 247 Neoplasms of the brain. **2014**, 245-248
- 246 Prostatakarzinom. **2014**, 513-676
- 245 Possible Chemosensitizing and Potent Anticancer Effects of D-Fraction in Combination with Vitamin C on Three Prevalent Urologic Cancer Cells. **2014**, 05, 1402-1411 0
- 244 Automatic Segmentation of Lung, Airway and Pulmonary Vessels using Morphology Information and Advanced Rolling Ball Algorithm. **2014**, 51, 173-181
- 243 HORMONE RECEPTOR STATUS AND HER - 2/NEU EXPRESSION IN BREAST CARCINOMA AND ITS CORRELATION WITH CLINICO - PATHOLOGICAL FEATURES: A STUDY AT MEDICAL COLLEGE HOSPITAL. **2014**, 3, 4591-4594
- 242 SIGNIFICANCE OF ESTROGEN AND PROGESTERONE RECEPTOR STATUS IN PROGNOSIS OF BREAST CANCER. **2014**, 3, 6011-6017
- 241 Evaluation of the Relationship Between Prostate-Specific Antigen and Prostate Size and Also PSA and BMI in Subjects Referred to the Check-up Clinic of Razavi Hospital. **2014**, 2,
- 240 Percutaneous Ultrasound-Guided Microwave Ablation of Liver Metastasis. **2015**, 29-40 1
- 239 The Cumulative Recurrence Rate of Colonic Adenomatous Polyps After Colon Polypectomy in a Single University Hospital Health Check-up Examinees. **2014**, 39, 137-145
- 238 Squamous Cell Carcinoma of the Anal Canal. **2015**, 513-535
- 237 PRIMARY PAPILLARY ADENOCARCINOMA OF VAGINA: A RARE CASE REPORT. **2014**, 1, 842-845
- 236 Benign Prostatic Pathology. **2015**, 159-181
- 235 OCT in Gynecology. **2015**, 2305-2334
- 234 Simultaneous surgical treatment of giant infrarenal aortic aneurysm and transverse colon cancer complicated by ileus. **2015**, 8, 89 1

233 Colorectal Cancer Surgery in Extreme Elderly Population. **2015**, 06, 12-20

232 Biomarkers for Early Detection of Familial Breast Cancer. **2015**, 167-190

231 Therapeutic Impact of Vitamin C on the Anticancer Activities of Genistein Isoflavone in Radiosensitized Lncap Prostate Cancer Cells. **2015**, 2,

0

230 Epidemiologie, Diagnostik und chirurgische Therapie des Nierenzellkarzinoms. **2016**, 21-30

229 Kopf-Hals-Tumoren. **2016**, 631-672

228 Urologische Tumoren. **2016**, 247-325

227 Lymphome. **2016**, 369-414

226 Gynäkologische und Brusttumoren. **2016**, 167-246

225 Colorectal Cancer in the Elderly. **2016**, 289-310

224 Malignant Melanoma and Nonmelanoma Skin Cancer. **2016**, 387-408

223 Does Adjuvant Chemotherapy Improve Outcomes in Pancreatic Adenocarcinoma?. **2016**, 261-272

222 Expanding the Role of EGFR Inhibitors in Prostate Cancer. **2016**, 227-240

221 Novel Biomarkers for Disease Diagnosis, Prognosis, and Prediction. **2016**, 57-76

220 Neurological complications of malignant melanoma. **2016**, 265-278

219 The Role of Radiation Therapy for the Treatment of Pancreatic Adenocarcinoma. **2016**, 245-260

218 Elevated ZC3H15 increases HCC growth and predicts poor survival after surgical resection. **2016**, 7, 37238-37249

217 ASSESSMENT OF THE RISK OF METASTASIS IN PATIENTS WITH ENDOMETRIAL CARCINOMA. **2016**, 55, 5-12

216 Ovarian Cancer in the Elderly. **2017**, 113-132

- 215 Patient-Reported Outcomes of Chemotherapy Involving Non-Small Cell Lung Cancer: Evaluation by Questionnaires of Quality of Life Regarding Anti-Aging and Anti-Cancer Drugs. **2017**, 06, 13-35
- 214 Introduction: The African Diaspora and Disease-Specific Disparities. **2017**, 1-14
- 213 Endoscopic Ultrasound-Guided Fine Needle Aspiration Accurately Diagnoses Smaller Pancreatic Neuroendocrine Tumors Compared To Computer Tomography-Guided Fine Needle Aspiration. **2017**, 4, 1-7
- 212 Pancreatic Cancer Cachexia: Current Concepts and Clinical Management. ○
- 211 Reduction in training time of a deep learning model in detection of lesions in CT. **2018**,
- 210 ERKEK HASTALARIN PROSTAT KANSERİ TARAMALARI HAKKINDA BİLGİDİZEYLERİ 184-191 1
- 209 Carbon nanotubes: versatile nanocarriers for effective delivery of anticancer drugs. **2019**, 193-225
- 208 Breast Imaging in Oncoplastic and Reconstructive Breast Surgery. **2019**, 43-69
- 207 Marker-negatives Nichtseminom CS IIA: Therapie. **2019**, 1-4
- 206 Epidemiological and Clinical Profile of Cervix Cancer at Bamako Radiotherapy Center. **2019**, 09, 92-97 ○
- 205 Computational Cell-Based Modeling and Visualization of Cancer Development and Progression. **2019**, 93-119
- 204 HER2/NEU PROTEIN EXPRESSION IN COLORECTAL CANCER. **2019**, 8, 341-345
- 203 Resection of the Primary in Unresectable Colorectal Cancer Liver Metastases [Is It Worth?]. **2020**, 445-453
- 202 [Survival and prognostic factors of non-small-cell lung cancer among young people in central Tunisia]. **2020**, 35, 19 1
- 201 Brush cytology-alternative to endoscopic biopsy in diagnosing malignancy. **2020**, 11, 104-110
- 200 In Vitro Inhibitory Effect of Recombinant Human Calprotectin on Nalm6 Leukemia Cell Line. **2020**, 20, 951-962
- 199 Therapie bei isoliertem PSA-Anstieg. **2020**, 1-12
- 198 F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in the Evaluation of Unusual Cutaneous Manifestation of Carcinoma Urinary Bladder. **2020**, 35, 251-252

- 197 Ultrasonographic features of ductal carcinoma in situ: analysis of 219 lesions. **2020**, 9, 1945-1954 1
- 196 Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study (Preprint).
- 195 FKBP51 induces p53-dependent apoptosis and enhances drug sensitivity of human non-small-cell lung cancer cells. **2020**, 19, 2236-2242 2
- 194 Using time to solve cause and effect dilemmas. **2020**, 167-199
- 193 Magnetic Resonance Imaging (MRI) in Rectal Cancers. **2020**, 15-28 1
- 192 Role of preoperative MR volumetry in patients with renal cell carcinoma for prediction of postoperative renal function after radical nephrectomy and nephron sparing surgery. **2020**, 46, 234-241 0
- 191 Imprints of tumor mutation burden on chromosomes and relation to cancer risk in humans: A pan-cancer analysis. 0
- 190 CTIP2 and lipid metabolism: regulation in skin development and associated diseases. **2021**, 1-9 0
- 189 Simultaneous gastrectomy with D2-lymph dissection and prosthetics of the occluded branch of the bifurcation endoprosthesis. **2021**, 180, 68-71
- 188 Optimization for Lung Cancer Prediction Using Support Vector Machine with Artificial Neural Networks: A Review. **2021**, 307-313
- 187 A Serous Cystic Neoplasm of the Pancreas with Synchronous Pancreatic Ductal Adenocarcinoma. **2020**, 25, 118-122
- 186 Geographic Disparities in Cancer Survival and Access to Care. 90-99
- 185 Melanoma cutaneo. **2007**, 207-216
- 184 Prevention and Early Detection of Endometrial and Ovarian Cancers. **2006**, 12-19
- 183 Soft Tissue Sarcoma. **2006**, 1048-1081
- 182 Cutaneous Melanoma. **2006**, 1082-1101
- 181 Prostate Disease in the Aging Male. **2006**, 235-270
- 180 Medical management of pancreatic cancer. 102-113

- 179 Pancreatic carcinoma: surgery, palliative resection and value of lymph node resection. 114-119
- 178 Integration of Biological Therapies in Locally Advanced Non-Small-Cell Lung Cancer. **2006**, 261-270
- 177 Chemoprevention of Lung Cancer. **2006**, 609-626
- 176 Molecular Biology of Lung Cancer. **2006**, 67-80
- 175 Pathology of Lung Cancer. **2006**, 93-105
- 174 Gastroenterologie. **2006**, 69-161
- 173 Gyn&ologie. **2006**, 163-238
- 172 Breast Cancer. **2006**, 485-510
- 171 Carcinoma of the Lung. **2006**, 525-544
- 170 Extremity Soft Tissue Sarcoma in Adults. **2006**, 755-784
- 169 A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). **2006**, 24, 343
- 168 Mechanisms of Tumor-Associated T-Cell Tolerance. **2008**, 7-27
- 167 High Dose Interleukin-2 Therapy. **2007**, 431-452
- 166 How can we prevent colorectal cancer with ursodeoxycholic acid?. 201-206
- 165 Breast Cancer Risk in Women with Abnormal Cytology in Nipple Aspirate Fluid. **2008**, 203-216
- 164 Metastatic Breast Carcinoma. **2006**, 117-121
- 163 Lung Cancer. **2006**, 141-155
- 162 The Clinical Use of Molecular Markers as Predictors of Disease Outcome and Response to Therapy in Malignant Melanoma. **2006**, 551-576

161 Antiangiogenic Therapy of Renal Cell Carcinoma. **2008**, 427-439

160 Colorectal Cancer Screening and Surveillance. **2007**, 51-68

159 Linkage Studies of Prostate Cancer Families to Identify Susceptibility Genes. **2007**, 285-299

1

158 Gene Therapy for Advanced Prostate Cancer. **2007**, 139-163

157 Pain in the Whole Body. **2007**, 165-184

156 Molecular Targets in Ovarian Cancer and Endometrial Cancer. **2008**, 291-308

155 Targeted Therapy For Breast Cancer. **2008**, 309-342

154 Papillary Thyroid Cancer. **2008**, 109-119

153 Induction Therapy for Clinical Stage I Lung Cancer. **2007**, 82-87

152 Advanced Disease: Nonpulmonary Metastases. **2008**, 257-278

151 Staging of Renal Cell Carcinoma. **2008**, 41-52

150 Pankreaskarzinom. **2008**, 241-258

149 Survival After Medical and Surgical Treatment of Pancreatic Adenocarcinoma. **2008**, 695-704

148 Maligne Hodentumoren. **2007**, 521-609

147 Staging of prostate cancer. **2007**, 175, 109-30

146 Die Entwicklung des Europäischen Pankreaszentrums Heidelberg (EPZ). **2007**, 109-126

145 Kopf-Hals-Tumoren. **2006**, 373-450

144 Radiation Risk Management in Low Dose MDCT Screening Programs. **2007**, 237-253

143	Deciphering the Conundrum of Estrogen-driven Breast Cancer: Aurora Kinase Deregulation. 2008 , 49-62	
142	Androgen-mediated Control of the Cyclin D1-RB Axis: Implications for Prostate Cancer. 2008 , 63-81	
141	Gastroenterology. 2008 , 85-203	
140	Gynaecology. 2008 , 205-301	
139	Erectile Function After Robotic Prostatectomy: Anatomical Aspects and Treatment. 2008 , 153-175	
138	Ultrasonic Strain Imaging and Reconstructive Elastography for Biological Tissue. 2008 , 103-132	
137	Prostatakarzinom. 2014 , 513-676	0
136	Maligne Hodentumoren. 2014 , 677-782	0
135	Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. 2009 , 34, 593	1
134	The Role of Diffusion-Weighted Imaging and Apparent Diffusion Coefficient Maps in Characterization of Solid Renal Lesions.	
133	Comparative study of histological changes (thermal artefacts) in resected specimens of monopolar and bipolar trans-urethral resection of bladder tumours. 2020 , 1-7	
132	Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer. 2006 , 28, 1429-39	5
131	Surveillance strategies for renal cell carcinoma patients following nephrectomy. 2006 , 8, 1-7	112
130	Detecting Prostate Cancer with Molecular Markers: uPM3. 2005 , 7, 236-8	4
129	Magnetic resonance imaging and spectroscopy of prostate cancer. 2006 , 8 Suppl 1, S4-S10	20
128	Contrast-enhanced ultrasound imaging of prostate cancer. 2006 , 8 Suppl 1, S29-37	27
127	The emergence of radioimmunosintigraphy for prostate cancer. 2006 , 8 Suppl 1, S20-8	3
126	Pathologic guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. 2006 , 8, 54-60	4

125	Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic adenocarcinoma. 2005 , 7, 15	4
124	Immunotherapy for advanced prostate cancer. 2007 , 9 Suppl 1, S29-38	8
123	A combined approach to women's health is associated with a greater likelihood of repeat mammography in a population of financially disadvantaged women. 2007 , 4, A89	2
122	Expanding the delivery of clinical preventive services through community collaboration: the SPARC model. 2008 , 5, A20	15
121	A review of the role of capecitabine in the treatment of colorectal cancer. 2007 , 3, 421-31	11
120	Racial disparities and trends in radiation therapy after breast-conserving surgery for early-stage breast cancer in women, 1992 to 2002. 2007 , 17, 122-8	37
119	Prostate cancer screening and detection in inner-city and underserved men. 2006 , 98, 515-9	9
118	Endobronchial metastasis of thyroid follicular carcinoma. 2006 , 98, 803-6	3
117	Knowledge, beliefs and barriers associated with prostate cancer prevention and screening behaviors among African-American men. 2006 , 98, 1286-95	76
116	Racial variation in colorectal polyp and tumor location. 2007 , 99, 723-8	58
115	Preparing African-American men in community primary care practices to decide whether or not to have prostate cancer screening. 2005 , 97, 1143-54	44
114	Lower vitamin-D production from solar ultraviolet-B irradiance may explain some differences in cancer survival rates. 2006 , 98, 357-64	60
113	Epithelial ovarian cancer stem cells-a review. 2008 , 1, 260-6	13
112	HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. 2007 , 1, 221-7	16
111	Accomplishments in 2007 in the management of curable metastatic colorectal cancer. 2008 , 2, S13-8	5
110	Gender differences in sleep disruption and fatigue on quality of life among persons with ostomies. 2009 , 5, 335-43	18
109	Front line treatment of elderly multiple myeloma in the era of novel agents. 2009 , 3, 99-109	5
108	Skin cancer in asians: part 2: melanoma. 2009 , 2, 34-6	24

107	Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care. 2007 , 2, 81-8	1
106	Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. 2007 , 2, 31-49	3
105	Comparative analysis of early perioperative outcomes following radical cystectomy by either the robotic or open method. 2006 , 10, 145-50	64
104	Neuroendocrine tumor of the bladder. 2010 , 12, e197-201	15
103	New Therapeutic Approaches for Waldenstrom Macroglobulinemia. 2010 , 35, 53-58	1
102	In vitro cytotoxicity study of agave americana, strychnos nuxvomica and areca catechu extracts using mcf-7 cell line. 2010 , 1, 245-52	5
101	Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke. 2012 , 5, 195-202	20
100	Novel agents in Waldenstrom Macroglobulinemia. 2010 , 1,	
99	A tale of mice and (wo)men: development of and insights from an "all human" animal model of breast cancer metastasis to bone. 2012 , 123, 135-50; discussion 150-1	3
98	Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. 2009 , 7, 677-81, 687-90	10
97	The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy. 2013 , 6, 239-51	27
96	Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. 2009 , 182, 216-24	46
95	Risk stratification of prostate cancer patients based on EPS-urine zinc content. <i>American Journal of Cancer Research</i> , 2014 , 4, 385-93	4.4 5
94	End-of-life expenditures by Ohio Medicaid beneficiaries dying of cancer. 2006 , 28, 65-80	17
93	Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy. 2014 , 7, 5792-800	
92	c-Myc and transforming growth factor β enhance the development of hepatic lesions due to mutant β catenin in transgenic mice. 2014 , 64, 351-9	
91	Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article. 2015 , 44, 176-84	2
90	Factors associated with prostate cancer screening behavior among men over 50 in Fasa, Iran, based on the PRECEDE model. 2015 , 7, 1054-62	4

89	Over-expression of Orai1 mediates cell proliferation and associates with poor prognosis in human non-small cell lung carcinoma. 2015 , 8, 5080-8		25
88	Synergistic effects of snail and quercetin on renal cell carcinoma Caki-2 by altering AKT/mTOR/ERK1/2 signaling pathways. 2015 , 8, 6157-68		12
87	MicroRNA-145 inhibits migration and invasion by down-regulating FSCN1 in lung cancer. 2015 , 8, 8794-802		19
86	Expression of protein TARBP1 in human hepatocellular carcinoma and its prognostic significance. 2015 , 8, 9089-96		6
85	Adenocarcinoma cells isolated from patients in the presence of cerium and transferrin in vitro. 2015 , 8, 436-9		1
84	Association between EGFR polymorphisms and the risk of lung cancer. 2015 , 8, 15245-9		6
83	Association analysis of a chemo-response signature identified within The Cancer Genome Atlas aimed at predicting genetic risk for chemo-response in ovarian cancer. 2016 , 7, 41-4		2
82	Deregulated miR-296/S100A4 axis promotes tumor invasion by inducing epithelial-mesenchymal transition in human ovarian cancer. <i>American Journal of Cancer Research</i> , 2016 , 6, 260-9	4.4	13
81	Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression. <i>American Journal of Cancer Research</i> , 2016 , 6, 1287-301	4.4	12
80	Radical prostatectomy in the treatment of prostate cancer. The experience of the Urology Clinic of Prof. Dr. Th. Burghel Clinical Hospital. 2009 , 2, 279-87		
79	Fertility Preservation in Iranian Cancer Patients: A Continuing Neglect. 2017 , 11, 234-237		
78	Protopanaxadiol and metformin synergistically inhibit estrogen-mediated proliferation and anti-autophagy effects in endometrial cancer cells. <i>American Journal of Translational Research (discontinued)</i> , 2017 , 9, 4071-4082	3	10
77	Salivary Chemical Factors in Relation with Oral Cancer in Smokers and Non-Smokers: a Literature Review. <i>Journal of Dentistry</i> , 2017 , 18, 237-243	0.5	5
76	Evaluation of Silibinin Effects on the Viability of HepG2 (Human hepatocellular liver carcinoma) and HUVEC (Human Umbilical Vein Endothelial) Cell Lines. <i>Iranian Journal of Pharmaceutical Research</i> , 2018 , 17, 261-267	1.1	6
75	Toward Automated Pre-Biopsy Thyroid Cancer Risk Estimation in Ultrasound. 2017 , 2017, 734-741	0.7	1
74	[Advances in the research of glycolysis and lung cancer]. <i>Chinese Journal of Lung Cancer</i> , 2012 , 15, 228-33.6		
73	[Screening of metastasis-related microRNAs in the large-cell lung cancer cell lines with different metastatic potentials]. <i>Chinese Journal of Lung Cancer</i> , 2011 , 14, 835-40	0.6	2
72	[High expression of DNMT1 was correlated with beta-catenin accumulation and malignant phenotype of lung squamous cell carcinoma and adenocarcinoma]. <i>Chinese Journal of Lung Cancer</i> , 2010 , 13, 856-60	0.6	1

71	[Correlation between pulmonary function indexes and survival time in patients with advanced lung cancer]. <i>Chinese Journal of Lung Cancer</i> , 2013 , 16, 359-63	0.6	
70	Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer. <i>American Journal of Cancer Research</i> , 2018 , 8, 1317-1331	4.4	14
69	Lenvatinib in the Treatment of Differentiated Thyroid Cancer and Advanced Renal Cell Carcinoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017 , 8, 757-764	0.7	5
68	Evaluation of in-vitro cytotoxic effect of 5-FU loaded-chitosan nanoparticles against spheroid models. <i>Journal of Nature and Science</i> , 2018 , 4,		4
67	KLK11 suppresses cellular proliferation via inhibition of Wnt/ β -catenin signaling pathway in esophageal squamous cell carcinoma. <i>American Journal of Cancer Research</i> , 2019 , 9, 2264-2277	4.4	4
66	Cytotoxicity and pro-apoptosis activity of synthetic 1,3-thiazole incorporated phthalimide derivatives on cancer cells. <i>Iranian Journal of Basic Medical Sciences</i> , 2021 , 24, 604-614	1.8	
65	Kidney cancer trends and risk factors in Lebanon: a 12-year epidemiological study. <i>Cancer Causes and Control</i> , 2021 , 1	2.8	0
64	GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2021 , 21, 1241	4.8	0
63	Percutaneous Microwave Coagulation Therapy: A Promising Therapeutic Method for Breaking the Barrier of the Intertumor Heterogeneity. <i>Journal of Healthcare Engineering</i> , 2021 , 2021, 7773163	3.7	
62	Tolerance and outcome of hypofractionated post-mastectomy radiotherapy among elderly breast cancer patients in a specialized center in Nigeria.. <i>Translational Cancer Research</i> , 2020 , 9, 6833-6840	0.3	1
61	Velscope guided oral cancer screening: A ray of hope in early oral cancer diagnosis.. <i>Journal of Oral and Maxillofacial Pathology</i> , 2021 , 25, 548-549	1.2	0
60	The effect of performance score, prognostic nutritional index, serum neutrophil-to-lymphocyte ratio, and thrombocyte-to-lymphocyte ratio on prognosis in non-small cell lung cancer. <i>Marmara Medical Journal</i> ,		
59	Clinical Clues of Pre-Symptomatic Pancreatic Ductal Adenocarcinoma Prior to Its Diagnosis: A Retrospective Review of CT Scans and Laboratory Tests.. <i>Clinics and Practice</i> , 2022 , 12, 70-77	2.4	
58	The effect of performance score, prognostic nutritional index, serum neutrophil-to-lymphocyte ratio, and thrombocyte-to-lymphocyte ratio on prognosis in non-small cell lung cancer. <i>Marmara Medical Journal</i> , 94-99		
57	Point-of-care detection assay based on biomarker-imprinted polymer for different cancers: a state-of-the-art review. <i>Polymer Bulletin</i> , 1	2.4	0
56	Computerized Detection of Lesions in Diagnostic Images with Early Deep Learning Models. 2022 , 175-204		
55	Metastasis of malignant melanoma in ovarium simulating primary ovarian cancer: a case report. <i>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</i> , 2022 , 180,	0.6	2
54	Laser induced fluorescence of cervical tissues: an in-vitro study for the diagnosis of cervical cancer from the cervicitis. <i>Journal of Optics (United Kingdom)</i> , 2022 , 24, 054002	1.7	0

53	Downregulation of MiR-1538 promotes proliferation and metastasis of colorectal cancer by targeting DNMT3A.. <i>Biochemical and Biophysical Research Communications</i> , 2022 , 609, 119-126	3.4	o
52	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro.. <i>Cancers</i> , 2021 , 13,	6.6	o
51	Lung Cancer Prediction using Extended KNN Algorithm. 2022 ,		1
50	Table_1.xlsx. 2019 ,		
49	Table_10.xlsx. 2019 ,		
48	Table_11.xlsx. 2019 ,		
47	Table_12.xlsx. 2019 ,		
46	Table_13.xlsx. 2019 ,		
45	Table_14.xlsx. 2019 ,		
44	Table_15.xlsx. 2019 ,		
43	Table_2.xlsx. 2019 ,		
42	Table_3.xlsx. 2019 ,		
41	Table_4.xlsx. 2019 ,		
40	Table_5.xlsx. 2019 ,		
39	Table_6.xlsx. 2019 ,		
38	Table_7.xlsx. 2019 ,		
37	Table_8.xlsx. 2019 ,		
36	Table_9.xlsx. 2019 ,		

35	Image_1.TIF. 2018 ,		
34	Image_2.TIF. 2018 ,		
33	Image_3.TIF. 2018 ,		
32	Image_4.TIF. 2018 ,		
31	Table_1.docx. 2018 ,		
30	Data_Sheet_1.pdf. 2019 ,		
29	New therapeutic approaches for Waldenstrom macroglobulinemia. 2010 , 35, 53		1
28	Role of phytoconstituents in the hepatocellular carcinoma management: current perspective, challenges, and future perspectives. 2022 , 175-196		
27	Thyroid nodules: When to biopsy. 8-18		2
26	Riesgos y Beneficios de Prostatectomía Radical con Anastomosis Uretrovésical sin Sutura, Hospital Nacional Zacamil. Enero 2011 - Diciembre 2016.. 2017 , 4, 17-20		
25	The effect of quantization at different resolutions on the classification of lesion texture in dermoscopic images using support vector machine. <i>International Journal of Imaging Systems and Technology</i> ,	2.5	
24	Bone tumors effective therapy through functionalized hydrogels: current developments and future expectations. <i>Drug Delivery</i> , 2022 , 29, 1631-1647	7	2
23	Racial inequity and other social disparities in the diagnosis and management of bladder cancer. <i>Cancer Medicine</i> ,	4.8	
22	A Comprehensive Review on Medicinal Plants against Lung Cancer. <i>Oriental Journal of Chemistry</i> , 2022 , 38, 688-697	0.8	
21	Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma. <i>Frontiers in Oncology</i> , 12,	5.3	0
20	Ultrasound-Assisted Synthesis and In Silico Modeling of Methanesulfonyl-Piperazine-Based Dithiocarbamates as Potential Anticancer, Thrombolytic, and Hemolytic Structural Motifs. <i>Molecules</i> , 2022 , 27, 4776	4.8	
19	Small bowel obstruction caused by metastasis of nasal cavity basal cell adenocarcinoma. 2022 , 9, 125		0
18	Clinical, Therapeutic, and Prognostic Experience in Patients With Glioblastoma. 2022 ,		0

- 17 Risk factors for small intestinal adenocarcinomas that are common in the proximal small intestine. 28, 5658-5665 ○
- 16 HALP SCORE: A SIMPLE AND EASILY ACCESSIBLE INDEX FOR PREDICTING PROGNOSIS IN COLORECTAL CANCER PATIENTS. ○
- 15 Nine-year survival of a 60-year-old woman with locally advanced pancreatic cancer under repeated open approach radiofrequency ablation: A case report. 10, 11845-11852 ○
- 14 Association of Ultrasonography With Final Histopathology in Diagnosing Thyroid Malignancy: A Single-Institute Retrospective Study. 2022, ○
- 13 Association of Fine-Needle Aspiration of Thyroid Nodules With Final Histopathology in Diagnosing Thyroid Malignancy: A Single Institute Retrospective Study. 2022, ○
- 12 Role of serum cathelicidin in diagnosis of patient with prostatitis and prostate carcinoma. 2022, 28, ○
- 11 Ginkgolide B Suppresses TPA-induced Metastatic Potential in MCF-7 Human Breast Cancer Cells by Inhibiting MAPK/AP-1 Signaling. ○
- 10 The Impact of Sarcopenia on Overall Survival in Patients with Pan-RAS Wild-type Colorectal Liver Metastasis Receiving Hepatectomy. ○
- 9 Anti-Metastatic Activity of Tagitinin C from *Tithonia diversifolia* in a Xenograft Mouse Model of Hepatocellular Carcinoma. 2022, 2, 400-411 ○
- 8 Classification regularized dimensionality reduction improves ultrasound thyroid nodule diagnostic accuracy and inter-observer consistency. 2023, 106536 ○
- 7 Peritoneal carcinomatosis secondary to metastatic lung cancer complicated with acute suppurative appendicitis: A case report and literature review. 2022, 101, e31866 ○
- 6 Accuracy of Ultrasound Scans as Compared to Fine Needle Aspiration Cytology in the Diagnosis of Thyroid Nodules. 2023, ○
- 5 Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma. 11, ○
- 4 Analysis of the prognostic factors affecting 5-year colorectal cancer survival rates in Makassar, Eastern Indonesia: a retrospective cohort study. 2023, 182, ○
- 3 Development of a magnetic solid phase extraction method for gemcitabine from rat plasma by using magnetic graphene oxide calix[6]arene composite and its application to pharmacokinetics. 1-11 ○
- 2 Operative Treatment of Nontoxic Goiter. 2016, 92, 485-487 ○
- 1 Breast Cancer Prediction Based on Feature Extraction using Hybrid Methodologies. 2023, 13, 20-28 ○